var title_f31_4_31808="Auvard weighted speculum";
var content_f31_4_31808=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F58171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F58171&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Auvard weighted speculum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 332px; height: 478px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31808=[""].join("\n");
var outline_f31_4_31808=null;
var title_f31_4_31809="Isoechoic nodule";
var content_f31_4_31809=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81788&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Isoechoic nodule",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFEAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5fUbuo4qaNWA6DFSIdgO5RzUh+58q8UAQOrEjINKvlj7361aWJio25yalWyZm+dD+VMCFGjK47exqOZ8cqP1q9/ZjHiJCT71G+mTHOYyPbNAFUzNIg3DGPWnY3KOw9jU39n3EYzsYg037Ky5LBgaAIUaJSfmcGmSsGbd5hNONtIzEKpY9hTDE6nbJEQ1IB0c7EgAiiR5G43fhmlFhMfn2hQfelkt3jA35yemKAIGEjMAHHHqakjRw2XYfnUsdnI3Y49cVdt9EubiPdGQyj86YFRHwcEZz7055ZQuEYqPTNXDpzquxk2Ef3uKryWZVgoPzfWgCqTOTksfzpY1lI2lqt/YZEy0h7UyNFjYmRSR60AM2uB0/GnRxyMckZHtV+BY5ECgZB5waVV2bhE20jsaBFNvMBwvH0qJjLGf9YT9a1I4fMiLSSohPfFQeTGAckHnr60DKCXErNtIIHrVosVTJdgOvSpPKypbhQPSmrE7qdzH2oAbHfzAHbO4FEeo3J+UXBqdLBCNzzAY7GpJrJUiDoAM9DjrQIjW9nzkzfN9af/bV5GwKyLnpyKbHYSlcvsIPTFQvYmZ9sWQR1oAuQeIryBXzN97sKQeJ7zy2B2MrdcrVOXTn2nAJx1NV5NNl2gITk9qAOgtdZgkgIkhCynvjinQT2q7jI43H0Fc0tndRsAUb8aSVZo2zIOPSi4G5fMEbzY5IZPRcc1mGWZnL4U57YqiVbBPzCmiSVAdjEkdjQM0Vuo0kBmtlPHarsN7p02ElhVF96wo7lsHeuWqvNIhPzAg+1FwOgubfSZfmgdlf07Cqs+nLt3I6keoNYqhjkpIce9CySjGWIAoAtSW7q3cL60ohZh8mTTU1CQJjdlQehqWO+cnIUBTSArMrqSGzj0pmCOWOBWgbqLrKo9aWSaGcAhQo6UAZw8ts4HPrTGU7ug2+9bVlpUdwQPMVCfWp5/DrRcmQMp9KdgMBAoPQfnTi4HYfnV+TTiq4iG4VWNptfEkbfhSAqthjzwetJJgrkgfhVtol5+RsCqxiJ5XI+ooAVMnvipCuF5NNEZxzn2NL2wwJoAXcoXOAahZ89RxTlUKSFH50khK4wBQAiL856/jVtI9yioBvP3yMU8MQMA0Ab0OnSlRuCn61ettJ3ffXC+x6VWtPMlUJFuA7GrtsW84xySsO2TVCK13p4RtsR5HOaktmurMrgq6H1GRVy5DldqyqT/eHemh4Xt/L8sq69T60AaVvrKuhibTklYDG5Risi8V2dmVWjOc7CKLSO4Ry8Lbv9nPNWnS68zzJRtI/v9DQBnw30sKMsxIx0BFCXwkK/u0Jz0x1rVuxvQSXiQBMcFaxJ7aNx50TgAdhxQBom6hEiPNCiAdQBg1Hcm3lJaJHCnkEjmsuNJFO9hvHYGrErSCNX3EKO1AEYihMhZmcEHoaWU/v0KbSB6irUFwoiIKLk/xNVW4czNsACkdGFAGvLcQCzXdEnmdMpxWWl6ySbIC6E1RaV4yRK+WHQA1E97uAVcZ7k0gNK7uJGIVsO3c5psk6qEkVFJHUVmTTOqZyNx7ioFlmHDKSDQBtf2mZCAwTk9MVZuJYJoFyEDD0rG+yiQhh+OO1TJA5IBU7fWgB884HC5yO4qL7YwwuR7mpZI1yAhO7HIIqqIPMY7/kPTgUASySxBPllyfTFRmRJEGXIPamtbFDtABJ7irttZOsRYREgdSOaBiRuAm12Az3NPNszjfE4cCqsqo5y5wf7ver1vD5dsZf+WfYA80CHw2Mcg/0hyjds9K19Pv7Y2Uml6pma0GWgkTl4X9vUHuKwriSSeNSj9ByCa1tH0+1h05tR1F0mkfKW9qsmOf77kcgD06mgC5YzQaKJpJopP7VQ7Y1lTCw5GdxB6tzx+dYrTz3ErGPMjsSzOTyTWtHBZzajeafqt2kl8zAx6ispdGO0YVif4e2exHpWZsktnZIwhZSQdhyD+I60ANEskcZL9c9KUaiigGQc9MEdKfJDiPeW+c849Kz5Wk5VkDHtxTA17e6iWPKKJHPdu1VtQSF1XzF+Y88dqyyXQjzQUUenWo5rlGIG5gO1AGvBZxScxk7VHNNu7JFQtGFPqTWIJZEY4uCoPaphqflweWWZsUrgXrbSEu12QrmX1FZ1/pLwymE531Yt9VWSRUA2L6rUpkUXAkcuT2LUAc7cW0tu5EgKfWoVYg5bJrr5LP7biWYbo/WqcmnWcsmFDg9OKLDMO2Hm5yVAHangxo/JwB2q/eaBLHl4iWBPAxzWVNaTREh1IYUgJpp1lO3auB3FV3OxsKWAqJlKnng07eSMHBA9aAJ1vplUAMasx6tdjgSFvaqCBG4OQTSvGVPykn6UAattqssLHdznmra6zGF3SRKz9q54SOOD+tMJLHNO4G/HdwzSb5nKkn7oHFa6CzdcF0KemOa4rdjG0kGpIp5Q+Mmi4HXyWlpKAsQGCeT6VHPoSRqrJKpVulYMF0ehYj2rRg1do1UEggcAGgC4+hFE3nB7mqc2lnDEI2e1aS+IGn2pJtIXgGti0mtrmIAzqrelGgjkRpcyoDIu0H1oOnPk7VyPWupaN/M5dSnQZNSZEgKrKT22gDFOwGIplWVRGrRg9yKuyT+U2bjaVx1A5qWYzRSfvApx096Z9rtirpcWm5z91g1AC2slq7MSTjsDUrKZG2QBVQ96jh0qaUCSMbYj2DCq8sTWshHmnZ3BPSgAeGSO4KMcZ5BU1K8UxAUzNKP7pOMVZEdubYSxOGYdR0NVo3ZgR5Qx/eJoAYY/JjLylnA6JnIpBPuiZREkamq0yyglVbcDzwarhmV9s3KelAFi0ugjsMq3bJGag1Bnd12OGTvgdKiuFiRsplabbyqj5BOf0pARXe8qPKfIHUVDHJLwTnFWjOskx4A9eKAoY/IpOO5oGDpGV3NyT2qjIOWKpgVqFo8KG27/SoXaPzeRtX2oEQQ4Mf71Tt9RTkXzGAU9OxqR5WZNqqMds0Qwzph2j+X1oGW7RHDEYBB4IFWHtIgp8uYh/TPSqp3JINpwx9KlZMJ9xmLfxUCKx86GTEg3Dsaljni2kOhBbvSNEAv3zkdfamv+9Xy48cdTigCR7dCN/m4bsKsWN01oSp+ZGHIJrOeMkfO3C+9PzCqrj5m96ALcUdvJI7vhV/OpRHCyFGYIo6Y71XVAE+UhSexFTmOYxhyq4A60wLlvZWs1u3lzjco+7jrUMtrbiNP3jIfSqB3p88RwfUHrSf6ZcXESBXldmARAM7j6YoA17+0tIrmZrEubVseWZMFgMDOccdc1SWOW3+dScdjU2pXMlzezyyRpa5ba8Ea7VQgYIA7dPzqvBf+W3lrGWB7mgBftKvITJJz9KlWWGRCzE+gxS3V1E21Ht1HGcqOtOs2VHDskYTsDzQBXSzjkkBlDMp4zVe+0xYZs7fk7YrWklVsrvUMfugVTYI2VkkYt2FAGJNp7MxcKxwagETFmUoSa7KykRIGhLhV7gjOaryyxLlY4V543UrAczBbqr5f5T7VO0Us2BGGK1qSW1sF3sWLnpzxUsVy9ogMca7T1NFgMmOaWFDG5YLSLdKPuls1ob3vn+WNQB3xU81qrQBBCm4fxDigCOweYxmR5QsY5wT1p91PZuuNq+Y38VVLi2EGFJPuoPFV3tDcE+QvTtmgAl0tLtyYQNtZt5pcsDFSBj25p8pubViuXGOwNEWoEhg2d/vQMyzGQTgEAHrQrMrZBzWzBtkVhtBaoZrDdkowHtSAzDIT94A1JGisQxbFSz2ToR8pqvJGUHOaAF3BSQFBx3ppLctxzSKxyOakUo7kMOaAItxDZBpSQR1JNTmAAnac/Wm+UB26UASRsApycGp4pWH3Wx71U3Luxx060LIBGcA8d6ANZLtsffyfc1cs7yVXxkDHOawYskbgMCpBMc9PyoA6dp5JWCtE5TsaJozGu6RMKemRU8WqQQIAr7x6MK0kvk1G0aENAOOjDFUIz7dztVYpTg9MGnXluJIQ8jEY6mk0/RpcybmXHUANVS5hVGKzSFSD0PegB8Ekanaq7h2JNLcT7MqYyPxpkywmNSnQdwapusrEsJA49CaAJxMwXOAiHvUL3Ksm3I474puxm++Dt9qikiXzQnRfekBXmfzGyDnFTQWkrAMu3ntVyK0GMxsCB14qVCpYBmyvtxQAyDT/ACCTcKMnng1DdyoCPLP4CpJpSxKI361nOWLNtGW9aAHHY7ZUEGrSwh1HmIc9sVVhfbguM4qc6nJnEQCr0oGWfLigQAkFvamLeS79pOVP8NQxlZNxlHJ6U1FRZCTlSKBExQmQF+M+lWHuSsQjjJx6mofNBA28diTVhVhQMSw3Y6GmBnOJC26Rix9qsRxqycE89TRN+9GIztA65qJInOAGIpDEaBuUBBB70otvKdR5gY+46VNKzRKqMwDe1SwRA5bO73agQsjZ25ILD8KgdZ8Nk/KfenyRqdxfqehFSx2shtiWBKDmgClG7IAxyUHUVpWMst3fWwSVbcl1CSk7RGc9Se2KZAYpIzH5blh0AFS2sSpcwmeOb7KWHmbMbtvfHvQBT1LKX0ytKJXWVgzg5DnPLZ7565pnmkLnIX2xV4xW5upfLiYRl28sv1254z74qC6g8osrH3HvQBGtzhCzAMexqKNpUbfng9jTlifYAAAakZDsVnbmgCNmec5VdretTWYaOT95GJQDzzUTu3mrtyF9Kc87xShl+tAHRiS2dB50PloB96sWWEz3DC0YmLPeoXu5bgZk+5U8Vy0cREY49qYEqWjryP3hH6UybKRnz1JB6Yq3Yak8DCQIpI7MOtP1PV47iEh4I42x1UUAZ1jKzMsYUKuetXLsbnOxScDseKzYXVo8YO7Ocik85gdu5kTvnvQA6eN9pznmmWhRAcvjB5xTprrFtsB4+nWqaESLtXgnrSA1byG1uIVWJi8relUJtFCQ7zhf1p0JWMEJ1Hemrdyo37shsdmoAzJITb885qW3bd9/OKu3rfaFzhQ3cCsqRZF4YYoGaP2gAYyNg7VWlWC4ywG32FRRlSApGD60ojMTkrzQBUuLcqMIuB9OtQJEV5Y1u2xWRgJh8tLPp4uSfs67iO1FgMeJgv3lJ96euyRsfd96tvbT26Ykj4+lVhsIORtpANNsGztwfelW2cDheKkaIxoGV85pVnZdoY8egoAqOCoI6UkR455rSKwyAljyRVb7PtyYwTQBoCxleRVVSWPSrElneQkLLHs96sJMYUAKc/3qQ3EzS4jk8xT2PamIWF57dflmZQajkinumJeRSD3p7BlP7wHB/KnLOUOAuV+lMCt9jeL/AFjAqPQ1ED+82pwPpU5t/PdiG2/jTHinZgiEZHrSAR94UgmkjiM3zcnHtVa6EsOUkIJ9Qat2crJGoHzetAy7CziIiMhlHUYp8kgWJVEaoT3NSqLQx74mZZe61TkuRM20jp04piA2rOCU2s/qKzp1aI8n5u4FakW9vlkQpF6qKz7uIQykoSynuaQEUbMVPyjHuOaaskTclMEdaep+cZII71YS3jZslQqfWgYwKjL8jdfWkeAkg7iVHXAqSSIeYotssPSpjeTI2zygoHUYoEQukRQeWSre4p5tA+1mkBpTdBk2GMbj3q/ZRbwu9UNAFd40iUEjcKhkkhBBUHJ7Ctsi3LbZU8sD9azJ1jSU+XnbnqRTAqpIhkAZSatRQs771O1Ae5pwlhyAE3N6io51Ejjc+B/dHBoA0TCgYOjKRjrigxNJG2ZwV9AKp5ZAu0vtHUYqzb3EcT7yCy/3RQAqgQJ5ibU7Y7mr2izJ9vty0bTZcYRkyGPpjvWXfXEMjjG5ST0NaumxPdTQRw3VvAw+ZZXfbtI569jQAakkE0tysCNG4kcsCMbDk5XHbHTFZCTQ7wHDOw49a1LeNzmUTYaX53V/vMTyc+9ZgRxfFmxsB6LQBcuLJRCJo84P8JFUUt9xO8hR71o3snmKrA4X0zUtxBHPaqE5kAyStAGTc2HTy33NUcUX7zE4BXoa0FtmjiBHzY681XUxQzBpMMPQ0AK0C5CIqlW6cUyRGtHwFDcdq2JpBdJGtuYkGOeOlZV3ABLzPkD070AZzyyo+SdpPQUmyWRgThm7+1WY0fzt4i3KO70rwSIxdYSuepB4oAlW0McPm+YFc+1VRFn5pslfWtGziQoBcSNn+6Khmt4Q5xJweimgCiYoXb5TyPWohtilJ6j2FaLQW+zeRll9DVaSZX+XYFUUgILeJZ5cCTZmluLH7McCQOT6GkMYlkHlpj36VYltXQA5V+OxzQMrJG33WcAdapXal2IXt3q/GjNuJHPvVKSV97ApmgRVSKVBuwNvqanR5JflAz9Ko3EsjZBbAqzYGSPHzAfU9aQy15UqYOw0+LzUcFJCp9jUkl2xAUHn1pki+Ym5WGR1xTA1rSI3JEbfOzdc1JfeGLuRC0MBwvfHFZFleG0mSTO7B6ZrYv8AxteTRmIYVMYCimI5W6t3hkMUgwRxiofLVgADzVia8M85Z+N3emG0d2JTlRzmpGQyRlSFFWYbjyF2suT6mmSCTAHANRBtv38GgDrJbqOWPYkY/GqXlqGyxK/SoFlR1AbII6VbgngVCJ8+2DVCE8sk7A2B70IDGSGLOo6cVagYS5KSqMdMimXMlw52KQE9qAM+4nQE+WCHqiJZHJLMw9xV64soiwbzGDepq/qtpc+HzaiYQTLdQLOuBn5W6Zz34pDObaNzL94keprRtEeLDMxwaWNllLSMm32FTqzFP3agY9aAGnIlydwX1AqbdCEPlsxb6UovGeIwsQvqSKkt4k2MUzx3B4piKyXTxsB5hOexqre+ZI+5mwvYVakeJZMEZb1qGRFeUhXIFICssOGUythTVpHiC4+bZ65qMpEi/M5dgemKuL9ndFV1KDFAyNAok3JIQvY1ZCRSISZMk+tVZQqJ8q9DwTVjSVSeXZdYCnoRQIWIwAYaAD0er0E6hgURW7elV9SsYYHHkyM+egBqnEkkcoDYUdeTTA0XgMkjSuxUjopPFV5X8yUqOfrUqyIVIkYjPaoFmSFsxxgt2GaAHpbtb/vd/wA3pipwEYhid0p7YqH7R5sga549h2qykiJmSJt+OxFADrh1UKZjx/czSwG2zlMRseeOaqOwuJg0qgHrS27I1wVAVADQA6W3VnaR9xJPBq/YPpsLp9ujm2YOfJxuzjjr71U8wea0ahjn16Vd0iWVbtBbWEV1OoYCN13huOuPbrQBXjmaZEygDKPmNNgY+czFFKn0pmnmWNVSRyUbv1yPrV7yR5pjhOQ3c8UANjtQWXKmQE9BVm8eSJ1htotq4wQeM1Ksf2WNY0bDk8sDnFUtVt5xMkgk3If480ATJAI3Pnx7cjPB4p8Wmwagv7qIqF6samtIpZolJjzGOCxqaNxYq2JlJP8AAKYjLmtYbTKK5dx2B4qpDbJPdLtJj289eDV3VjCkQkUAu/PBqOy5gBYKid2xyaQx5MayAXKs4zxjpVrUbwmKKCFUVCP7tEt2k9qIoIFwON9UZ0EaqzlifrQBTniezJkil3ueuR0rPlxuDs2XathAkkbZIJPY1mTxjeVVSpoASFFUHexANOhMBOMk+5FV/KAjbezFj0qIxXEWMgBO3PWgCzKWjLBNnPSk3S+VwoA9qrbJC6naee5rTiDQR5dlOelAGSJGMm0nA9TTpiFIWIgnvxVlgkkhMob8BUEqxIpZD+tIDKuAHkJ28imwqXbByPQVO+WOFHBpYojG+cc9qBixjYxDD86sCdEjK+XwfWs6bzfM3MTUsRMnUZ+tADpTEVygOaq45OetXUt2HLYFVp42DdM+9ICHGDyea1NNmixhhk/WqdvYT3DfukZvoKuf2dc2hDSR7PrQBNcRK0mGIQHpiqctoq4UMGz6VM0bzy4ByfamFNkgUseDTA0pH2oB5asSOtU41cOS8IIPrU7cqGWTA96haSVn2liR2waBF+Kz3R7oxz6A1IIihXzSOe2elUo5THjczK3pViK5QNm4Vm9MUwOk0/TtEe2V7zWRBOwOYfs7Nj8am1KDTdQaBdV1O6svLtY1ha5td24c/d24+Udieea5eWMXh3QowUdal8S6o+qyWKrEYvstslty2d23PP60gI7extDdXaPqSrHGrGGTyifOIPAx/Dn36VOLWN7Dzku91wH2/Z/LI+XH3t3T2xSadYwNaFnkQydhnkVebTpYUR1fcPTHSmBQk021N5ag348qRFMsnlECFj1XGfmx7datWljZNNcwjUFCRhjG/lE+cR0GM/Ln36Vn38bRTYMgIbt6UkETxyB4RnHOTQBZn06D7Ablrgef5mz7P5Z+7j727p+FMnsbKK6tIhfBo5lUySiEjySeoIz82PbrTpxLcMm+TAPVRVa4GW2opyO/WgCVdNtnurqP7eFjhRmik8onzmHQY/hz79Kd9jjXT1uGuN9z5m025jOQuPvbuntio1MkKA5GOuamFw1wQSgA9QKAH3tiZLi0tjPYr56KwcS/Km7s5xwR3qG104/aLuBLmz/0ZWdmaTCybTjCHHJPao7qMls+XyOhqWAqyBJVCKeM0ALcWYksFu1nt1Xf5Zj8z95nGc7fT3pzWflXNnbme0lNwqsHEuUjz/fOOCO9NfTolJK+Yw9RUMkIjQpCW9yaANeK2hnluLfzrMNbqzO5kwrgf3Dj5j6VTv7OCLTxcRywbTJ5ewP+9zjOdvp71SVC0QEQG4dT61IbWSNfMeMP7ZoAlSzaG6tLUXNm/wBpVWDiTKpu7OccEd6tW1htuLuNbm1XyAzMzSYV8f3Dj5j6dKzYo0kb7rJJ1zjpV4I6jZPEct0Y8A0AOktriOy+2tHutC/liXI+9jOMdelM/s3UIrm2iW1/fXSq8S7l+dW6Hrx+NMkZlQpJEdo6FelPiQmDzUZ1ftigC2bC9dbmP7MWuLdWeVd6jYq9TnPP4VZ0mzvm06e/gxbJArHzllAZ2A+4o65INZal1LGUnJHc1NaiExXBuJJlYRMYRGQB5nbd7UAWhZ6oj21ubM/vVUxLlfmB6d+PxpjWN7PLcRmEiS2BaVAyjYB1PXnHtmiG7dIUAlCnHPvTZIxJnI3M33iDQAyE3UFn9qEB+xmTyvM3A5bGcY69K0H8wTWltNZuJrgK8SF1+cN0xzgZ98VQe3MEYKo2eoWpoEW5TdKqiQcAk0AaZe6kme0e0mWKM7XWJd2wjrkjPHv0qlJZF2LBJUhzjzCh2/Td0z7VYjlexR44LpkeUbWA7j0q7JC1vYiO5uXaJjuVN3GfXFMChLp4ktvLFtM0o5TdG2WH+yMc59qqyWVwIwrJONoy0axklR6sO341oT3s1v5MkN28kqABQSfkA6AVRlubtmmuGmkQygq5DcuD1BpAVACIGcrOId20SBTs3ememfapYTMqpHNbykuAY0KNucHoVHfPtU1kDOY7Nmf7Kz7ihY7QemcetaOtXUNnLF5ErSzRKFjffnZjpj0xQBz0VrdPdyH7LMI0J3L5ZJQDru9Me9TT2czKZtj+T/fCHbn03dM+1S2s9211I0lzKPNBD4b7wPUH1pt3dXCQtbhpRCDuCZ+XPrigDPul8rC3MEkOV3L5ildy9iM9R71AYkkVXkkCjoOavRXty13b3MzO8sGPKZvm246Dnt7Uq6lcpc3s8TbWuVZJjtB3Bjk/T8KACxihCsshDtjIHtVGYiSckEbFOCOwq1FfTvYfYTJttRJ5u3Azuxjr1rU+1s7Wl3PcfvrVVWIhR8oXpx3/ABoA5qWRWkIOAh9KpskSs3Broo7qf7Xey2dwDNeKyzEqMFWOT9Pwq0tjd/2Ebe6mRbTzPNCbRndjGc9elAHHBe4HAqZ4ysIkU/N2FbN7qF0t3Zz+fvmtVVITsA2henbn8aNO8SXek391f+XBcS3KssiTx5U7jk8DFIZHpNjbXPhLxBe3MWby1MIhYkjbuYg8d65eF283nOK7kahc69pl3rDwWFvFpMkTCzit8RzF2wd3PsKwfEWsNq7Qn+zrCy8rP/HrFs3Zx19elIDNmdgMlwCO1FtIjNmXc2ewqoyO5J5qxbZjIYrQB0Omag1p8sK+XGeuRT/EVzBcxxvDcl2/iGMVks5lUbXyT2FNnjKwjIzTESWYLSZ3AfjirVxp6+UZnmGT2NZ0GHHPygd6WaR8bclkFAycD99tIDIfSpGjjSUbMgVPMrA4kQKvtVTyCDvydn1oEK6CV+ZCMeopwUzMIg3HqKZG+99pO5a9s/Zw8DaP4sv9SbxFol5dWkSq1vdB3jg3A/MhKkZbkHGegOeooGeQCzmgA8iY4PGM81a1fw/q2n6dFqF/p15DaStsSaaExq5xnCkj5vwr7P8AFN/4M+FGhC+XSrK2nOVtoLaFRNO+OgbrjpliePyB+RPG/jfVvGuvTahqzg5yIoAfkhTsqj+vU0CMDTb2OJQFiG73rf02KbULmONLq2tVlO3fcy7I19ye1cpLLEJT8vPtVm0uwRsnBMftTA+hvCn7P1rrVsl3f+JrO4ibBP8AZZE6n6SHj/x016Fc/BvwnonhDV47KGP7X9imEd9qc52QtsOJGIAVQDgk7eMV8nWd+9tMJNIurqynXgSwyFG/MYNdnD8UfGEGgXumahrDX1pd28lsy3aK7bXUqSH+9nB7k0rAXYvhsjoRc+PPAm7ts1cY/wDQK4DUbOGxvLyzjuYLgwzNF58Em6OTaSNyN3U4yD3FY8geGQGRdwPIwacpaaYDyyB7UwLkNtbybo3lIJ9elPzHC/lbl2r3J4qBY5El3FMKPWr5t0eMO0aOp7DrQAgjgZQ3+sc9geKie3XcMkbuyZ5rRTTXlRWVBGg6Z4qnNaE3Gd3I4yOlAFa5eVXG5NoHUZ61CRvzkfKeQM1pvGVYCfa7dqqfZZBPvRRigCrCUR9pVlXvitaG4t1tmWGImTsTUcnm4XzoEQdMkYzUc1mWnQJKETr8tAGey3L3IYIQM+la8k87QhZ3SRQMLg1ozWUcUCbWDA9fm5qlqGmERL9mxs6nnJoAptaMwD7jjqVFErXCMPIOFA6VZthPCCFcA4+6armMyOWZm8wdqAI2s5X/AHkjFmPOKv2KYiuybUTK0DK5I3eUvdx6EetNIcQjyTvY9m7VYt7eVLG6nacKQFiaJXw0gY4Ix3Hc0AZbxRpNtt1JjHXdViEqkoIc8+g6VJ5boNrIHXqfameQJJgY2Oz+6OtAC3krlgqF/ZjxmpIrSO3RLi5kJQnoBV427PCPMOxRxgiorxftECRKXZF646UAXoY7G7njnEse0dFNVNZuRcXIhkj2BOFYcCo7KJYiI4ItqnqW61cmsroSfv4t8P8ACAeaYjAZN8xCg4HU561opEjqiRK23+Ik9KtLaW8WXcP52eI8VRE0humRo2RCeQDxQMv3n2eGNVVw6DuOtZ7WiSRCYRsEz+daX9mrdNtt+vtzitCLT3WIQ3DMPTjAFAilaxW7W7GGMF1GcnrWU7zKxknVQrHGT2roljtbNZBHukfGMjpWX5SzygOqMmeh60AZM2XlCwbSp6k9KhuInUFUQNn0HWtnU7V4ArQRhV/u9M1ThnmAIuMIvbApDM8QGKNWnQoTSlRPAyo23HqK1ncPaOyRnHctWRFcKQyIwPPJNACW1ugi2+aQxPJqzdW+IQPPaQAcAGqnzJJkcxdwKsyXCG3KJGFB6nqaAMeTezcdqp3McjDqPetWUoISixnee9ZdyJEQ4GBSAqxTXcUc0EMrrBKR5kYYhXx0yO+KRy7jb6VAzMDksc06N27c0DLMJ4Cbe9WJVL4WMjj0FQQOVIyhNWUnCscRigCACaJ8Rrk+1Munm3APke1aImCDK8MfaoLplcZP3/WgRnJuzjufSrkalduFyvcmovJxyWHPpUkRXoWJFAzcF7E8YAjHHrVWeaF+I857rVSKdVwHi5+tTia2jO5FIemI3PBd/oWkas17ruitrMaRHybRpTEnm5GC+Oq9eO9bGsfE/wAVaxq1jcC6FlBYTJLa2FknlW0JQ5XCDr+Oa4pppJW3KAAP1p4u2hjzHGu+kBv+MvF+qeJ9cn1PWbg3Fy/yqmMJEvZEHYD/AOuckk1z3lSySCVY8KaSOdZQfPUq59qn3uqBVl2j+dAFO5URyZEZ561q2x03yVMxbceu2qjxSMMu4VT+tUCRBIUc5U9xQBvSxPKjNZlREP72Aaz5ZHZCJCzFexp8bOIlCbceveiONDueUOfftTAmtis7IGRlI49a0fJmtTuQb0buVrNgkt1lBDSIw7Z4q5JqnmyiJlcJ0yDQAtxI0agzABGqJrqBHQWrsH9SeKtTRl4NgkjZfQ9ajXTisaSeWozQBehS7crunBTqcmo9Ru1gT5ZPm/uqODUzQS3MKohEIX+8etZt/BOVCFGyOhA60AQLeSTnLcY6bRTpZS0edxDD0GK0NLc2cPMG5j1yOlJOj3EoJOSx4VR0oApQxT3C5kZpEA43HFWrKFQrbww7DB6US6fKSEDyK3+zSQhrZXil3ux9aAJ7goUVEJUj+I1ZhV2ZTuJjXqwpltEZIfnKBR3PamRW5ilDFmeI+/FMDoLbTIJIzKrRuzdM9aqy20ensTLbKe+4tVWOVJQUilPmDnAbGKrardRlFS4mZnXrzmgRKZoSDLGU25yV71ExsL+CYJLJFdgr5e44TGfmz+HSqYAmVTBEVQ8b8Vr3GmLb6PMPLSRJWjLT7PmjO7gA9snj3oGUtM0e5dpGNwixdyTnNO8qS1uBLGcoD1xV6wt7iGIlSiqvZ+9Z97du0x3/AHj0GOKBGyLkTWxcxlsDJwODVGJ1uJlVotiE9jim273U1uIoikbfTrUiWAbLSzxrKvJUnFAFnUJ4rG2KptmJ/SsqO7vpIh5JKx+pq3JH5kbqqK6jup4NWtPsnltWH2fBPdjgCgB0VncNAs0twhIGeBk1Av2cqVlhk3E4DKOtEsH2ICKK5UyN1VTkUPNOoSKG5Dn+IBelAFSUzWE4a3nMSk9N3WtP7Y93ERIX6csaZf6Q88cUiMv+0xHSoZLAx25IneRv0oAkjmgjhcBifpVae2QsLq1uSD/d9Kr3fkRW4CI5mHXaabAJGi3QFYx33mgC2ZbieBkMbSv/AHu9QpZSmM/aI2GOmTU9tqgtI2CsHbuw6Vny66/mFiCyj1oA0StqloUllBk7LWE9p87PsVU9RWhY3a3HmSvGiehbvRdGBl3mXL/3OgoGVY7ISpttlfHcnpTLe1mty+VEjHjOM0+XUGlj+z20Lbz3XgCmwLdRzopZsDrzxSAets0MbPPEEB53GuV1KQNKRyVzxit/Wby6dmiDHYvoeK5szKsh8zLMO1DAjlhRoxtJNNt4CG3AZFTCYysDtA9gKnlkdY84Cj0FIZWd5GbaBtX1q7bWy+X5hPHqaobz1IOKuANLAFDAL7UALI6O4CHOKidGZ8HkUjRNEuE6etReYVXvuoANm18U+A4cqOT9KbzgdKYXdWyn50AWDNsflPl6dKldVZCyMvPY1JICxxKefSpI7UiLc6Er6igQyFFERJcFvSqIY+f3PPSrM0S5/dnA+tSNbYjDDbz1NAEbedKcxq3FRK7g8nJzVyxbyJgX+Yeual1LypmBjCq3qKAIZcPDyWJ9KrfYpTC0qoXVa09NYWxzK67DxgjNT3czFv8ARCNhHzADFMDGtJV2FWXD9uau29w8R2zR7kPY1Ue2+zziRwST6Va89WwGVhjuaAJZnhEgdIdp9DVd+H3fdY9Kc9wZDjblemcUG4iX5ABk9SaAH2TlnZdxLfWt9LdhApLhcercVhxJCvzxNl+4Faltb3E0YKY+knAoAnAvFnjlgQTYP4Ve1e7uH8otbGOQdappFPFLGs7bR28s1au4GjILzFt3Tc2TTAc1w6whnXAcYKjvVYxFX8xZCijnZTZbfy+Xk+YngnnFWDKkUIDPHKzdSRQBH9oJc+QxkY9Qo6Uxle5kVTDkjqelaNtPEgCQQAMerL2qvqls0iiSB9qj7xzigCaa2R0SHfHHx2NQsYYV8iRs+hU1WtreUTeYqGQD1q9PYNcQvJFGu8dVzzQBlvp8STebHLuJ7BuaJfIjUCR927sV6VZtdOuFdMqgDHmr9/p1uSqSTbW7YGaAMfzHFviCbbEDwverZmlawjaS5xC8oRoN/wA2QNwYr6ZHX1q5JpkMcCSzHfgcFR/Os+awgktxJ5sgu/NJYEfL5eOMe+cfhQBJPqFzOVU4WEdz3qO4aWWPK42jjIHShis1o0ThvlHBHFQIvk2nlbyMnPLUAW4LY+SrrJICepJpl7B5JG7bMW9DzUS2twsSvI7CM/d5yKmMuIgksDuw6Y4oAkht726iEVsBDH6+lNuNP1q3+RpXmjxkbX4q7Y3qxbVlIjVuCueaVWaC6cs+23IOMk5xQIyraz1CRv3sZU9ua2NM0mVsRySMkjHncMCm27Rbi8DS8HPJzV03bzqEJ8vHO7qaALrWl1Zo0R2yREdc1ny2csyeXgx989qZBLdSzFVmJiU5JPU1Ol0bmTygzFc46dKAKKW4iDr5SytjsabB5CjyruPyw3txVnW5IbPyltQ0shOW2ioLqafVQkc1uUiUdhQAyaOD/VpEgi/vetYd0sM0vkIuMdCBW5Pp8q2wfyjHAnqetZs86hGZIQpHcCgZWtLFi22Le7L2PSpZJxL+6MABXjKj+tQWcl5Kj5mEcfU+pqxbXcKL5bhirHBcikBHDKIImVI9uf4qgSRXmHm7mHfnAFb82npcW/mWroqAcA96565u47VipIlcdcjimBD4hn8iMLbbNrD8a5uGDzNxJIY+lad1Ibw7/lz0AHak0+CTLBUBPvUgVPs/kL82CfrSxQyupJ+771LcRFLjDA7j2zVn7HJJFhAxPtQBV8q2KjzpMEdhzVuBrGIARMzn3FUZLQFduNrio7eNkJBbJ+lAFq9njkPyNj2qqyHb8wx6cU4Krf8ALQAimN5jN9/cooARSrY3qRVlbbcu5SCD29KdEsbRYZiDT4LiGAnchdfSgDo7nw9cAmVJI5EPYday5BMCYCxjI9RW9bahLG/7z5oz3NNu9VtZG2eSpzwSOtMDAtdNaV2HlM59V5rotI8NtKjCeyuAuOG5ojmNuA2ngRv1w3erC+PtasF2eUpA74zQByWtaV9huSMSImeNwxVdIUUCQSbh3FdTqviltbt9l/FGATknbg1ikQopNouU75FACSJa7UkSRiR/CRVyG4jlYqE2EjjisuJS7mQKWIPSpWndpQrBlPbAoAuTxGGIvIAfSsh7li/KbU966OK0NxbqMZkH941n6jA0Y8tUUsfvbeaAK6SRy4aJE4688U1o0GGCRlm6k9qry2qjChznvirkRjSJVKFj0yTQA6OOOH50cM3cCte2je5IeSVQoH3d3NYckqREqIwM9OakTO5Am456gGgDUur5rVz5SEgdDirKanJcqmLSORh/F3qEy20Vrh7VnkPQls0toZmQiIeUvX0pgMm+1vKpnUIpPQDmr72a+UTbIWYdd1Nubt0QGR9zAYB64p2mXSvFKHkkdm9ulAFOOSYyAKojxxzxmtmaLfYoJ1wc/wAPGayGZ0OUzNg556Cp57k3ESBsgg8he1AGuI4kt12uqhRk5PNY91eus5a2lUL3GetRz3m6QJC+/AwQVpqqhO+VArDoNuAaBFuxNxJJvkG2I8896lu7yNGEikLt4C9c1HFq0fl+RN8/YBegpVijE6gxidH7DtQBYiiuZbd7lioDfdG7FBNxHp0YuYhCPOJWXbzIdp+XPcY5x7UXH2O2LRPFMMjIXP3TV+3HnQWqSyNOJA0ka5yIiPl59CQePbNAGNa2somLSsefu5HFV9Ttz5iYAk56KK6qeyaKHEh8yTsFHSsbyZTc42bMdSBzRYBIpXQI1xEnlqOmelVLiea5uQIJUWIddtWNS0+F1VmuiFP8JFS6fpawrugkRl70AMuChjjdIFfb/FjmpYZTcN5UkRfdwCwxgVqQRwMm5gCR/ABjmsv7TMt88flhU6Ad6AIp7d7aUQpMFDHoOatWkcluzebiRTxmqFxIYpxhWck88Vqw3YWzO+22k/dyaALXmG1jEttbsxPciqk2oBDvIVZm/hxgCrVj580QizIgY5JxUV9ptvBN5k5aRR60wMGWe/8AN3CNCGP3h0rYvL6RLaOJCE3D5ioohZLliqKViXoMcVFfRbxzJs444pAQXEM81uN1y0iL0UmuW1Cdlu/LLFQOqgVrqojEiGZy/Y54FNso7ZHZpiJJOu7GTQMhtwW2pEh567utF9sJ8raoA/GtWe2jvIgLJJAw5ZzWNFbyC5KM5dwcAUAUpLyeAhF3FOnPSs6+3SnlNvvW9cZtp1+0oCpPPFVtSjSZ/MgA2gZApAZ9jYJtDSMwX+db1rZMYGaDy40H8TNVG1t5LzmRtuOMDgVefw3dm2eQTqE/hBbrQBnXFoXmIiZZZR3FSm8vbGH5vKUdOgzVQvcafuRiuT3HNVp3klIYnK+9ABc3DXGWJ+Y9doqvAjOduDUjJ5aZ3AZqzaNEYtzP8w9KQEMluEOEi3MR6VFGFyRMCnsBV271AqhSLAb171URwyFpDlvegBDbljiJcL7mrcWjySphiFz3qCzuI0yzcntk1dtdRdtykgL60wK7/adwMYJT61BKS8gIBBB7UQXUyEjeBntT7V0+05lIyfSgCaO9vI5Vxkqvc1Lc30sw3cR+uR1pl7MY5AYzx6ipJXSe2Ak3c+1AGa9yzSgNsP0rUhiLbFQomRzWWLEPJtDYx0OKuadbuLgK7NtHcUAX/s88TnyIwSP4lFSw20Ux3XMpSb3rXsr2XT1ZUxJEw9M4rLu1iu1d5HKueQNtAECxSW9zuknYR+tV5riMzP5bSN6HHWr1nGZF8rrj1q9NbJDa7pYue2KAMCONZh5jsUPpjrSfY3aQ45X61rLbt9nG+ErGx+8TStDGWEdupcnrjgigDGurIKi8MH9aURRrsDFt3fFbN1biFVHf+6Tk1RkICEoSW96AHmOSJEKgeV71PcOssXE4jbsg71RlM3lIHDLz0FTRCNVAZDv65xQBaghZ0CFznr0qxavLDJ5MQTD8E45rO86WGXeGJi9SMYq0l2ZiGgUqyj7w70Aad1Eltwj7y3VQKgWVBGSUaJuhOOtIjGcbpiS/Xk4zUl9au1qGwGUnoGpgZcISO58xJC27sorYiVpogk6u6jsOKqaQVhkdRheOSRkirM8DD99DeHB+8CaBEd7AiqpihEe3qPWq9tfGOb9yhDDuOasNpyXSb47v5sdDUFtK9rJ5W6IMncDOaAGX095n7RLETnoWrZ0rUBcWttAp8uQK3nbsfeyNu32xnNUp9YmkiMNzGkkWeops4ZYbJmto4lVH8tgNplBIySe+On40DNK8nu4JCIp3kx05zUlmA0bXV1O+/umMVkW04lXZs2N/eHWrxttQmt28v5VXn5u9Ai4n2O8cM0DP/u8YqxaWHll/sUTDPd+lc3ZalcRStEsO09+cCt+XW7lNNXy7XGeCc5oAkliu4pQHkiPspqHUkijiDnBY91NW9LEd5blpEZXHUtTZ3tUtpF2KznpzTAwoLiKGT5UMpPUVI6T3E4ltvuryAe1QG0a3fzSVy/b0q7p85RwsknttUUgLdlcXUiM8+Qw4B7Gr0VykSh9RnjA7KaztTu57aDeQ3kd8DmsqQ22pxElGVs8bjQB0B1O3nnxHIpj7KgrM1W7hcmPYc9iOapi2isbYhCDIemO1LYSsrbiQx9MUAVo3ESNuh3E8ZPWlcRpH+8BiyOABk1YvnSaYNcsyKn8KjrVW8lSX5oydo6ZoGKJ7tYCscm2M8belZsMVzLcFgcbTywNWIVMjEkkk8AGt2xsIba3wVUyv1UtnNAGeLeKcDBEk+OhqrNazWw3yRZz/AAgcVqEQ2b75AsZPUKeRTbnXLYvGscUkijuaBGIZJcldnlg+gq1CpihZnucD0zmpNRu3uGBW2CIehIxmqUMTTSnzdu326UhkMFobqRyCG9C1aMOiiO0eVjvk7AdKuQCC2iIjTcT1apEjubiAiOR0TtgUxHIXlrtUmXcMn0qS2jsobVt4kaQ9OMVr6navDb5nkAYfdBHJqhDaSyQedKVVR0yaQzIljIbmIKv60yaPamc8ela8rQIm8SK3tWY7JIWIJAPTNAGfEpMmOg96lm3RHKk4pJMxk+WxJqHdI7AFqQyWR0Q5Q7sVPbNDOuVRt9QCFSuQ3JqW33xg+WMH1oAtPGGKgkgVqx6NJPbAwSYx2JxWAZJd+Xz9aspqFynyhyFPFMRdEZhJSQkuOOKs2XMjLv25/vHFZ1o4kuMSN14LV0drpKyAG3nVn9DzQAwIYFLrIuR0INSS6qJbTy2hRpP7wWkutHui4wuB39Krzvc2KCMxwsPXHNAD7SMzKzIVjc/3uKPKu1YKJCy5wSDms83zkhZUC89a39LuLKJF81iz9QRTAdOGgEaPlh1weKkiaGFGklti7MMKVPSq91OlxOTHK8nYKV6U2OLYGWefYMZ2igQRaeZLnfPH945Ubqnu9LhhHm3KBOPlUHrWba6nELhlkWeTacKVPSrU9ytxEMvJkHGDQBThcSTEujeWvAwOlE6ICpt93uSORWzaxxm1IikYS+h71HYvbJIUuoGLk9c0DMmdG8vaxaUH24FRyW3kQLJGSqn3zit67nhto3RArM3RcZqCymsZIzFeWLseuUY0AZvmpFt2SGUnqPStW11HdatstvMI/vN0qJNN0ied2iuZbZ+yyDgVT+zRWl4BNcb4c/ej5oA0Vv14AsGDHqxrMNqJJDKjuozyM8CtMCC8k/dXExA4VcVWuIri1kPkpJj+LI4oESWpiRSFYOx7Y5p15pKPGshcxuexqG0lKSsWUKx/iXnFPKtLP5vmtIF6ZOKAKqQpYykXOWVuhq7NayS3FvHJcJPbpEHTa2QgYnK+x45H0q79nF7F5kEeZB/f5FXotOIfdGuIjEu7f/z053fh0xQByd1HJa3mbdcDOcg5rrdL+1S2fmSlCD2Y9qrRWTwzmXMUkffaM0t3FbtHuBfBPIXigCGZomlYvHENp4BNI8zvKixSxKD0Q9KpNJDby5QeYvZW7VYuGW5s8xpFFLn71AE04vELqrqP92oxDcCNWZlZepqO0kle3KNOoYfmauwGT7IXceXEnVv71AGbeXbqw86PaBwO1QpJmRXh+6OtXbdm1G4YwxRyKOPnqxNZRQBeEY98dBQATP8AbrfyTLuH90Cs2RIrIiOMs7993QVoPJHG42SoCvZaiudo+cRxlm9TnNAEMMcs0D4dFHp3quIpIIi4IjAPVjyauTQzsuVTHH8IqJNJuJXVWVhnsaAKr6qH+V1QkcDikW3acqYjknqK63T/AAvFhXuDHtHrWjcRaZbReXCYw2PvelFgucommuq751YKB97HWpJ47aOLfvZcjHHWt6GS3lUxyXCuAM57VlRxWVxeOnnlYgck4oAyb3TpJoozEhdW6Y5JrZs/DMkkEbAeW+OdwrodKu9NV0ghSSbtkDFaOqs8dufs1vuc9FzTsBx19oEUZHnzCbA5APArCuzYsfLt2ZdnUgcVsavcXtvCRJDsZ+y8msAJKPmFuxk69OBSAg8y4bcq7mQdyKlt9SvBG0UbiMKOOOTSy30oIE8gTHXimJdWaz+dKHcdh6mgZhXZu5Z2aWRnbPXsKbdTssI3T5P92tPUWfUZCbOBl/2V6VktaTRybZFCn3pAV1ZmjIAGT0qI/LIok5x2qWdPKcfMPwqpI6BsnJJpDJZpIy2M7RSARgZUA+5qrPvbHy59MU+IknGACPWgBXO/lRtqax3qSC/HvV46cAuSeB1Bqt9mIlBQnbQIJXKttJDDtSA7kyCOvSnNDI5yApp6KUOx4Tk98UDHxSqwEZUL/tCrqCS2ZJBKxA54qtCDvClcjPIrZgaJYyrKuwjo3UUxFhvEE8qCPynYdOazriWa4kI5VR2I60kEDmdjG+1B0q0FmOf325R7UAUotkjqk3y4PpWn9kZ9ptY2bHNVLPAuN8qGQCt2LWo4WEcEIK+/agBLR57ZyTBuY8nI4FLNfFmdmtoiTxjPWppdWtpgY3Dbz2A6UxbT7QVG5A38OOv40xFCyke2ujIsCgHqCM4q+nkyXIlecLnsVGBWimlun7nAZ253VW1DQ5YbcvIBkd+9AE11aWzSI8ckjZH3lHFY88Di6OYiVB4yasQTXkkC20caqvUNmrssVxHp4dpEaUdcUAZt3Z3K2wkjtwuO7dTTLKaQIHiMaSjs3erS6rN5ZS4UvDjBPemLYQXMRkhjkJ7DNAF61nt7rMepRws/+yOtV5IbISmCItbO3HzDIqGwt7hLgRCME+p7VPqCQx3KltzyDrt5oApANp1yViYSue6mteG9le0CiEvIDzGeSax7j7MfnhbLfxKeCKt2M6REvDlHUZ4bJNAHQaVa20ivcTWIWQfwZ/pVG4MM7SO9usCJwAvFQW9rqd7M1xbySRH/AGuhp8/h/VLwH7TcLGevXrQAwG5gsPPtiGtmYrkdj6HHSljm1K9uhAIMM8KARgYBXnD8+vPPtT7K0u9FglUsssUqlXjYZVqyo9R1BIJIVHEgCNMM79g6ID2HPSgDUtNXt4le0jKpsJDnOQT9ag+2OkjuEjmiPA7VSj2j5IrYjPVmXmllVbQEJGzlu1ADWVGlaQQsFPpzSBbaOMl/OjzzgirVtrj2qBRaKQOxFS3evTXS7ZLSMRngHYKAMN7xHl8uLbHn+I1r2mowwxGC4U3MQ9+KpQ26S3I8q3SXnn2qxcWL3EpHlrAF/AGgYQSQTGY2u62QdhzVaG8lMzRt+8j9elIlqYpT/pKgDqvY1uaVcM6GIWsLJ3YDmgRl25UylVhdl/2RWtZrY3bkEeWyddxxSmeM77azyHPUqOlZSrLpheWWMy7uORQB29iY0hPlxx+WP4t1UpdQsYZWJkaVxztUcVzNrrc0iPGbdtvTgVmStcXc7JbwSxge1FwOj1DxTKcpDaKsXq1clqurNcyBVx7hTUz6VePEUklwT602y0G4STcqlx3bFAwspb2VlSOIiMdPet6z02/YB5BtB9e9WtK0a6ixLMxx29q6e20+Yw7jMpbt3NFhFTRdPms5BMzAv1AxwK077zroHN2kWP7tWLfey7J+WA6YwKzr2JNkg82JWPRVpgZUdg5mYzXKFP7zcmqesPZQ28kcLNLNjr0ApQ6Qn/S2JP8ADtaszVo4ZG3QF89wTSA5S4Z8sfKL4NSJBcSQeZlVPYYp94rxHklQT0FMTU5PLMSAAjjPpSGQW893au5WXaO9U727klcl2zmpJ/MfO5snOSTVSWEgEgHnvQBDK3A2ZJNN89OFZAGHWnKTEc5x9aikXzGL0hkrSIVG0DIqvIY3BOcN6Ux2QDABJ9aRVPc8e9AG9ZuHZVlB/OtZJba2ABTzAe1c8D8wZdwqWFkMoJZifemI7HT7TS7obxlSf4WHSodQ01IFJiKY7bjWfp16m8I/C+1dTb6FFqESyQXJIPO0mmBxv9nyKfMDANn8KbKnlyqZcYrW1m3u9MufKlA8vs2OKyr0DaCHDH0pAQ3rY27JDt9qn0+CSRgRJke5pI7UuisqEqeuTV9oIvJCjIk9qAEntCrAs+1f9mq0o8gfIwY9qs7JolCswIPb1pbiONolKRsGHXnNAFJbphjeBn1Aq9YzmMFo33uTnBPSqzRLIu3axHtUYtJJnxbGRMeg60AdZY+JJIAplhRnX866Oy8XQ6hCYprEM3pjrXnJgkgI8yJuR1PFa2nPFapv3FZOxBpiPQYbXTdRQRi2Nu7cE56VT1PwO0cBNnPIwPPXNZdl4hjW2P2zlh0IGKv6f4nuVkXAk8g9DnOKYGJLpstrGIry1bAPD44NJeiR4ALQbdo+6o5NdwnjDTbsraXpRvcrWqbXRbi33wbRJ1B6UWA8rtpLi2i864RwO4ZeTQmoQJepNaqjZ+8r16YLe5mBjEFvNFjgkDNcTq3hS7kuNwszCm7OQOtAFW5sluJ/tctqqxMMnbV3ToNPmgbyrfZj+Ju9WR4avZLZF+07VX+AnrT5ree3h+zvbskfQyLQAXEix2pWKbyz9cVQmklEKpHOjyt3J6VYgh0+0bdjz2PXec1lXuoW51EFAUA6BF4oA27NGt7RlMjSXcgIL/3B/s+/vVawhm03MUtoZ7SRssCeVPqPesoXl9Gxktm4zwT/AIV0Vld3r2oaVBIzDkkYxSAhmhVo2L22M9OcHFZk0MUfysWAbqauGK7e4IA2E/3jxVtdLkkTZMUX/aPNMDmQh88RsqmHPB61LJDtYlLd3I6A8CtByLKdleBZUX+LGMVaFzaXUYDyAY5OO1AGDpjyvekNbmNc/wAIrpZ7R54gqx7c9mWora6hkl2xxKY16N0OafPfb7hUd2wOwNAEK+GIZhmdmZh2HApsmkC1zHBvA9F61q72ji32jE5/vHgVXtmCO093fASjoq9KAK9nok1sPOjgYdyzjmpnsb27nT/Rg0Y9RWtH4iJVYftKktwMCt3S0iuWCPfbT1OBQIzrSwgS32ywRrJ7itWwTTLK333VmJvUYxXQWiWFpEzGIXLdi9cvr2sIfMVEjjUdhTAoXtxpEt1uTT1jI6LVqzutNaPZJZKrDptHFYkHm3u6Qwrj+8xqWXULW2CxKHDgchR1oAsXlvG5byGVs/wVFp9mbOQvPG2CeFBrm9R157eZhBHJ5jdMioLPXdQd9qKd3cv2pDO0eVzPuVVUHorVi66LcwtJM0a+0Z5rOjvpJWL3LMSPQ1l6rcRytsCyQRnqzDrQBBFFb3E+FKgf3nbmrF1YWkKFnuWd+yqOKwDtsZujup5XPenjVwqlmVQ3+0elIDK1K2uriUgYjiB49TVEaVex5JU+WOdx6V0FrdfbJ8vIGYdM03UzNM3lSTEL6LSGc1JK33G6D9aZPO+0KuFXvRd2zpI20jGeOap3LtjazfkKAGSbmbdkEdqi3MpwR196TngA04jcME/jSGMlByCAMUijueakJWMYJ3fSoiA5BViPagC1Hu253GpiQcbeo9KrPKvTOM0ittJKk5NAGxp7bXBYj8a7rQ9SjRkhuCqKeAwNeYQMwPGWGa6HTJI5HVXJUj1poR6HqkFvFCZkuFlz/C/Ncte6WbhftDRovpt6VYu4g9uHVyxHZTUdleGMbFDPEeGVl6UxFS1tJo+fM289Ki1PcXTYhDj+IV0JthHA88A8xj/Ce1ZstpdXOH2EEdcdKLDKMbMvMoLt9amtFhaU73kUseq8gU6eK3ikj3sd3QitOwMMZIhwPrQBFJI8MDJCqFM437eau2NrcmHdneh6lVqESLK7CUrgds4rT03UGjLxW+QpHOW6UxFM22xWYl3A5wwrFuRd306omIYx0Kr1rpodPjupHeO4Yk9V3Yq6bGIRDyomMqDhh0pAcZApX/R5QzHPJbgV0FnasqgRsDtGRtNWo9IkaQXN0qkA/dA61tI1gsewW0qNjqopgcG9pcXGqsVh8tM8mrw1G9hkEPnAJ0roP9ERmG51ZuAHqGfwyrxrMLpBntSAjs7q8tNkkVxIwzkjNd3Z3s95aRmdwfbPJrirHw1erKxt5C8Xpuq1a3Fzbytb3KeWV6Fu9MD1DTrjShGFubCVHA+91BqbydN1NjFEqxZ4G84ritM1nUQFjjjEir0zzkVq3GqzFRnT0DHq3TFO4ie++H6u7eVNbkt/CG5rJb4eNA5V5Idzepq7Zwi4zI0skTnoS3AqWG0DOzXF6XK9MNQBmf8ACvNmC02B1+U5rctPAwWBfLllLepqJ50deZ50K9MHrUUuoXFsm6a7lSEcjJ60aAOufB8yThm81yPReKqar4S1G6TZCWhbsx4rTtfEWYQ8dzMQOuTWyNb05rRWFy7XJGcNzRoB563gjULKFmnlM5PXgmqC+HlJMLgQsepYYr0mXxNB8kbStnuAOtYetXiSzq527T0zRYCDQvCFpFEDK/mHrwOKh1zTra0DEWse0fxtWzFqyW8CRySBFI4O2sDxJLEyebHdJIg6qaAOI1W5uPKZIAY4v73QVztzqMkTfu2MhxyWHFa2uagUiYsgkjb24FcZNqLbWAGEB6AVLGbqaqkkflxnbOecit3w5rUVjcqskzySt78Zrz22IvZx5AC+pPBrrdJ0pHeNZARn+IChAegXniK8khwrbfQetUH+0TRb7lMyN0AqT7LbRRRxsxCr1Jq5c39lDZqbdmdl6mmBj2VzNBMyykKvQAmr/wBgiu8yS3Hzf7Hap0eG9gDG2G8jgkUWmmXkTFSq4f07UAZ979jtbXDXMUsg6BuCa5abWpVuWVI4wvtXR6j4YiS7M95KnsM1nXGk20cvmGYZP3VAoAbb3URjE2F83+6DS3tza3MIMkJV1HVulWLfRzt8xlG49zVHVLUykQgk+pHagDKd9PiBedy8nYDpWTN9nllZyhyemKt6vZW9rGNrc9y5rKjkLKTHIhfsKQyezljhm3OuxB+ZqxqmsQ3O2G3iWNRwWPU1kyQzs2+Z1RPSqE4iikypJ980gLV5bgDcrM2e/asiS3LNkPke9Tyu8keSzBO2TVckDjnFICHJD7c8+tNLc4fAFPYZbjGKibggntQMHIB6dRTSrKM9Kaz4bcAc0MzyDIP4UAOmdT97IoBygK1GwDLyeaTlRQBeg3Y4IFXrafy5BubI71io7KemRVqI7urY9KAOvtdSjVl8s5rc0/xJFGSlxbhs/wAQFefQff2tkD1rTWSOIBXdgexp3EdvHqVtcz/ui+M/cOAK3NPtzM22SJDEf7p5ridCt7QyBpmJJ6EV18GpW9gAqZGeB3piJ77w7prSby2wn+FjxWDceFllu99vM67ewORXRwMNQbMoYjtxxWjbqlq3ylQPpzTA8+v7Ca3uAske1R0YnrRaqyygoPmPGAc16cbW3vI/39vvT/aqGDStItgzWq4kP8JosFzg1WSyUyhXDMfwq7ba9cLEY48F+4Na17Y3V3NIm0LF2OKrz6F5cOAyh/XFAGfY65fvK0c0RA6jHSuj07xEADFexBRjhmFYqWL2seY23tjqOoqGBbq4jYXEcuexZeKANuOzttWumeJ0LE9jXQ2XhpjFzdKsg6J1rg7eFrZyE8wNnJA4rbgup41DxzSo/qWoA2Zo5rbfHOj4B+9HkVILHTb+FSZLjzB3xTY/E1zZ2+LkRzIRjJGat6Xq0dyMiSBA38PSgDPjtLaJ9j3s6KPQc0+4g3ITbXFy4z3FaUsEEknEsYJ7rg0wCeJf3Ei8HqTTEUw0hjETI4HduRU7adbQorfapBnsatpfzJExZIXbu2apy60twPJltckdGA6UAQT2TS8x3LbB74qlILtnMYZpIx/eqxLqSxsImcBT7dKli1KG3JIu43z0UrSGV4nmiQr9xPfnNXY9SsLSEGdRn1NUW8TolyFkjEi57IMUzVPEmmSoIzpyO59VoA2I7zRJ2DiQGTrgNVG+1Gx2sd6gj7q55rEOq21tGHXSowD/AHaWO9sr6XcsEUTDruNAjXstYs7iM/aI5HA4G7pWNqJW4aVbe2k2E8jOKsXWqRWqBI4oHPbFRWuuOCzS2qD8eKBmRcaMstuQd2OwA6VizeE5y262kBJ/hI5rqNW8VW0QAjhVX74qpa+K4dhLoqyGkBzcXh82pZ7pkQqc4FX9M1hILyNfm2A46Vv3kCalYG4jjMjkZC1wN/I0J2mHbID69KNgPVLnU7Ce3VWJ3MO4rKjvLO2by1lR8nOwGvOjrNwV8sN8wFJDeOwzIwWQdGAouFj1GbxQY1WKGJY1UdcZNZ8fiG5mlZmlYAejYribNpJ5G3z9uPmp8+2CJso2T3zRcDr73ULGeHdNJKz+oPSoILq3kVRbsXZe7npXIC8YwhI0aT1Bpj3TLKNqgL3x2ouB2eo39zHbhRNGmeOG5qsZY4rLL3HzMOqnJNc8qwT4eSXAHbNV9QvYQAquVRfai4DdSFiz77uWaQ9lFVBcWafNCmz0HeqzXKO5JViPXFNeWIL8gGT3NIYt3K0nzkjaOgzVJ90vIXAHeoZZGkcgH6Yo+0Oq7C34UgHM7SnYKglDQnkZ+tN807s7qWWfzFGfzoGN+YDPJP0prx7+eh9Kazvg7W496jBI/iz70APAAOHPNKi5bpgVGcZ+Y80oYkZ5xQAwMhODU3kgjgiqYGG5INSLKR+FICwCVG04xSxuQcAAiomcMAeoNIJBG3yimBeaUsAp61ft0LKDICR61kiUsAw/Kp7eWdjs37RQBupI8ZUo+FHbNdLZ3rzwLvkjYehHNcTE5iyJsOOxFSwXGJMRqQPrTuI9It9ee1TyY4iWxwe1Qrq1/PdL5K5bPIrkEuZgnDHNaenybSGSYiTvk4piPRrLWJrSMfayCpHKmt7T7/T7q3LCEq3rivNk2XKr9puGfbzjNX11O3t4vKgkYMOMGmB2V85VCUAC+9Lp89pHg3MTsT3NcxDqZjtlebE3+yTWpp2qyTlP9ECx9yfSgC3qcdrJLutAEz1DUnlyR24ViFj7nvWnNa2l/BsiuQkn0xis6SwjjHlC5MjjqR0oAjt7XS0QyK8jyHrvNQy2gl5icKmenFWodG8oNI1yhDc7W4qrqdrI8W2JWPulAFXVLS0a3xLcsn+7XPW0P2OWRYZjsIzvda1zMLMp59tJIB1yM1ppqOl36CN7Qqw6qeKAORtmbzpHF5Kx7c8VcjurhkUSyMVJ4cNjH1rdfRtHjyyCSMv23dKiTQIUwIp98Z/hJzmgCg9xsiAa6Qse4NYOpXl/DdqsdxsQ985/Ste60a7iuNqorQ9Rk1SuNJuPOLY49etIBq3d/HHv8xZRjq2ADTBqkBiLyI3n/wCz0qA3DWm5JoTOg654xQ1xFOyiKJYlbsOcGgC/ZXq+SWeQxsegYCqFzdXH2ogzqy9s07UtMleNF8zcTyMDmqsemmPlmUlefmPNADP7QuZJHt2Jz29KrfvIJGDxksf4smr0E7WzmQrFj/aqxLeJdKGkkiK/3VoAq2u+IiSWRcegbJovb95CRbgr79avT6bBPbGdXVHA4CGsGRpLdtzZ47UAOe1u7kCUo+//AHetV7mOSAhpYiDjritSx1tHA84OuOy96uXOqaf5BYo288fvOaBmNZapqXlMkLttHQdqpXVy9yQrqEfPLHrXS6FqOnwSOLiNpA3QKvFNvbfSrkyukW0npk80AcnLHGmAhLSd8VNBPGikyRlv9nFXkTTrQl3L5H8I71VkuYJZQbaIKB3JzSAZIBI29I2T2FMkuplIUMdvuM1Ykkb72SR7dKYySMo8oFiaAEiiIiZxc7SewqBArbllmz9Kik0+7mmxhgKJEltj5aYLDqQKAFCMhzkovb3qjeOZHC5K81JNJLOdrsQBULW4jG99231oAsRQExEGTIqjMRG+N24j1qXzPOwsRZfTNTppUu4FpE3H1pAZjzMDwoHfNRswkBY5XFbl1p8SRbnkG4dlrLEab9ucigZntgjIJpyFQPvZNTXURB/djj0qttGMcbvSkBI7ZXtimZBwetRHIJAqQDjk80AOxhs5pwfjHQGow3978qRm3dKAE285obH40zeSOOtNBYnnJNAEmCR8o6U+NWY9MCkjfaMGpM5GVJz6UASJE6HgjHpUyb1PTIqqpYt1PHY1Kbgg4U4pgXrUqz9efRqssQG7KfasoSNjJPPrVmBy45OGHegRpQ3Dp1JxVyzRppRI54FZdpeGOXEuGWpXuWeTNq2D6UwOhS6jSb5yTj0q6dUXZ+5jXI/vCuUka4+VgcP3xV+3uXQD7SmSe4oA1WvLmdg0C7T+YrRs9avcCCQbm6fL1FYEUqrISrlfTmmfbZ7e88xwSg70AejwTRpbgzTsrdea0NJuraRyQ4X1561wFprgkc+Yu4MOBUttJcLIZYxj2NO4j1RYbadCWmBQf7VVGu/JkKwzK8Y/hrgLm6n+ziRTj+8FarmjXgEW4yHf6MaYHXvdrK4XZ8h6HFU7+xkhBmWMk9Q2Kh0m5neZidix56Eda6Brq3UZnnCoR0BzQBzNkPOUtcyfhU88y2RVoJP+A4rTitNJuJy3muB6CoNct9PkhaO3kYMB1oAqPqZltz5xUEdDWYdWuIFOYYypP3s5NY5t5xP9mZsxN0I5zTW06e3VnLFQOmTxQBvq8N5GZJIVB75wM1bsra0kXcqxDHoozXDX19cQ7IwwfPoasWOt3tmvywExd+OaQHWPDEXdpN5A6DFc/qyzM+2DCnvkU1deN0hMpZeeF9KlS4SXaRNkdz2oAyZbNlQ7wH4ycistba1jZnWSTd6Y4rX1TVRHN5cLgg8Fqx57iOLIj2ySHrSGaWnQy3D/ALqV1UdhVPV/Phn8vY/zfxMKt6VrjW0GPswLE4qW/wBRlucKsClj3I6UxDdG0J5Aslxcom48cZxXTx6To1uAby4WVz/e4rlnubuG14K8dsVlrrUbyn7ehZx0x0oGegrDpcknl2yKAf4qivrDS7OAkspJ6nNcA2tZckIyx+gOKBqFtNG2+Z1bsDzRcVjsBYaTe2pjgiO/+9VY6VaWsflqFLE+lcvY6lcQsRasST61d/tCSNWedmMp9D0oAuLEPtRhfYsQPpzT5rmOJikMOQOwPWspLzOXc5H5moLu9U4NtEQfWgZffViGKTRtEPTFVQ6SB5lBVO5PU1BILiZFMw5PbvUUttJHbNuk2j+7mkBG91HIxEKDPqaq3Ehf5FOT6CoiGKlUTDetNiDxEhgNx70gEyqH5h831pss+fm8w5HvVe5A3ZD5NIoUrhhn6UAPWdpG+/mpVXbyBmoFEangc0wzuCQKBkkvmHO5gBVGRecDqe9TSSt/FUJc9xSARRsye9IdxxnpSb/mPHNKrDoaAE6sc4oU4PPSlHzHBFNlB6AYoAjJx1p4Yr0phALc07K+v4UASfMeSPyp6ygHsM0xT8vvTWVs5IyPWgCdZNr/ADcg96HAJyvJpsa4xk1MyrjI6+tADFMiD51ytOVt5+UkCjzZOg6e9IWJXlce4oAfG+1+nFW4mAkyDVRDGY+Sc0IhZss2BTA0xfGFwVUE1KdTlkcFkHHtWUhxJgsCBVjzBn0FAGlHcecuCuG7GpFuZghjZGcdjVJCFUNGG3U1rqZeXYgHtTEaEF75Jy6gnscVq2mpROhWSSQN2x0rnFdXTPOamM7NCEAAP0oA2W1URbo9hYN3HWmQXSLNvYufqcYrPRlihyfv+tU/OaSXAOSfWgDrY9XkkIAldYx6NV+2vkkmQGUg+rtXN6bPBATHOpLe3SpLrUI43AjjU49aLgdlJqbIDh/kxy4GKh0u+t285zLK5PWubju7i8gyNsae/Sqa6lNbhkEifh3p3FY7Y3tjECS+X7Fj0rH1S4aRWkFwMH+HPFc5/aBuCUkhUe4qrPOkbqrZAHY0rjNmyWS9lOFUYGN1WR59o20zK4/ug1lWd1EMMpIPcjpUdzPFLKTHIc+tAF2a+lEhRoF2n+IVGZNgO4tg9s1BHPBGAGJY+tMmlEjHy1xigCykkbEpuAXrk8mlEKYBiUlj0JFUoFHVh83pVk3KvhFUpjqSaALNsstvIEdgM+2asXLXMPzKQg9TUdisLSjzmMje1XNSS0n2hZGQAcg0Ac7PeTNIRI5fPpSRzxREGSEO3qwresodKjGHYPL60y8tbeeQCEFj6L0oA525jebLhAE9AarNCpI+Uitq+tZIWCGM+2Bms8/aRI22A5HTcKAK0PnW7F42OKf5lzMcxliO+TS3BnUDeoz6YpsMpL8rtHekBeSMRw7mk2k9R61NaXsKHbJGMetUHuYnypTJ9c1CgjBzuyaYHQSX9uFPlxnPY1kTThnLSgn0qnM6YwrNn603LCIncrD0oAsJeKHLFBjtTlImcsRgGqEXznIAHtUskjKuAQKQWHXdvCin5ssapqGiU89aGlGck5NRvNk4HJoGJ8p5bNIJgpwq8e9LvwOfmqu5LcgUgJphuAJwKqlsMRjiiSQkYfI+lB+57UAClc9KV1bGRTQemKfhscdKAGjjknmh+B9abyDk0Fc8FqAGAY6UqqMk96KKAAMTSq7FsE8UUUAWEOFqVRwaKKAGMvfJzSknYB2oooAVeGHFWIEV3+YUUUwFeBFuABmpZlGcc4FFFAhqTPGnysaQMZTmQ5NFFADy5VSAeKZakuzFiTiiigZJISASCc0iZIDZOaKKALG9ldSDzTLonh8nJoooEaen3Dm02HG2qFx/ryO1FFMCxayFImIAz71QnuJJZjvI/KiigCOCeRWZQ3y+lR3Urh1AYgUUUhk63EjpsbGB7VbgX5M7mz9aKKBG7pVvG1v5jAls9SaS5t4w7MB17UUUwKNjK0M5aM4NLfXEkzEu35cUUUAUrJi0/wA3OO1bun3cqyNtwAO2KKKAJLm/mSXcpXPuKdDcySbnfazH1FFFAFRUVpWLKCfesvVUCyfLxn0oooAgMaiLgdqqxqBk80UUgIbvpmq0TsTgk4oooGPckZwSPpTicxZPWiikBHgFaURqcdaKKYCzfKuB0p0camLJFFFAFV+C3FQIxccmiikBIg5FSseKKKAIm46UxTk0UUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A longitudinal image of the left thyroid lobe that shows a 2.76 X 1.65 cm isoechoic nodule (+ --- + &amp; X --- X). A thin halo (arrows) is evident. A 10.0 MHz transducer was used.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31809=[""].join("\n");
var outline_f31_4_31809=null;
var title_f31_4_31810="Verrucous lesion in blasto";
var content_f31_4_31810=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F71630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F71630&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Disseminated blastomycosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 227px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Verrucous plaque on the upper cheek due to disseminated blastomycosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Charles V Sanders, MD.",
"     <br>",
"      Reproduced with permission from The Skin and Infection: A Color Atlas and Text. Sanders, CV, Nesbitt, LT Jr (Eds) Williams and Wilkins, Baltimore 1995. p.174.",
"     </br>",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31810=[""].join("\n");
var outline_f31_4_31810=null;
var title_f31_4_31811="Periungual squamous cell carcinoma";
var content_f31_4_31811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F65527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F65527&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Periungual squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 379px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An ulcerated papule is present on the periungual skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31811=[""].join("\n");
var outline_f31_4_31811=null;
var title_f31_4_31812="Extrahepatic manifestations of autoimmune hepatitis";
var content_f31_4_31812=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Extrahepatic manifestations of autoimmune hepatitis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31812/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31812/contributors\">",
"     Edward L Krawitt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31812/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31812/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31812/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31812/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/4/31812/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 20, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoimmune hepatitis (AIH) is a chronic hepatitis of unknown etiology characterized by immunologic and autoimmunologic features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=see_link\">",
"     \"Clinical manifestations and diagnosis of autoimmune hepatitis\"",
"    </a>",
"    .) In the spectrum of autoimmune disease, classified from organ-specific to non-organ-specific, autoimmune liver diseases fall somewhere in the middle. The diseases are usually confined to the liver but can be associated with a number of other autoimmune diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EXTRAHEPATIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several extrahepatic disorders associated with AIH have been described (",
"    <a class=\"graphic graphic_table graphicRef59606 \" href=\"mobipreview.htm?39/63/40955\">",
"     table 1",
"    </a>",
"    ). Concurrent immunologic diseases are more common with AIH than with viral hepatitis. One prospective study, for example, found that concurrent immunologic disease was present in 38 percent of 122 patients with AIH compared to 22 percent of 63 patients with chronic viral hepatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/1\">",
"     1",
"    </a>",
"    ]. The nature of the extrahepatic diseases was the same in both groups.",
"   </p>",
"   <p>",
"    The associated diseases may antedate the appearance of AIH or occur after the diagnosis of the liver disease is established. The clinical expression of the associated disease can be extremely variable and at times may even be occult and unrecognized unless specifically sought (such as measurement of antiendomysial antibodies to detect celiac disease or routine proctosigmoidoscopy for the detection of ulcerative colitis).",
"   </p>",
"   <p>",
"    Extrahepatic disorders are seen in both type 1 and type 2 AIH (",
"    <a class=\"graphic graphic_table graphicRef65135 \" href=\"mobipreview.htm?8/0/8203\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=see_link\">",
"     \"Classification of autoimmune hepatitis\"",
"    </a>",
"    .) Associated diseases are seen in both types of AIH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antiendomysial antibodies, anti-gluten antibodies and anti-tissue transglutaminase antibodies reflect the co-existence of celiac disease in AIH and other autoimmune liver diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. The prevalence of celiac disease in AIH may be as high as 10 percent. Because liver transglutaminase levels may be elevated in patients with liver disease, it has been hypothesized that circulating anti-tissue transglutaminase levels may merely reflect liver damage; more likely they reflect the co-existence of celiac sprue and AIH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Type 1 AIH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common extrahepatic disorders associated with type 1 AIH are thyroiditis, Graves' disease, ulcerative colitis and rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/1\">",
"     1",
"    </a>",
"    ]. Ulcerative colitis is more typically associated with primary sclerosing cholangitis but can be seen in AIH without any features of cholangitis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=see_link\">",
"     \"Epidemiology and pathogenesis of primary sclerosing cholangitis\"",
"    </a>",
"    .) In one study of 105 patients with AIH who had been screened by annual proctosigmoidoscopic examination, 17 (16 percent) had findings of chronic ulcerative colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/9\">",
"     9",
"    </a>",
"    ]. Twelve underwent cholangiography, five of whom had features of primary sclerosing cholangitis.",
"   </p>",
"   <p>",
"    Other conditions which have been described include uveitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/10\">",
"     10",
"    </a>",
"    ], celiac disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/6\">",
"     6",
"    </a>",
"    ], pernicious anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/11\">",
"     11",
"    </a>",
"    ], Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/11-13\">",
"     11-13",
"    </a>",
"    ], mixed connective tissue disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], Weber-Christian panniculitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/17\">",
"     17",
"    </a>",
"    ] and CREST syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/18\">",
"     18",
"    </a>",
"    ]. There are also isolated associations with nonimmunologic diseases, including thrombotic thrombocytopenic purpura [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/11\">",
"     11",
"    </a>",
"    ] and sickle cell disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A survey of AIH in the elderly in the United Kingdom found no significant differences in the prevalence of concurrent immunologic disorders comparing patients &lt;60 years with those &gt;60 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Type 2 AIH",
"    </span>",
"    &nbsp;&mdash;&nbsp;In an early study of 65 patients with type 2 AIH, 22 had an associated autoimmune disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/22\">",
"     22",
"    </a>",
"    ]. The most common were type 1 diabetes mellitus, autoimmune thyroid disease, and vitiligo. More recent studies also show a variety of associated autoimmune diseases in Type 2 disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Type 2 AIH has also been associated with a syndrome of vitiligo, nail dystrophy, and alopecia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/23\">",
"     23",
"    </a>",
"    ], and with autoimmune polyglandular syndrome type I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/24\">",
"     24",
"    </a>",
"    ]. Liver disease has been described in approximately 10 percent of patients with the latter disorder, which is an autosomal recessive disease characterized by hypoparathyroidism, candidiasis, adrenal insufficiency, and gonadal failure (",
"    <a class=\"graphic graphic_table graphicRef67520 \" href=\"mobipreview.htm?9/25/9629\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=see_link\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"    </a>",
"    .) Anti-liver-kidney microsomal antibodies have been described in patients with autoimmune polyglandular syndrome type I and liver disease, and the hepatic autoantigens have been identified as the cytochrome P450 enzymes CYP2A6 and CYP1A2 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/24\">",
"     24",
"    </a>",
"    ]. These differ from CYP2D6, the typical target for anti-LKM-1 in type 2 AIH. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42902?source=see_link\">",
"     \"Serologic markers of autoimmune hepatitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Type 2 AIH has also been reported in a patient with a genetically determined defect in immune tolerance associated with an autoimmune lymphoproliferative syndrome due to mutations of the",
"    <span class=\"nowrap\">",
"     Fas/Apo1/CD95",
"    </span>",
"    gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     GENETIC RELATIONSHIPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several observations have suggested a genetic influence on the relationship between AIH and other autoimmune conditions. In the original study defining type 2 AIH, 22 of 65 patients had other autoimmune diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/22\">",
"     22",
"    </a>",
"    ]. The same autoimmune diseases were present in first-degree relatives from seven of the families. Similarly, in a study of type 1 and type 2 AIH in children, autoimmune disorders were found in approximately 40 percent of first-degree relatives [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The tendency to extrahepatic disorders may be associated with HLA-DR4. In a series of 122 patients with type 1 AIH, HLA-DR4 was more common in those with extrahepatic immunologic disease (62 versus 33 percent in those without extrahepatic disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/1\">",
"     1",
"    </a>",
"    ]. A similar relationship was noted between HLA-DR4 and extrahepatic disease in patients with chronic viral hepatitis. A study from Brazil, where HLA associations differ from those in Europe and North America, showed no genetic predisposition to concurrent autoimmune diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31812/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the other hand, the association of type 1 AIH with ulcerative colitis shows that simple HLA associations are insufficient to explain these findings. HLA alleles that seem to confer susceptibility to autoimmune hepatitis may be associated with resistance to ulcerative colitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several extrahepatic disorders associated with AIH have been described (",
"      <a class=\"graphic graphic_table graphicRef59606 \" href=\"mobipreview.htm?39/63/40955\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Extrahepatic disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common extrahepatic disorders associated with type 1 AIH are thyroiditis, Graves' disease, ulcerative colitis, and rheumatoid arthritis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Type 1 AIH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common extrahepatic disorders associated with type 2 AIH are diabetes mellitus, autoimmune thyroid disease, and vitiligo. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Type 2 AIH'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The associated diseases may antedate the appearance of AIH or occur after the diagnosis of the liver disease is established.",
"     </li>",
"     <li>",
"      The clinical expression of the associated disease can be extremely variable and at times may even be occult and unrecognized unless specifically sought.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/1\">",
"      Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Genetic predispositions for the immunological features of chronic active hepatitis. Hepatology 1993; 18:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/2\">",
"      Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/3\">",
"      Bittencourt PL, Farias AQ, Porta G, et al. Frequency of concurrent autoimmune disorders in patients with autoimmune hepatitis: effect of age, gender, and genetic background. J Clin Gastroenterol 2008; 42:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/4\">",
"      Muratori P, Grnito A, Quarneto C, et al. Autoimmune hepatitis in Italy: The Bologna experience. J Hepatology 2009; 52:1210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/5\">",
"      Teufel A, Weinmann A, Kahaly GJ, et al. Concurrent autoimmune diseases in patients with autoimmune hepatitis. J Clin Gastroenterol 2010; 44:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/6\">",
"      Abdo A, Meddings J, Swain M. Liver abnormalities in celiac disease. Clin Gastroenterol Hepatol 2004; 2:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/7\">",
"      Caprai S, Vajro P, Ventura A, et al. Autoimmune liver disease associated with celiac disease in childhood: a multicenter study. Clin Gastroenterol Hepatol 2008; 6:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/8\">",
"      Rubio-Tapia A, Abdulkarim AS, Wiesner RH, et al. Celiac disease autoantibodies in severe autoimmune liver disease and the effect of liver transplantation. Liver Int 2008; 28:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/9\">",
"      Perdigoto R, Carpenter HA, Czaja AJ. Frequency and significance of chronic ulcerative colitis in severe corticosteroid-treated autoimmune hepatitis. J Hepatol 1992; 14:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/10\">",
"      Bloom JN, Rabinowicz IM, Shulman ST. Uveitis complicating autoimmune chronic active hepatitis. Am J Dis Child 1983; 137:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/11\">",
"      Czaja AJ, Davis GL, Ludwig J, et al. Autoimmune features as determinants of prognosis in steroid-treated chronic active hepatitis of uncertain etiology. Gastroenterology 1983; 85:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/12\">",
"      Biasi D, Caramasch P, Carletto A, et al. Sj&ouml;gren's syndrome associated with autoimmune hepatitis. A case report. Clin Rheumatol 1997; 16:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/13\">",
"      Ecoiffier EB, Tubery M, Adoue D, et al. [Systemic manifestations of primary Gougerot-Sj&ouml;gren syndrome. Nature and incidence apropos of 34 cases]. Presse Med 1997; 26:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/14\">",
"      Tomsic M, Ferlan-Marolt V, Kveder T, et al. Mixed connective tissue disease associated with autoimmune hepatitis and thyroiditis. Ann Rheum Dis 1992; 51:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/15\">",
"      Wada T, Motoo Y, Ohmizo R, et al. Association of mixed connective tissue disease, Sj&ouml;gren's syndrome and autoimmune hepatitis: report of a case. Jpn J Med 1991; 30:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/16\">",
"      Maeda M, Kanayama M, Hasumura Y, et al. Case of mixed connective tissue disease associated with autoimmune hepatitis. Dig Dis Sci 1988; 33:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/17\">",
"      Allen-Mersh TG. Weber-Christian panniculitis and auto-immune disease: a case report. J Clin Pathol 1976; 29:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/18\">",
"      Ishikawa M, Okada J, Shibuya A, Kondo H. CRST syndrome (calcinosis cutis, Raynaud's phenomenon, sclerodactyly, and telangiectasia) associated with autoimmune hepatitis. Intern Med 1995; 34:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/19\">",
"      Chuang E, Ruchelli E, Mulberg AE. Autoimmune liver disease and sickle cell anemia in children: a report of three cases. J Pediatr Hematol Oncol 1997; 19:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/20\">",
"      el Younis CM, Min AD, Fiel MI, et al. Autoimmune hepatitis in a patient with sickle cell disease. Am J Gastroenterol 1996; 91:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/21\">",
"      Al-Chalabi T, Boccato S, Portmann BC, et al. Autoimmune hepatitis (AIH) in the elderly: a systematic retrospective analysis of a large group of consecutive patients with definite AIH followed at a tertiary referral centre. J Hepatol 2006; 45:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/22\">",
"      Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of \"autoimmune\" hepatitis. Hepatology 1987; 7:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/23\">",
"      Sacher M, Bl&uuml;mel P, Thaler H, Manns M. Chronic active hepatitis associated with vitiligo, nail dystrophy, alopecia and a new variant of LKM antibodies. J Hepatol 1990; 10:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/24\">",
"      Clemente MG, Meloni A, Obermayer-Straub P, et al. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology 1998; 114:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/25\">",
"      Pensati L, Costanzo A, Ianni A, et al. Fas/Apo1 mutations and autoimmune lymphoproliferative syndrome in a patient with type 2 autoimmune hepatitis. Gastroenterology 1997; 113:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31812/abstract/26\">",
"      Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997; 25:541.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3678 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-60.18.131.125-6AD27EA953-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31812=[""].join("\n");
var outline_f31_4_31812=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EXTRAHEPATIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Type 1 AIH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Type 2 AIH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      GENETIC RELATIONSHIPS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3678\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3678|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/63/40955\" title=\"table 1\">",
"      Extrahepatic symptoms in AIH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/0/8203\" title=\"table 2\">",
"      Classif autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/25/9629\" title=\"table 3\">",
"      Polyglandular autoimmune syndromes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/32/27140?source=related_link\">",
"      Classification of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/44/35528?source=related_link\">",
"      Clinical manifestations and diagnosis of autoimmune hepatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/32/35334?source=related_link\">",
"      Epidemiology and pathogenesis of primary sclerosing cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/57/42902?source=related_link\">",
"      Serologic markers of autoimmune hepatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_4_31813="Vemurafenib: Patient drug information";
var content_f31_4_31813=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vemurafenib: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=see_link\">",
"     see \"Vemurafenib: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13187339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Zelboraf&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13864012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Zelboraf&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F13203883\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13203888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin cancer.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13203877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516727",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vemurafenib or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13203879\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516748",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an ECG checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697788",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, and tanning beds. Use sunscreen and wear clothing and eyewear that protects you from the sun.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697828",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust during care and for 2 months after care ends.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697022",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are a man and have sex, protect your partner from pregnancy. Use birth control that you can trust.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13203959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698113",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698195",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Joint pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698191",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Itching.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699092",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in the feet or hands.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698276",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698306",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry skin.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13203881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699078",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin wound that will not heal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516753",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color or size of a mole.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any skin change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699087",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13203958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A tumor sample test will be done to see if you can take this drug. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695912",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Always take with food or always take on an empty stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695712",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swallow whole. Do not chew or crush.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F13203878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it has been 8 hours or more since the missed dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13203960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13203882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16799 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-199.231.185.123-90A40F4040-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31813=[""].join("\n");
var outline_f31_4_31813=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13187339\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13864012\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203883\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203888\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203877\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203879\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203959\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203881\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203958\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203878\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203960\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203882\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?16/48/17159?source=related_link\">",
"      Vemurafenib: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_4_31814="Ultrasound-guided thyroid biopsy";
var content_f31_4_31814=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ultrasound-guided thyroid biopsy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31814/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31814/contributors\">",
"     Manfred Blum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31814/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31814/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31814/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31814/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/4/31814/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H630451\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-resolution ultrasonography provides a detailed map of thyroid nodules and helps to characterize the nodules and adjacent structures in the neck. Thyroid ultrasound, in conjunction with fine needle aspiration (FNA) biopsy, plays an important role in the evaluation of a patient with a suspected thyroid nodule. The use of ultrasound-guided thyroid biopsy is reviewed here. Other clinical uses of thyroid ultrasonography and an overview of thyroid biopsy, including palpation-guided techniques, limitations, and complications, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21482?source=see_link\">",
"     \"Overview of the clinical utility of ultrasonography in thyroid disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=see_link\">",
"     \"Thyroid biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H630736\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid ultrasound should be performed in all patients with a suspected thyroid nodule or nodular goiter on physical examination or with nodules incidentally noted on other imaging studies (carotid ultrasound, CT, MRI, or FDG-PET scan). There is increasing evidence that the presence of suspicious ultrasound features is more predictive of malignancy than nodule size alone. The decision to biopsy a thyroid nodule should be based upon a combination of ultrasonographic features and nodule size. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H2#H2\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H11#H11\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27370272\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ULTRASOUND-GUIDED FNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle aspiration (FNA) biopsy is the procedure of choice for evaluating thyroid nodules and selecting candidates for surgery. If the presence of a thyroid nodule and indication for FNA is confirmed by diagnostic ultrasound, and the nodule corresponds to what is palpated on physical examination, FNA can be performed directly without ultrasound guidance. However, ultrasound guidance is sometimes preferred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Compared with palpation-guided FNA, the use of ultrasound improves the cytologic diagnostic accuracy rate and reduces the nondiagnostic rate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/3-7\">",
"     3-7",
"    </a>",
"    ]. In a retrospective evaluation of 9683 patients with thyroid nodules, 4986 and 4697 patients were evaluated by palpation and ultrasound-guided FNA, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/3\">",
"     3",
"    </a>",
"    ]. The nondiagnostic rate was significantly higher after palpation-guided FNA (14.1 versus 8.5 percent). Over a 15-year period, over 1000 nodules were resected because of suspicious or malignant cytology on palpation or ultrasound-guided FNA. The false negative rate was higher in nodules that were biopsied via palpation rather than ultrasound (2.3 versus 1 percent).",
"   </p>",
"   <p>",
"    When available, we suggest ultrasound-guided FNA for the majority of nodules. Ultrasound-guided FNA is essential for those nodules that are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nonpalpable or difficult to palpate",
"     </li>",
"     <li>",
"      Predominantly cystic",
"     </li>",
"     <li>",
"      Nondiagnostic after palpation-guided FNA",
"     </li>",
"     <li>",
"      Small and located in close proximity to blood vessels",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, we typically use ultrasound to guide FNA in an area in a goiter that is different from the rest of the goiter (ie, firmer, painful, tender, growing, or has suspicious ultrasonographic characteristics) for assessment of recurrent thyroid cancer and for nonpalpable lymphadenopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonpalpable or difficult to palpate nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpalpable thyroid nodules that are noted as an incidental finding during a radiologic procedure, such as carotid ultrasonography, neck computed tomography (CT), or positron emission tomography (PET) scanning, are called incidentalomas. These nonpalpable nodules have the same risk of malignancy as palpable nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/2,8,9\">",
"     2,8,9",
"    </a>",
"    ]. In some settings, especially nodules discovered on PET scan, the risk of malignancy may be higher (30 to 50 percent), but in other settings (cystic nodules), it may be lower. The initial evaluation of an incidentally discovered nodule should include a dedicated thyroid ultrasound to confirm the presence of nodularity, assess sonographic features, and determine the need for FNA. If FNA is indicated, it must be performed using ultrasound guidance.",
"   </p>",
"   <p>",
"    In some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/8,10,11\">",
"     8,10,11",
"    </a>",
"    ] but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/12,13\">",
"     12,13",
"    </a>",
"    ] reports, the success of ultrasound-guided cytological diagnosis of non-palpable nodules depends on the size of the lesion. As an example, in one study of 1440 nodules &le;10 mm in size, the likelihood of obtaining adequate material for cytological analysis was significantly better with nodules &gt;6 mm compared with 2 to 6 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/11\">",
"     11",
"    </a>",
"    ]. For nodules measuring &gt;6 mm, the sensitivity and specificity of ultrasound-guided FNA were 91.1 and 98.5 percent, respectively. In contrast, a study of aspirates from 317 nodules in 267 patients reported that the size of nonpalpable nodules (mean 0.9",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    0.3 cm, with a range of 0.2 cm to 1.5 cm) was not related to the probability of getting an adequate specimen for cytological diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/12\">",
"     12",
"    </a>",
"    ]. Another group also reported comparable success in aspirating nodules that were 4 to 10 mm in size compared with larger nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We generally do not routinely aspirate nodules smaller than 10 mm. In patients without risk factors for thyroid cancer or suspicious ultrasound findings, we perform periodic ultrasonography (initially at 6 to 12 months, then at increasing intervals over time, assuming stability) to monitor for growth. However, in selected, higher than average cancer-risk patients, we have had limited diagnostic success in sampling incidentalomas as small as 5 mm and greater than 70 percent success with nodules at least 8 to 10 mm. Indications for FNA and the monitoring of small nodules that are not biopsied are reviewed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H10#H10\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Fine needle aspiration biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H630788\">",
"    <span class=\"h2\">",
"     Cystic nodules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mixed solid and cystic (complex) nodules offer a cytological diagnostic challenge. The diagnostic accuracy of FNA performed by palpation is reduced in nodules with &gt;25 to 50 percent cystic component [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. When ultrasonography shows a solid component that is either small or posteriorly located, ultrasound-guided fine needle aspiration directed at the solid component or the cyst wall may reduce the risk of a nondiagnostic result. In general, pure cysts should not be aspirated unless it is to alleviate compressive symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/16\">",
"     16",
"    </a>",
"    ]. Purely cystic lesions rarely contain cancer, but the likelihood of cancer in complex (cystic and solid) nodules approaches that of solid nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/17\">",
"     17",
"    </a>",
"    ]. The evaluation and management of cystic thyroid nodules is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37111?source=see_link\">",
"     \"Cystic thyroid nodules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Non-diagnostic aspirates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 15 to 20 percent of percutaneous thyroid biopsies are insufficient or nondiagnostic. The highest frequency of nondiagnostic cytology results occurs in cystic nodules and in very small nonpalpable nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/14,18\">",
"     14,18",
"    </a>",
"    ]. The diagnostic yield of sampling palpable nodules is enhanced when ultrasound-guidance is employed, especially when a prior aspiration was unsuccessful because the nodule had undergone cystic deterioration. If ultrasound-guided FNA is nondiagnostic, a repeat ultrasound-guided FNA will yield a diagnostic cytology specimen in 75 percent of solid nodules and 50 percent of cystic nodules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link&amp;anchor=H30#H30\">",
"     \"Diagnostic approach to and treatment of thyroid nodules\", section on 'Nondiagnostic'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Lymphadenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytological, immunocytological, and biochemical diagnosis of lymphadenopathy is facilitated by ultrasound-guided aspiration biopsy, in particular when the nodes are not palpable or are close to the jugular vein or carotid artery. Combined cytological and biochemical analysis of enlarged cervical lymph nodes can differentiate accurately between thyroid cancer metastases and inflammatory lymphadenopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/19\">",
"     19",
"    </a>",
"    ]. The presence of high levels of thyroglobulin in needle-washings of aspirates of lymph nodes is presumptive evidence of metastatic thyroid cancer despite negative cytology, and serum anti-thyroglobulin antibodies do not adversely affect tissue thyroglobulin measurements [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37496?source=see_link\">",
"     \"Serum thyroglobulin in the management of differentiated thyroid cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Recurrent thyroid cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;When nodules in the thyroid bed or lymphadenopathy are of adequate size, ultrasound-guided biopsy can usually identify recurrent thyroid cancer correctly. In one retrospective study of 37 treated thyroid cancer patients, ultrasound-guided fine needle aspiration produced 29 true-positives, six true-negatives, one false-negative, and one inadequate biopsy, with a sensitivity of 96.7 percent, a specificity of 100 percent, and an overall accuracy of 97.2 percent in detecting return of tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/21\">",
"     21",
"    </a>",
"    ]. One potential diagnostic pitfall of biopsy may be cytological misdiagnosis. Examples include identifying normal residual thyroid or parathyroid gland as recurrent tumor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/22\">",
"     22",
"    </a>",
"    ]. When assessing the post-operative thyroid bed, careful attention to cytological details and the use of selected immunohistochemical staining may help to prevent these errors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of differentiated thyroid cancer\", section on 'Management of recurrent disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Non-cytological examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to cytology, ultrasound-guided tissue sampling can provide cells for biochemical analysis like calcitonin in medullary cancer, tumor markers such as Galectin-3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/23\">",
"     23",
"    </a>",
"    ] in papillary thyroid cancer, chromosomal and genetic information [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/24\">",
"     24",
"    </a>",
"    ], or can lead to a non-neoplastic diagnosis such as tuberculosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/25\">",
"     25",
"    </a>",
"    ] or amyloidosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As mentioned above, biochemical analysis of aspirated fluid or needle-washings may reveal thyroglobulin when a lymph node is involved with thyroid cancer, even when cancer cells are not detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/20,27\">",
"     20,27",
"    </a>",
"    ]. It is noteworthy that any thyroid cells in an aspirate from a lymph node, even if the cells look benign, are presumptive evidence of thyroid cancer metastases because thyroid cells do not typically belong in a lymph node. Furthermore, a non-thyroid diagnosis, such as a parathyroid cyst, is possible when cyst fluid that is as clear and colorless as water is aspirated. Biochemical assay of the fluid will demonstrate a high concentration of intact parathyroid hormone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TECHNIQUE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Samples of thyroid tissue may be obtained percutaneously with a narrow-gauge needle, such as 25- or 27-gauge, to obtain cells for cytological analysis, or rarely, with a cutting needle to obtain a core of tissue for histopathological study. FNA has largely replaced core needle biopsies at most centers. The fine needle technique is popular because it is low risk and cytology provides diagnostic information about nuclear and cytoplasmic detail that is not available with a core biopsy. Some clinicians prefer to do cutting needle biopsies, which provide only a single core of tissue for histopathology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/28\">",
"     28",
"    </a>",
"    ]. Core biopsy is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=see_link&amp;anchor=H7#H7\">",
"     \"Thyroid biopsy\", section on 'Other techniques'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The technique for ultrasound-guided fine needle thyroid biopsy involves three steps: puncture of the nodule or goiter, obtaining the sample, and preparation of the slides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Puncturing the nodule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The simplest and most frequently used but not the most accurate method for ultrasound-assisted tissue sampling for palpable nodules is to locate the lesion on the film or screen, taking note of the location of solid or cystic components of the nodule in relation to palpable or visual landmarks. The operator then punctures the proper site to sample solid tissue. This approach to biopsy often does not yield diagnostic material when there is an extensive cystic, degenerated space within a nodule.",
"   </p>",
"   <p>",
"    If this simple approach is not possible, has not been successful, or the specimen is too bloody for interpretation, real-time ultrasonography may be used to observe the insertion of a needle free-hand or using a special needle guide attached to the transducer. The free-hand technique offers greater flexibility. With the free-hand method, the needle is inserted into the skin at a distance from the transducer, aiming at the palpated nodule. For nonpalpable nodules we use a blunt 1 mm dowel to produce a dimple in the skin over the nodule that was identified by the sonogram. We prefer this technique rather than using a permanent marker to establish a point for entry, as described in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The needle trajectory can either be parallel to or at an angle to the ultrasound beam. The parallel approach is technically challenging, and special attention must be paid to sterility, but it has the advantage that the image of the needle shaft may be viewed as it traverses the neck into the nodule. The needle path is observed on the screen in more than one plane, while the operator maneuvers the needle to puncture the nodule. Many experienced operators prefer the simplicity, speed, and lack of complications that result when the needle is inserted oblique or perpendicular to the ultrasound beam. In this case, the needle tip is seen when it crosses the plane of the ultrasound as a very bright spot. With either method, the position of the needle tip within the nodule must be verified at the instant of sampling. It is essential when interpreting negative results to be mindful that it is difficult to be certain that the tip of the needle actually was within the nodule at the instant of sampling, especially for nodules less than 10 mm in diameter.",
"   </p>",
"   <p>",
"    Transducers fitted with a needle guide are preferred by some clinicians, but are cumbersome and require considerable practice and hand-eye coordination, unless a dedicated sonographer is assisting with the procedure.",
"   </p>",
"   <p>",
"    Doppler ultrasound can be used to identify and avoid puncturing blood vessels that are encountered in the process of biopsy, thereby improving the specimen and cytological interpretation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/30\">",
"     30",
"    </a>",
"    ]. This feature is a distinct advantage over palpation-guided biopsy.",
"   </p>",
"   <p>",
"    As noted above, it is important to avoid a bloody specimen because of the potential dangers of hemorrhage, and because blood obscures the cytology and may result in a non-diagnostic aspirate. There is limited data on the safety of thyroid FNA in patients on systemic anticoagulation. Medications that can be safely discontinued (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , nonsteroidal antiinflammatory drugs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) should be stopped five to seven days before the FNA procedure. The risk of stopping systemic anticoagulation before an FNA procedure must be weighed against the risk of complications related to clotting and thrombosis. For patients who have a high risk nodule and who cannot safely discontinue",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , FNA of nodules using a 27-gauge needle and a minimum number of passes may be performed, with compression for 5 to 10 minutes following the procedure. Some clinicians repeat the sonogram 15 to 30 minutes after the procedure to assure hemostasis and absence of hematoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=see_link&amp;anchor=H9#H9\">",
"     \"Thyroid biopsy\", section on 'Procedure'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tissue sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sample of tissue may be obtained in either of two ways. Many operators aspirate (FNA) the material with a syringe and exercise a to-and-fro motion to produce a large quantity. These maneuvers frequently yield excessive blood, dilute thyroid cells, and complicate cytologic examination. This technique should be reserved for low-yield or fibrotic lesions. The preferred mode involves a non-aspiration method for most nodules and goiters. Minimal trauma, tissue pressure, and capillary action (FNC) are employed to achieve a small, concentrated sample that remains in the needle shaft. The specimen is then quickly but gently expelled onto a microscope slide with an air-filled syringe and suitably spread. FNC is easier and faster to perform than FNA and has been reported to result in comparable diagnostic cytologic adequacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=see_link&amp;anchor=H5#H5\">",
"     \"Thyroid biopsy\", section on 'FNA versus FNC'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H630862\">",
"    <span class=\"h2\">",
"     Preparation of slide",
"    </span>",
"    &nbsp;&mdash;&nbsp;The aspirated material is smeared directly on slides, fixed, and stained, or collected in a liquid preservative from which thin-layer preparations are made. Diff-Quik and Ultrafast Papanicolaou stains are the most commonly used preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31814/abstract/32\">",
"     32",
"    </a>",
"    ]. Air dried Diff-Quik stained smears are frequently used for on-site evaluation of the aspirated material. Background colloid is easily identified with the Diff-Quik stain. Papanicolaou stain is applied after fixing the smears in alcohol. This stain is better for identifying cellular details such as nuclear features. Most cytopathology labs use a combination of staining techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27370264\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Fine needle aspiration (FNA) biopsy is the procedure of choice for evaluating thyroid nodules and selecting candidates for surgery. When available, we suggest ultrasound-guided FNA for the majority of nodules and, in particular, for nodules that are nonpalpable or difficult to palpate, predominantly cystic, or nondiagnostic after palpation-guided FNA. We also typically use ultrasound to guide FNA in an area in a goiter that is different from the rest of the goiter (ie, firmer, painful, tender, growing, or has suspicious ultrasonographic characteristics) for assessment of recurrent thyroid cancer and for nonpalpable lymphadenopathy. (See",
"      <a class=\"local\" href=\"#H27370272\">",
"       'Indications for ultrasound-guided FNA'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If ultrasound-guided FNA is nondiagnostic, a repeat ultrasound-guided FNA will yield a diagnostic cytology specimen in 75 percent of solid nodules and 50 percent of cystic nodules. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Non-diagnostic aspirates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To puncture the nodule, real-time ultrasonography is used to observe the insertion of a needle free-hand or using a special needle guide attached to the transducer. When ultrasonography shows a complex nodule with a solid component that is either small or posteriorly located, the needle tip should be directed at the solid component or the cyst wall. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Technique'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The management of thyroid nodules is reviewed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=see_link\">",
"       \"Diagnostic approach to and treatment of thyroid nodules\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37111?source=see_link\">",
"       \"Cystic thyroid nodules\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/1\">",
"      Tollin SR, Mery GM, Jelveh N, et al. The use of fine-needle aspiration biopsy under ultrasound guidance to assess the risk of malignancy in patients with a multinodular goiter. Thyroid 2000; 10:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/2\">",
"      Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999; 84:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/3\">",
"      Danese D, Sciacchitano S, Farsetti A, et al. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid 1998; 8:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/4\">",
"      Deandrea M, Mormile A, Veglio M, et al. Fine-needle aspiration biopsy of the thyroid: comparison between thyroid palpation and ultrasonography. Endocr Pract 2002; 8:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/5\">",
"      Izquierdo R, Arekat MR, Knudson PE, et al. Comparison of palpation-guided versus ultrasound-guided fine-needle aspiration biopsies of thyroid nodules in an outpatient endocrinology practice. Endocr Pract 2006; 12:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/6\">",
"      Cesur M, Corapcioglu D, Bulut S, et al. Comparison of palpation-guided fine-needle aspiration biopsy to ultrasound-guided fine-needle aspiration biopsy in the evaluation of thyroid nodules. Thyroid 2006; 16:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/7\">",
"      Carmeci C, Jeffrey RB, McDougall IR, et al. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid 1998; 8:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/8\">",
"      Hagag P, Strauss S, Weiss M. Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. Thyroid 1998; 8:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/9\">",
"      Steele SR, Martin MJ, Mullenix PS, et al. The significance of incidental thyroid abnormalities identified during carotid duplex ultrasonography. Arch Surg 2005; 140:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/10\">",
"      Carpi A, Nicolini A, Casara D, et al. Nonpalpable thyroid carcinoma: clinical controversies on preoperative selection. Am J Clin Oncol 2003; 26:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/11\">",
"      Moon HJ, Son E, Kim EK, et al. The diagnostic values of ultrasound and ultrasound-guided fine needle aspiration in subcentimeter-sized thyroid nodules. Ann Surg Oncol 2012; 19:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/12\">",
"      Nam-Goong IS, Kim HY, Gong G, et al. Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. Clin Endocrinol (Oxf) 2004; 60:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/13\">",
"      Accurso A, Rocco N, Palumbo A, Leone F. Usefulness of ultrasound-guided fine-needle aspiration cytology in the diagnosis of non-palpable small thyroid nodules. Tumori 2005; 91:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/14\">",
"      Alexander EK, Heering JP, Benson CB, et al. Assessment of nondiagnostic ultrasound-guided fine needle aspirations of thyroid nodules. J Clin Endocrinol Metab 2002; 87:4924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/15\">",
"      Redman R, Zalaznick H, Mazzaferri EL, Massoll NA. The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. Thyroid 2006; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/16\">",
"      American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/17\">",
"      Henrichsen TL, Reading CC, Charboneau JW, et al. Cystic change in thyroid carcinoma: Prevalence and estimated volume in 360 carcinomas. J Clin Ultrasound 2010; 38:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/18\">",
"      Mittendorf EA, Tamarkin SW, McHenry CR. The results of ultrasound-guided fine-needle aspiration biopsy for evaluation of nodular thyroid disease. Surgery 2002; 132:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/19\">",
"      Pisani T, Vecchione A, Sinopoli NT, et al. Cytological and immunocytochemical analysis of laterocervical lymph nodes in patients with previous thyroid carcinoma. Anticancer Res 1999; 19:3527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/20\">",
"      Boi F, Baghino G, Atzeni F, et al. The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. J Clin Endocrinol Metab 2006; 91:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/21\">",
"      Breslin M, Lawrance JA, Desai M, et al. The role of ultrasound-guided fine-needle aspiration biopsy in the previously treated patient with thyroid cancer. Clin Otolaryngol Allied Sci 2004; 29:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/22\">",
"      Krishnamurthy S, Bedi DG, Caraway NP. Ultrasound-guided fine-needle aspiration biopsy of the thyroid bed. Cancer 2001; 93:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/23\">",
"      Pisani T, Vecchione A, Giovagnolii MR. Galectin-3 immunodetection may improve cytological diagnosis of occult papillary thyroid carcinoma. Anticancer Res 2004; 24:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/24\">",
"      Nikiforov YE. Molecular diagnostics of thyroid tumors. Arch Pathol Lab Med 2011; 135:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/25\">",
"      Chung SY, Oh KK, Chang HS. Sonographic findings of tuberculous thyroiditis in a patient with Beh&ccedil;et's syndrome. J Clin Ultrasound 2002; 30:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/26\">",
"      Basaria S, Ayala AR, Westra WH, Cooper DS. Amyloidosis: role of fine-needle aspiration. Thyroid 2003; 13:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/27\">",
"      Uruno T, Miyauchi A, Shimizu K, et al. Usefulness of thyroglobulin measurement in fine-needle aspiration biopsy specimens for diagnosing cervical lymph node metastasis in patients with papillary thyroid cancer. World J Surg 2005; 29:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/28\">",
"      Harvey JN, Parker D, De P, et al. Sonographically guided core biopsy in the assessment of thyroid nodules. J Clin Ultrasound 2005; 33:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/29\">",
"      Brenta G, Schnitman M, Bonnahon L, et al. Evaluation of innovative skin-marking technique performed before thyroid ultrasound-guided fine-needle aspiration biopsies. Endocr Pract 2002; 8:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/30\">",
"      Rausch P, Nowels K, Jeffrey RB Jr. Ultrasonographically guided thyroid biopsy: a review with emphasis on technique. J Ultrasound Med 2001; 20:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/31\">",
"      Tublin ME, Martin JA, Rollin LJ, et al. Ultrasound-guided fine-needle aspiration versus fine-needle capillary sampling biopsy of thyroid nodules: does technique matter? J Ultrasound Med 2007; 26:1697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31814/abstract/32\">",
"      Baloch ZW, Tam D, Langer J, et al. Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. Diagn Cytopathol 2000; 23:425.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7836 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-B007036579-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31814=[""].join("\n");
var outline_f31_4_31814=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27370264\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630451\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H630736\">",
"      DIAGNOSTIC ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27370272\">",
"      INDICATIONS FOR ULTRASOUND-GUIDED FNA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonpalpable or difficult to palpate nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H630788\">",
"      Cystic nodules",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Non-diagnostic aspirates",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Lymphadenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Recurrent thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Non-cytological examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Puncturing the nodule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tissue sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H630862\">",
"      Preparation of slide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27370264\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/15/37111?source=related_link\">",
"      Cystic thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/53/28506?source=related_link\">",
"      Diagnostic approach to and treatment of thyroid nodules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/62/21482?source=related_link\">",
"      Overview of the clinical utility of ultrasonography in thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/17/44313?source=related_link\">",
"      Overview of the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37496?source=related_link\">",
"      Serum thyroglobulin in the management of differentiated thyroid cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/25/28056?source=related_link\">",
"      Thyroid biopsy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_4_31815="Valsartan: Drug information";
var content_f31_4_31815=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Valsartan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/15/21749?source=see_link\">",
"    see \"Valsartan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/1/22550?source=see_link\">",
"    see \"Valsartan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233186\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Diovan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233187\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      CO Valsartan;",
"     </li>",
"     <li>",
"      Diovan&reg;;",
"     </li>",
"     <li>",
"      Ran-Valsartan;",
"     </li>",
"     <li>",
"      Sandoz-Valsartan;",
"     </li>",
"     <li>",
"      Teva-Valsartan",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233191\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Initial: 80 mg or 160 mg once daily (in patients who are not volume depleted); dose may be increased to achieve desired effect; maximum recommended dose: 320 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Heart failure:",
"     </b>",
"     Initial: 40 mg twice daily; titrate dose to 80-160 mg twice daily, as tolerated; maximum daily dose: 320 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Left ventricular dysfunction after MI:",
"     </b>",
"     Initial: 20 mg twice daily; titrate dose to target of 160 mg twice daily as tolerated; may initiate &ge;12 hours following MI",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F5605992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/1/22550?source=see_link\">",
"      see \"Valsartan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral: Children 6-16 years: Initial: 1.3 mg/kg once daily (maximum: 40 mg/day); dose may be increased to achieve desired effect; doses &gt;2.7 mg/kg (maximum: 160 mg) have not been studied.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233192\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F233193\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;30 mL/minute: No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute: No dosage adjustment provided in manufacturer&rsquo;s labeling; safety and efficacy have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not significantly removed.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233194\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: No dosage adjustment necessary; use caution in patients with liver disease. Patients with mild-to-moderate chronic disease have twice the exposure as healthy volunteers.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment: No dosage adjustment provided in manufacturer&rsquo;s labeling; has not been studied",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan&reg;: 40 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diovan&reg;: 80 mg, 160 mg, 320 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233163\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alone or in combination with other antihypertensive agents in the treatment of essential hypertension; reduction of cardiovascular mortality in patients with left ventricular dysfunction postmyocardial infarction; treatment of heart failure (NYHA Class II-IV)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Valsartan may be confused with losartan, Valstar&reg;, Valturna&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Diovan&reg; may be confused with Zyban&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Diovan [U.S., Canada, and  multiple international markets] may be confused with Dianben, a brand name for metformin [Spain]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (heart failure trials 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: BUN increased &gt;50% (heart failure trials 17%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Hypotension (heart failure trials 7%; MI trial 1%), orthostatic hypotension (heart failure trials 2%), syncope (up to &gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (hypertension trial 2% to 8%), fatigue (heart failure trials 3%; hypertension trial 2%), postural dizziness (heart failure trials 2%), headache (heart failure trials &gt;1%), vertigo (up to &gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Serum potassium increased by &gt;20% (4% to 10%), hyperkalemia (heart failure trials 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (heart failure trials 5%), abdominal pain (2%), nausea (heart failure trials &gt;1%), upper abdominal pain (heart failure trials &gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Neutropenia (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (heart failure trials 3%), back pain (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Blurred vision (heart failure trials &gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Creatinine doubled (MI trial 4%), creatinine increased &gt;50% (heart failure trials 4%), renal dysfunction (up to &gt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      All indications:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Allergic reactions, alopecia, anaphylaxis, anemia, angioedema, anorexia, anxiety, chest pain, constipation, dyspepsia, dyspnea, flatulence, hematocrit/hemoglobin decreased, hepatitis (rare), impotence, insomnia, liver function tests increased, microcytic anemia, muscle cramps, myalgia, palpitation, paresthesia, photosensitivity, pruritus, rash, renal failure, rhabdomyolysis, somnolence, taste disorder, thrombocytopenia (very rare), vasculitis, vomiting, weakness, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to valsartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: May occur; risk factors include renal dysfunction, diabetes mellitus, concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use with caution with these agents; monitor potassium closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: During the initiation of therapy, hypotension may occur, particularly in patients with heart failure or post-MI patients. Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with valsartan.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Use caution when initiating in heart failure; may need to adjust dose, and/or concurrent diuretic therapy, because of valsartan-induced hypotension. Careful monitoring of BUN, serum creatinine, and potassium is necessary especially if preexisting renal disease exists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with significant hepatic impairment since clearance is significantly reduced.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use valsartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution with pre-existing renal insufficiency and severe renal impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Canadian labeling: Use is not approved in patients &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233218\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of SLCO1B1;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C9 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233154\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: May increase the serum concentration of OATP1B1/SLCO1B1 Substrates. Management: According to eltrombopag prescribing information, consideration of a preventative dose reduction may be warranted.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hydrochlorothiazide: May enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F233182\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Decreases the peak plasma concentration and extent of absorption by 50% and 40%, respectively. Potassium supplements and/or potassium-containing salts may cause or worsen hyperkalemia. Management: Take consistently with regard to food. Consult prescriber before consuming a potassium-rich diet, potassium supplements, or salt substitutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Some herbal medications may worsen hypertension (eg, licorice); others may increase the antihypertensive effect of valsartan (eg, shepherd's purse). Management: Avoid bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     The use of drugs which act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal renal function, may lead to fetal lung hypoplasia and skeletal malformations. Use is also associated with anuria, hypotension, renal failure, skull hypoplasia, and death in the fetus/neonate. The exposed fetus should be monitored for fetal growth, amniotic fluid volume, and organ formation. Infants exposed",
"     <i>",
"      in utero",
"     </i>",
"     should be monitored for hyperkalemia, hypotension, and oliguria.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5631008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if valsartan is found in breast milk; the manufacturer recommends discontinuing the drug or discontinuing nursing based on the importance of the drug to the mother.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F233171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Avoid salt substitutes which contain potassium. May be taken with or without food.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F233169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diovan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $112.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (90): $403.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     160 mg (90): $433.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     320 mg (90): $548.58",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline and periodic electrolyte panels, renal function, BP; in HF, serum potassium during dose escalation and periodically thereafter",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Dalzad (HN);",
"     </li>",
"     <li>",
"      Diopass (KP);",
"     </li>",
"     <li>",
"      Dioten (KP);",
"     </li>",
"     <li>",
"      Diovan (AE, AR, AT, AU, BB, BD, BG, BH, BM, BO, BR, BS, BZ, CH, CL, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, GB, GR, GT, GY, HK, ID, IE, IL, IN, IQ, IR, JM, JO, JP, KP, KW, LB, LY, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PH, PK, PL, PR, PT, PY, QA, RU, SA, SE, SG, SR, SV, SY, TH, TR, TT, TW, UY, VE, YE);",
"     </li>",
"     <li>",
"      Diovane (BG);",
"     </li>",
"     <li>",
"      Diqvan (KP);",
"     </li>",
"     <li>",
"      Disartan (TW);",
"     </li>",
"     <li>",
"      Divaltan (KP);",
"     </li>",
"     <li>",
"      Kovan (TW);",
"     </li>",
"     <li>",
"      Maxdio (KP);",
"     </li>",
"     <li>",
"      Nisis (FR);",
"     </li>",
"     <li>",
"      Provas (DE);",
"     </li>",
"     <li>",
"      Tareg (CN, FR, IT, KP);",
"     </li>",
"     <li>",
"      Valatan (TH);",
"     </li>",
"     <li>",
"      Valtensin (BG);",
"     </li>",
"     <li>",
"      Varcor (CO);",
"     </li>",
"     <li>",
"      Vector (IL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Valsartan produces direct antagonism of the angiotensin II (AT2) receptors, unlike the ACE inhibitors. It displaces angiotensin II from the AT1 receptor and produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 17 L (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 95%, primarily albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: To inactive metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Tablet: 25% (range: 10% to 35%); suspension: ~40% (~1.6 times more than tablet)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (83%) and urine (13%) as unchanged drug",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl ):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, &ldquo;ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration With the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):e1-e157.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/17692738/pubmed\" id=\"17692738\" target=\"_blank\">",
"        17692738",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Hand M, Armstrong PW, et al, &ldquo;2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2008, 51(2):210-49.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/18191746/pubmed\" id=\"18191746\" target=\"_blank\">",
"        18191746",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Conlin P, Moore T, Swartz S, et al, &ldquo;Effect of Indomethacin on Blood Pressure Lowering by Captopril and Losartan in Hypertensive Patients,&rdquo;",
"      <i>",
"       Hypertension",
"      </i>",
"      , 2000, 36(3):461-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/10988282/pubmed\" id=\"10988282\" target=\"_blank\">",
"        10988282",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K and Kjekshus J, &ldquo;Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction With Angiotensin II Antagonist Losartan,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, &ldquo;Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hillis LD, Smith PK, Anderson JL, et al, &ldquo;2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):2610-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/22064600/pubmed\" id=\"22064600\" target=\"_blank\">",
"        22064600",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hunt SA, Abraham WT, Chin MH, et al, &ldquo;2009 Focused Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation,&rdquo;",
"      <i>",
"       CIrculation",
"      </i>",
"      , 2009, 119(14):e391-479.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/19324966/pubmed\" id=\"19324966\" target=\"_blank\">",
"        19324966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification. Kidney Disease Outcome Quality Initiative,&rdquo;",
"      <i>",
"       Am J Kidney Dis",
"      </i>",
"      , 2002, 39(2 Suppl 2):1-246. Available at file://www.kidney.org/professionals/KDOQI/guidelines_ckd/toc.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lindenfeld J, Albert NM, Boehmer JP, et al, &ldquo;HFSA 2010 Comprehensive Heart Failure Practice Guideline,&rdquo;",
"      <i>",
"       J Card Fail",
"      </i>",
"      , 2010, 16(6):e1-194.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/20610207/pubmed\" id=\"20610207\" target=\"_blank\">",
"        20610207",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, &ldquo;Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, &ldquo;Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 349(20):1893-1906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/14610160/pubmed\" id=\"14610160\" target=\"_blank\">",
"        14610160",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, &ldquo;Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smith SC Jr, Benjamin EJ, Bonow RO, et al, &ldquo;AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(22):2458-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?31/4/31815/abstract-text/22052934/pubmed\" id=\"22052934\" target=\"_blank\">",
"        22052934",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10036 Version 49.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.1.191.153-8DAC4F1F78-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31815=[""].join("\n");
var outline_f31_4_31815=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708863\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233186\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233187\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233224\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233191\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5605992\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233192\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233193\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233194\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233160\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233145\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233163\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233161\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233232\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233222\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233166\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233149\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233218\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233154\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233182\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233156\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233170\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233198\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5631008\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233171\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233169\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233158\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869414\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233148\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233165\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10036\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10036|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?21/15/21749?source=related_link\">",
"      Valsartan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?22/1/22550?source=related_link\">",
"      Valsartan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_4_31816="Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor";
var content_f31_4_31816=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial systemic therapy for advanced non-small cell lung cancer with a mutation in the epidermal growth factor receptor",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31816/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31816/contributors\">",
"     Rogerio C Lilenbaum, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31816/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31816/contributors\">",
"     James R Jett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31816/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31816/contributors\">",
"     Michael E Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/4/31816/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of patients with lung cancer depends upon the cell type (non-small cell lung cancer [NSCLC] versus small cell lung cancer), molecular characteristics, tumor stage, and an assessment of the patient's overall medical condition.",
"   </p>",
"   <p>",
"    Patients with stage I, II, or III NSCLC (",
"    <a class=\"graphic graphic_table graphicRef80099 \" href=\"mobipreview.htm?36/41/37533\">",
"     table 1",
"    </a>",
"    ) are generally treated with curative intent using surgery or radiation therapy, sometimes combined with concurrent or adjuvant chemotherapy. In contrast, palliative systemic therapy is appropriate for patients who have stage IV disease at presentation. Palliative systemic therapy is also used for patients who have relapsed with advanced disease following prior definitive treatment.",
"   </p>",
"   <p>",
"    An improved understanding of the molecular pathways that drive malignancy in NSCLC has led to the development of agents that target specific molecular pathways in malignant cells. Therapy can then be individualized based upon the specific abnormality, if any, present in a given patient.",
"   </p>",
"   <p>",
"    The use of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the initial palliative treatment of patients with advanced NSCLC that contains a somatic mutation in EGFR will be reviewed here.",
"   </p>",
"   <p>",
"    Other relevant topics presented separately include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link\">",
"       \"Overview of the treatment of advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"       \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177153446\">",
"    <span class=\"h2\">",
"     Molecular pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tumor growth and progression depend upon the activity of cell surface membrane receptors that control intracellular signal transduction pathways regulating cell proliferation, apoptosis, angiogenesis, adhesion, and motility.",
"   </p>",
"   <p>",
"    These cell surface receptors include the epidermal growth factor receptor (EGFR, also called HER1 or erbB-1) tyrosine kinases (TKs). EGFR exists as a monomer on the cell surface, and it must dimerize to activate the TK. While the TK activity of EGFR is tightly controlled in normal cells, the genes encoding these receptors may have escaped from their usual intracellular inhibitory mechanisms in malignant cells (",
"    <a class=\"graphic graphic_figure graphicRef86507 \" href=\"mobipreview.htm?27/50/28462\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177151213\">",
"    <span class=\"h2\">",
"     EGFR mutation as predictor of responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced NSCLCs that contains characteristic mutations in EGFR are highly sensitive to EGFR TKIs. Analysis for the presence or absence of a driver mutation in EGFR is the standard approach to decide whether or not to use an EGFR TKI for the initial treatment of a patient with advanced NSCLC. Multiple reliable techniques are available to assay for EGFR mutations, and these are feasible on formalin fixed tissue. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"     \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If systemic treatment is required before the results of genotype testing are available, systemic chemotherapy is indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/1\">",
"     1",
"    </a>",
"    ]. If an EGFR mutation is identified after initiation of chemotherapy, we suggest continuing chemotherapy for four cycles as long as therapy is tolerated and there is no evidence of disease progression. When the results of genotype testing become available, the treatment plan should be reassessed. There are no clinical trials that directly address the optimal approach when a driver mutation is identified after chemotherapy has been initiated (",
"    <a class=\"graphic graphic_algorithm graphicRef86712 \" href=\"mobipreview.htm?39/0/39950\">",
"     algorithm 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=see_link&amp;anchor=H798956916#H798956916\">",
"     \"Overview of the treatment of advanced non-small cell lung cancer\", section on 'Chemotherapy versus targeted therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H619542310\">",
"    <span class=\"h2\">",
"     Other predictors of responsiveness",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies identified several clinical parameters that were associated with a high response rate to EGFR TKIs and a relatively favorable prognosis. These include adenocarcinoma histology, women, nonsmokers, and Asian ethnicity. Subsequent studies showed that these clinical parameters are surrogates for the presence of specific activating mutations in the tyrosine kinase domain of the EGFR (exon 19 deletions, L858R point mutation in exon 21) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phase II studies with EGFR TKIs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    ) reported objective response rates of 55 to 90 percent in patients with NSCLC who were selected based upon the presence of an activating somatic mutation in EGFR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/5\">",
"     5",
"    </a>",
"    ]. Subsequent randomized trials have consistently demonstrated improved progression-free survival with these agents compared with cytotoxic chemotherapy in these patients. Overall survival generally has not been significantly improved in these trials, due primarily to the use of these agents as second line therapy after progression on chemotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1506265\">",
"    <span class=\"h2\">",
"     Gefitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     Gefitinib",
"    </a>",
"    was compared with cytotoxic chemotherapy as the initial therapy in three randomized trials in patients with advanced NSCLC whose tumors contained activating EGFR mutations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       IPASS trial",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The most extensive data come from the IPASS trial, in which 1217 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/6,7\">",
"       6,7",
"      </a>",
"      ]. Patients were included based upon clinical criteria consistent with responsiveness to gefitinib; all were Asian, had adenocarcinoma and were either never smokers or former light smokers. For the entire cohort, progression-free survival was significantly better with gefitinib compared to chemotherapy (12-month progression-free rate 25 versus 7 percent, HR for progression 0.74). The difference in overall survival was not statistically significant (median 18.8 versus 17.4 months, HR for death 0.90, 95% CI 0.79-1.02) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/7\">",
"       7",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Results depended upon the EGFR mutation status. EGFR mutations were present in 60 percent of the 437 evaluable patients; among these, 96 percent had either an exon 19 deletion or the exon 21 L858R mutation. &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients whose tumors contained an EGFR mutation, progression-free survival was significantly prolonged with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      in contrast to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (median 9.5 versus 6.3 months, HR for progression 0.48) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/6\">",
"       6",
"      </a>",
"      ]. However, overall survival was not increased with gefitinib (median 22 months in both groups, HR 1.00) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      For those without an EGFR mutation, progression-free survival was significantly shorter with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      (median 1.5 versus 6.5 months, HR 2.85 for progression, 95% CI 2.05-3.95) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/6\">",
"       6",
"      </a>",
"      ]. However, the difference in overall survival was not statistically significant (median 11.2 versus 12.7 months, HR for death 1.18).",
"     </li>",
"     <li>",
"      The absence of a difference in overall survival between the two groups probably reflects second line therapy. Among mutation positive patients who initially received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , 64 percent subsequently were treated with an EGFR TKI; among those initially assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      , 76 percent subsequently received chemotherapy, most of which was platinum-based.",
"      <br/>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       West Japan Oncology Group trial",
"      </strong>",
"      &ndash; In a West Japan Oncology Group trial (WJOG 172), 177 patients with sensitizing EGFR mutations were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"       docetaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/8\">",
"       8",
"      </a>",
"      ]. Crossover to gefitinib after chemotherapy was permitted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/9\">",
"       9",
"      </a>",
"      ]. Progression-free survival was prolonged with gefitinib compared to chemotherapy (median 9.2 versus 6.3 months, HR for progression 0.49), but the difference in overall survival was not statistically significant (median 27.7 versus 26.6 months, HR for death 0.90).",
"     </li>",
"     <li>",
"      <strong>",
"       North-East Japan Study Group trial",
"      </strong>",
"      &ndash; In a North-East Japan Study Group trial, 230 patients with sensitizing EGFR mutations were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/10\">",
"       10",
"      </a>",
"      ]. Gefitinib significantly prolonged progression-free survival compared with chemotherapy (10.8 versus 5.4 months, HR for progression 0.30). The difference in overall survival was not statistically significant. A predefined analysis that incorporated elements of physical and mental well-being along with daily and social functioning found that patients randomized to gefitinib had a significantly longer time until deterioration in quality of life compared with those initially treated with chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The European Medicines Agency (EMA) approved",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    for the initial treatment of patients with advanced NSCLC and activating mutations of the EGFR tyrosine kinase, primarily based upon the results of the IPASS trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1506273\">",
"    <span class=\"h2\">",
"     Erlotinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     Erlotinib",
"    </a>",
"    was compared with chemotherapy in two randomized trials in patients whose tumors contained mutations in EGFR:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       OPTIMAL trial",
"      </strong>",
"      &ndash; In the OPTIMAL trial from China, 154 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/13\">",
"       13",
"      </a>",
"      ]. Treatment with erlotinib significantly improved progression-free survival compared with chemotherapy (13.1 versus 4.6 months, HR 0.16 for progression, 95% CI 0.10-0.26). Similarly, the objective response rate was significantly improved with erlotinib (83 versus 36 percent).",
"     </li>",
"     <li>",
"      <strong>",
"       EURTAC trial",
"      </strong>",
"      &ndash; In the EURTAC trial, 174 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      or a platinum-based chemotherapy doublet [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/14\">",
"       14",
"      </a>",
"      ]. Progression-free survival, the primary endpoint of the trial, was significantly increased with erlotinib compared with chemotherapy (median 9.7 versus 5.2 months, HR for progression 0.37, 95% CI 0.25-0.54). There was no significant difference in overall survival (median 19.3 and 19.5 months, respectively). However, 76 percent of patients initially treated with chemotherapy subsequently received an EGFR TKI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7874695\">",
"    <span class=\"h2\">",
"     Afatinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Afatinib is as an irreversible EGFR TKI, which has been shown to have clinical activity in multiple clinical trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Afatinib was compared with chemotherapy as the initial therapy for advanced NSCLC in patients whose tumors contain activating mutations in the phase III Lux-Lung 3 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/17\">",
"     17",
"    </a>",
"    ]. In this trial, 345 previously untreated patients were randomly assigned in a 2:1 ratio to treatment with either afatinib or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"     pemetrexed",
"    </a>",
"    . The primary endpoint of the trial was progression-free survival based upon independent review.",
"   </p>",
"   <p>",
"    Results of the trial based upon a median follow-up of 16 months were presented at the 2012 ASCO meeting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progression-free survival was significantly increased with afatinib compared with chemotherapy (median 11.1 months versus 6.9 months, 12 month progression-free rate 51 versus 21 percent, HR for progression 0.58, 95% CI 0.43-0.78).",
"     </li>",
"     <li>",
"      The objective response rate was significantly increased with afatinib (56 versus 23 percent). Time to symptom progression and quality of life were also significantly improved with afatinib.",
"     </li>",
"     <li>",
"      Drug related side effects led to discontinuation of afatinib in 8 percent of cases. Side effects reported in more than 25 percent of patients included diarrhea, rash, stomatitis, paryonychia, and dry skin (95, 89, 72, 57, and 29 percent of cases, respectively.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Afatinib was compared with placebo in the phase III Lux-Lung 1 trial in 585 patients who had progressed after at least 12 weeks of treatment with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/16\">",
"     16",
"    </a>",
"    ]. Treatment with afatinib significantly prolonged progression-free survival (median 3.3 versus 1.1 months, HR for progression 0.38), although there was no significant difference in overall survival.",
"   </p>",
"   <p>",
"    Afatinib is not commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177153170\">",
"    <span class=\"h2\">",
"     Brain metastases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy are the primary treatment modalities for patients with brain metastases from NSCLC. In selected patients with brain metastases whose tumor possesses an activating mutation of the EGFR tyrosine kinase, treatment with an EGFR TKI may possess clinically useful activity against the brain lesion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\", section on 'Overview of management'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/217?source=see_link&amp;anchor=H9#H9\">",
"     \"Systemic therapy for brain metastases\", section on 'Targeted agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1191492196\">",
"    <span class=\"h2\">",
"     Duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with an EGFR TKI is generally continued until there is disease progression.",
"   </p>",
"   <p>",
"    When initial therapy with an EGFR TKI is discontinued after a prolonged course of treatment, some patients have rapid disease progression. An observational study found that continued EGFR TKI therapy, in combination with cytotoxic chemotherapy, prolonged overall survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/18\">",
"     18",
"    </a>",
"    ]. In another pilot study, reintroduction of the EGFR TKI in conjunction with cytotoxic chemotherapy slowed disease progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, some groups continue therapy with an EGFR TKI in patients with progressive disease who had an initial response to treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/20\">",
"     20",
"    </a>",
"    ]. More data are needed before this strategy can be routinely adopted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H703880782\">",
"    <span class=\"h2\">",
"     Acquired resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost all patients who initially respond to an EGFR TKI subsequently develop disease progression. The causes of acquired resistance are not fully understood, but secondary mutations in EGFR and amplification of the MET oncogene appear to be responsible for a majority of cases of acquired resistance.",
"   </p>",
"   <p>",
"    The management of patients who progress following initial treatment with an EGFR TKI generally consists of combination chemotherapy and is the same as those who are chemotherapy na&iuml;ve. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177152184\">",
"    <span class=\"h3\">",
"     Secondary EGFR mutations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A secondary mutation in EGFR has been associated with acquired resistance to EGFR TKIs. The most common of these secondary mutations involves the substitution of methionine for threonine at position 790 (T790M) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. These structural mutations are thought to account for resistance in approximately 50 percent of cases of acquired resistance to EGFR TKIs.",
"   </p>",
"   <p>",
"    Low concentrations of cells with the T790M mutation have been identified in pretreatment samples from patients with activating mutations of EGFR using techniques that are able to detect this mutation in a low percentage of tumor cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/25\">",
"     25",
"    </a>",
"    ]. Although these patients had a similar response rate to traditional EGFR TKIs, the progression-free survival to initial treatment was significantly shorter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177152191\">",
"    <span class=\"h3\">",
"     MET oncogene amplification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amplification of the MET oncogene has been associated with resistance to EGFR TKIs in 5 - 20 percent of cases with progressive disease while on treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Amplification of MET can be a mechanism of acquired resistance in some patients, even though some of these patients also have a secondary T790M mutation.",
"   </p>",
"   <p>",
"    In addition, MET amplification can occur in primary tumors without EGFR resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/29\">",
"     29",
"    </a>",
"    ]. The absence of MET oncogene amplification may be an independent marker for improved survival in patients with surgically resected NSCLC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     EGFR TKIs plus chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    were extensively evaluated in combination with standard chemotherapy regimens for previously untreated patients with advanced NSCLC that were not selected on the basis of EGFR mutation status.",
"   </p>",
"   <p>",
"    Two randomized phase III trials, each including over 1000 patients, did not demonstrate a benefit in response rate, time to progression, or survival when",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    was combined with either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Similarly, two phase III trials in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    was combined with these same chemotherapy doublets failed to show any improvement in survival compared with chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31816/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the absence of benefit in these trials and the clearly defined role of EGFR TKIs as monotherapy in patients whose tumors contain an activating mutation in EGFR, there currently is no role for combining an EGFR TKI with chemotherapy as the initial therapy outside a protocol setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177152529\">",
"    <span class=\"h1\">",
"     EGFR TKI TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important toxicities associated with inhibition of the EGFR pathway include a characteristic rash, diarrhea, and uncommonly interstitial pneumonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177152536\">",
"    <span class=\"h2\">",
"     Rash",
"    </span>",
"    &nbsp;&mdash;&nbsp;All agents targeting the EGFR pathway, including both small molecule TKIs as well as monoclonal antibodies that bind EGFR, are associated with dermatologic toxicity (predominantly dry skin and an acneiform rash, although more severe reactions have been reported). This is thought to be due to high levels of EGFR expression in the basal layer of the epidermis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=see_link\">",
"     \"Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177152543\">",
"    <span class=\"h2\">",
"     Gastrointestinal toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diarrhea is common in patients receiving small molecule epidermal growth factor receptor (EGFR) TKIs. It has been reported in up to 60 percent of patients, but it is only occasionally severe and typically can be easily managed by the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/53/16214?source=see_link\">",
"     loperamide",
"    </a>",
"    . Rarely, episodes of gastrointestinal perforation, some of which were fatal, have also been reported in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H18#H18\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on 'Small molecule EGFR inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=see_link&amp;anchor=H49#H49\">",
"     \"Enterotoxicity of chemotherapeutic agents\", section on 'Erlotinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177152550\">",
"    <span class=\"h2\">",
"     Pulmonary toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially fatal lung toxicity has been reported with both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"     gefitinib",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=see_link&amp;anchor=H3#H3\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Anti-EGFR agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H177152557\">",
"    <span class=\"h2\">",
"     Hepatic toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatic failure and hepatorenal syndrome, potentially resulting in death, have been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"     erlotinib",
"    </a>",
"    . Patients with hepatic impairment should be closely monitored during treatment with erlotinib, and extra caution should be used in those with an elevated serum bilirubin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=see_link&amp;anchor=H217132150#H217132150\">",
"     \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\", section on 'Erlotinib and gefitinib'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H285002331\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with advanced NSCLC and an EGFR mutation eventually develop progressive disease despite treatment with an EGFR TKI. Cytotoxic chemotherapy may offer meaningful benefit in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"     \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=see_link&amp;anchor=H2#H2\">",
"     \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\", section on 'Chemotherapy agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=see_link\">",
"       \"Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence of a characteristic mutation in the epidermal growth factor receptor (EGFR) defines a subset of patients with non-small cell lung cancer (NSCLC) who are likely to have a favorable response to EGFR tyrosine kinase inhibitors (TKIs). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rationale'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whenever possible, therapy of patients with advanced NSCLC should be individualized based upon the molecular and histologic features of the tumor. If feasible prior to treatment, patients should have tumor tissue assessed for the presence of a somatic mutation in the epidermal growth factor receptor (EGFR) as well as for other driver mutations. (See",
"      <a class=\"local\" href=\"#H177151213\">",
"       'EGFR mutation as predictor of responsiveness'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"       \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with previously untreated metastatic NSCLC and an activating mutation of the EGFR, we recommend monotherapy with an EGFR TKI (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/12/19654?source=see_link\">",
"       gefitinib",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/13/36056?source=see_link\">",
"       erlotinib",
"      </a>",
"      ) rather than chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). In randomized trials, this approach significantly prolongs progression-free survival, although the impact on overall survival remains uncertain. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend not combining an EGFR TKI with cytotoxic chemotherapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). A combined modality approach has not resulted in an improvement in progression-free or overall survival. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'EGFR TKIs plus chemotherapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with previously untreated metastatic NSCLC but without an activating mutation of the EGFR should be treated with either chemotherapy or other targeted agents, depending upon the molecular characteristics of their tumor. (See",
"      <a class=\"local\" href=\"#H177151213\">",
"       'EGFR mutation as predictor of responsiveness'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=see_link\">",
"       \"Personalized, genotype-directed therapy for advanced non-small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients initially treated with chemotherapy whose tumor is subsequently found to contain an EGFR mutation, we suggest integration of treatment with an EGFR TKI into the overall treatment plan after completion of the initial chemotherapy. (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=see_link&amp;anchor=H1137259613#H1137259613\">",
"       \"Second-line therapy for patients with previously treated advanced non-small cell lung cancer\", section on 'EGFR inhibitors'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When patients who received an EGFR TKI as their initial therapy progress, subsequent management usually consists of cytotoxic chemotherapy, in the same way as for other chemotherapy na&iuml;ve patients. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=see_link\">",
"       \"Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/1\">",
"      Moran T, Sequist LV. Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations. J Clin Oncol 2012; 30:3330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/2\">",
"      Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from \"never smokers\" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004; 101:13306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/3\">",
"      Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/4\">",
"      Paez JG, J&auml;nne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/5\">",
"      Keedy VL, Temin S, Somerfield MR, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011; 29:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/6\">",
"      Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/7\">",
"      Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol 2011; 29:2866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/8\">",
"      Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/9\">",
"      Inoue A, Kobayashi K, Maemondo M, et al. Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-na&iuml;ve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol 2013; 24:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/10\">",
"      Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/11\">",
"      Oizumi S, Kobayashi K, Inoue A, et al. Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial. Oncologist 2012; 17:863.",
"     </a>",
"    </li>",
"    <li>",
"     EMEA approval document file://www.emea.europa.eu/humandocs/Humans/EPAR/iressa/iressa.htm (Accessed on June 14, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/13\">",
"      Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/14\">",
"      Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012; 13:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/15\">",
"      Yang JC, Shih JY, Su WC, et al. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol 2012; 13:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/16\">",
"      Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol 2012; 13:528.",
"     </a>",
"    </li>",
"    <li>",
"     Yang JC, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations (abstract #LBA7500). J Clin Oncol 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/18\">",
"      Nishie K, Kawaguchi T, Tamiya A, et al. Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations. J Thorac Oncol 2012; 7:1722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/19\">",
"      Riely GJ, Kris MG, Zhao B, et al. Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus. Clin Cancer Res 2007; 13:5150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/20\">",
"      Oxnard GR, Miller VA. Use of erlotinib or gefitinib as initial therapy in advanced NSCLC. Oncology (Williston Park) 2010; 24:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/21\">",
"      Kosaka T, Yatabe Y, Endoh H, et al. Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res 2006; 12:5764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/22\">",
"      Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12:6494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/23\">",
"      Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005; 352:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/24\">",
"      Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005; 2:e73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/25\">",
"      Su KY, Chen HY, Li KC, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol 2012; 30:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/26\">",
"      Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A 2007; 104:20932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/27\">",
"      Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/28\">",
"      Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 2009; 63:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/29\">",
"      Jagadeeswaran R, Surawska H, Krishnaswamy S, et al. Paxillin is a target for somatic mutations in lung cancer: implications for cell growth and invasion. Cancer Res 2008; 68:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/30\">",
"      Cappuzzo F, Marchetti A, Skokan M, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009; 27:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/31\">",
"      Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/32\">",
"      Gatzemeier U, Pluzanska A, Szczesna A, et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/33\">",
"      Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol 2004; 22:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31816/abstract/34\">",
"      Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. J Clin Oncol 2004; 22:785.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4630 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-125.39.66.147-2DA2A50332-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31816=[""].join("\n");
var outline_f31_4_31816=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177153446\">",
"      Molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177151213\">",
"      EGFR mutation as predictor of responsiveness",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H619542310\">",
"      Other predictors of responsiveness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1506265\">",
"      Gefitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1506273\">",
"      Erlotinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7874695\">",
"      Afatinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177153170\">",
"      Brain metastases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1191492196\">",
"      Duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H703880782\">",
"      Acquired resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177152184\">",
"      - Secondary EGFR mutations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H177152191\">",
"      - MET oncogene amplification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EGFR TKIs plus chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H177152529\">",
"      EGFR TKI TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177152536\">",
"      Rash",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177152543\">",
"      Gastrointestinal toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177152550\">",
"      Pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H177152557\">",
"      Hepatic toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H285002331\">",
"      CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/4630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4630|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?39/0/39950\" title=\"algorithm 1\">",
"      Initial approach to patients with newly diagnosed NSCLC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4630|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/50/28462\" title=\"figure 1\">",
"      Molecular targets in NSCLC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/4630|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/41/37533\" title=\"table 1\">",
"      Lung cancer TMN staging 7th edition",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/6/9322?source=related_link\">",
"      Acneiform eruption secondary to epidermal growth factor (EGFR) inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/2/44074?source=related_link\">",
"      Chemotherapy hepatotoxicity and dose modification in patients with liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42362?source=related_link\">",
"      Enterotoxicity of chemotherapeutic agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/54/34666?source=related_link\">",
"      Initial systemic chemotherapy for advanced non-small cell lung cancer without an epidermal growth factor receptor mutation or the ALK fusion oncogene",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/57/21401?source=related_link\">",
"      Overview of the treatment of advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/44/3779?source=related_link\">",
"      Patient information: Non-small cell lung cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?16/63/17396?source=related_link\">",
"      Patient information: Non-small cell lung cancer treatment; stage IV cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14809?source=related_link\">",
"      Personalized, genotype-directed therapy for advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/36/40520?source=related_link\">",
"      Second-line therapy for patients with previously treated advanced non-small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/13/217?source=related_link\">",
"      Systemic therapy for brain metastases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_4_31817="Metronidazole: An overview";
var content_f31_4_31817=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metronidazole: An overview",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31817/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31817/contributors\">",
"     Melissa Johnson, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31817/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31817/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31817/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31817/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/4/31817/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is one of the mainstay drugs for the treatment of anaerobic infections and the treatment of choice for most patients with mild to moderate Clostridium difficile-associated diarrhea [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. It is approved by the US Food and Drug Administration (FDA) for the treatment of anaerobic and protozoal infections. Metronidazole exerts its antimicrobial effects through the production of free radicals that are toxic to the microbe.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    for treating specific infections is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=see_link\">",
"     \"Anaerobic bacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=see_link\">",
"     \"Clostridium difficile in adults: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33671?source=see_link\">",
"     \"Intestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33031?source=see_link\">",
"     \"Extraintestinal Entamoeba histolytica amebiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=see_link\">",
"     \"Trichomonas vaginalis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MECHANISM OF ACTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is cytotoxic to facultative anaerobic bacteria such as Helicobacter pylori and Gardnerella vaginalis, but the mechanism of this action is not well understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/3\">",
"     3",
"    </a>",
"    ]. However, its activity against obligate anaerobes occurs through a four-step process:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Entry into the microorganism &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      is a low molecular weight compound that diffuses across the cell membranes of anaerobic and aerobic microorganisms. However, antimicrobial activity is limited to anaerobes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/3\">",
"       3",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reductive activation by intracellular transport proteins &mdash;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      is reduced by the pyruvate:ferredoxin oxidoreductase system in the mitochondria of obligate anaerobes, which alters its chemical structure. Pyruvate:ferredoxin oxidoreductase normally generates ATP via oxidative decarboxylation of pyruvate. With metronidazole in the cellular environment, its nitro group acts as an electron sink, capturing electrons that would usually be transferred to hydrogen ions in this cycle. Reduction of metronidazole creates a concentration gradient that drives uptake of more drug, and promotes formation of intermediate compounds and free radicals that are toxic to the cell [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/3-5\">",
"       3-5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Reduced intermediate particle interacts with intracellular targets &mdash; Cytotoxic intermediate particles interact with host cell DNA, resulting in DNA strand breakage and fatal destabilization of the DNA helix [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/6,7\">",
"       6,7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Breakdown of cytotoxic intermediate products &mdash; The toxic intermediate particles decay into inactive end products [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    exerts rapid bactericidal effects against anaerobic bacteria, with a killing rate proportional to the drug concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Concentration-dependent killing has also been observed with Entamoeba histolytica and Trichomonas vaginalis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Metronidazole kills Bacteroides fragilis and Clostridium perfringens more rapidly than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23159?source=see_link\">",
"     \"Clindamycin: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No apparent antagonism exists between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and other antimicrobial agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , and ticarcillin against strains of B. fragilis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RESISTANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite extensive worldwide use, acquired resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    among anaerobic bacteria is rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Anaerobes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surveys demonstrate that more than 95 percent of anaerobic isolates in the United States are susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Among Bacteroides spp, one large multicenter study over a seven year period of more than 4000 strains revealed no isolates resistant to metronidazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/17\">",
"     17",
"    </a>",
"    ]. A second survey also found no resistance in 542 bloodstream B. fragilis isolates from 12 US medical centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/18\">",
"     18",
"    </a>",
"    ]. Resistance to this drug has been reported among gram-negative anaerobes outside of the United States. First reported in 1978, metronidazole resistance has increased since, and transferable low-level resistance has also been reported. The rates of resistance differ depending upon the country:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The antibiotic susceptibilities of subgingival flora was compared between the Netherlands and Spain; the incidence of antibiotics resistance for a number of drugs, including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , was higher in Spain, a country in which systemic antimicrobials are used more frequently [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Most isolates were susceptible to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      in England and Wales [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Canada, rates of resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      and a number of other agents remained unchanged in Bacteroides spp over a six year period, while resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      increased [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In Auckland, gram-negative anaerobes and Clostridium spp were consistently sensitive to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      , but the drug's activity against other anaerobes was more variable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predictions were made that the incidence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    resistance would rise with increased use of the drug for the treatment of antibiotic-associated colitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/23\">",
"     23",
"    </a>",
"    ]. However, a study from France compared C. difficile isolates from 1991 and 1997 and found no increase in minimum inhibitory concentration (MIC) to metronidazole or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    among these strains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In Bacteroides species, resistance has been conferred by both plasmid- and chromosomally-mediated mechanisms, although plasmid-mediated transfer of resistance to susceptible strains has been rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/25\">",
"     25",
"    </a>",
"    ]. Multiple steps appear necessary for resistance to develop, which may explain why resistance is rare and infrequent in the absence of long-term therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/26\">",
"     26",
"    </a>",
"    ]. Resistance is conferred through a reduction in pyruvate:ferredoxin oxidoreductase activity, which limits cellular uptake of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and subsequent activation. The level of susceptibility and rate of drug uptake varies with the level of pyruvate:ferredoxin oxidoreductase activity. Resistant bacteria compensate for reduced action of pyruvate:ferredoxin oxidoreductase by increasing pyruvate dehydrogenase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Helicobacter pylori",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although development of resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in anaerobic bacteria is rare, it has been reported more frequently with H. pylori [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Surveys indicate that 10 to 30 percent of H. pylori isolates in Western nations are resistant to metronidazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/28,30\">",
"     28,30",
"    </a>",
"    ]. Although the mechanism of resistance to metronidazole is not well understood, resistant H. pylori may accumulate lesser amounts of metronidazole at slower rates than sensitive counterparts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Under microaerophilic conditions, the bacteria may not be able to achieve the low redox potential necessary to activate the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/33\">",
"     33",
"    </a>",
"    ]. One report describes an association between metronidazole resistance and mutations in the rdxA gene of strains of H. pylori from both France and North Africa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several reports have documented the development of resistance and subsequent clinical failure among patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    for H. pylori infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. One study found that eradication rates among 196 patients with H. pylori infection were significantly lower for metronidazole-resistant strains than metronidazole-susceptible strains (67 versus 87 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/37\">",
"     37",
"    </a>",
"    ]. A meta-analysis of 49 studies found that resistance to metronidazole decreased the efficacy of treatment by a mean of 38 percent, but there was significant heterogeneity in the results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/38\">",
"     38",
"    </a>",
"    ]. The outcome was more dramatic for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    resistance, although the number of studies available for analysis were fewer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Trichomonas vaginalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistant T. vaginalis strains have been isolated from patients with refractory trichomonal infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In these organisms, the pyruvate:ferredoxin oxidoreductase protein is contained in a hydrogenosome, since the organism lacks mitochondria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/42\">",
"     42",
"    </a>",
"    ]. Resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is associated with reduced transcription activity of the ferredoxin gene, which results in decreased intracellular levels of ferredoxin and reduced pyruvate:ferredoxin oxidoreductase activity. In addition, oxidation of pyruvate to lactate within hydrogenosomes is terminated and occurs instead in the cytosol via lactate dehydrogenase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Susceptibility testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Susceptibility testing for anaerobic bacteria is not routinely performed in the clinical laboratories, since it is cumbersome and not well-standardized. However, testing may be indicated for certain serious infections, including brain abscess, endocarditis, osteomyelitis, arthritis, prosthetic device or vascular graft infection, and refractory or recurrent bacteremia. Testing might also be useful for persistent infections, for infections in which medical rather than surgical therapy is chosen, and for those in which prolonged therapy is anticipated. The Clinical Laboratory Standards Institute (formerly called the National Committee for Clinical Laboratory Standards or NCCLS) has established a breakpoint of 8",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for susceptible strains, 16",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for intermediate susceptibility, and &ge;32",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    for resistance to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The primary benefit of susceptibility testing is not to document susceptibility, but rather to demonstrate unexpected resistance to an antimicrobial that is normally useful. Many clinicians will request anaerobic susceptibility testing from a reference laboratory when a patient has not responded clinically to an appropriate regimen directed at anaerobes. While awaiting the results of this testing, the patient should be changed to a different empiric therapy.",
"   </p>",
"   <p>",
"    The clinical relevance of documented bacterial resistance in the setting of mixed anaerobic infections remains unclear. Other factors, including surgical debridement and the presence of comorbidities, significantly affect treatment outcomes. One prospective multicenter study assessed mortality, clinical treatment failure, and microbiologic persistence in 128 patients with Bacteroides bacteremia; susceptibility testing was performed on all isolates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/45\">",
"     45",
"    </a>",
"    ]. All of the outcome measures were higher for patients who received drugs that were not active against the organism compared with those with susceptible isolates (45 versus 16 percent 30-day mortality; 82 versus 22 percent clinical failure rate; and 47 versus 12 percent microbiologic persistence). No isolates were resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in this study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SPECTRUM OF ACTIVITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is active against a broad array of anaerobes, protozoa, and microaerophilic bacteria. Metronidazole exerts potent bactericidal activity against Bacteroides spp, Clostridium spp, Prevotella spp, Porphyromonas spp, Fusobacterium spp, and Bilophila wadsworthia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. Clostridium spp are usually susceptible to metronidazole, although C. ramosum may require higher concentrations of the drug for inhibition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among gram-positive anaerobic bacilli, 75 percent of Actinomyces spp, Propionibacterium propionica, Propionibacterium acnes, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/16/32004?source=see_link\">",
"     Lactobacillus",
"    </a>",
"    species are resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. Susceptibility of Mobiluncus is variable; Mobiluncus curtisii is usually resistant to metronidazole, whereas Mobiluncus mulieris is often sensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Anaerobic cocci such as Peptostreptococcus and Veillonella species are also inhibited by this drug. Capnocytophaga species are usually sensitive, whereas H. pylori can vary as noted above.",
"   </p>",
"   <p>",
"    Although Gardnerella vaginalis and Actinobacillus actinomycetemcomitans are usually susceptible to the parent compound, the hydroxy metabolite of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is two to eight times more active against these organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Metronidazole is also active against anaerobic protozoa such as T. vaginalis, E. histolytica, Giardia lamblia, Blastocystis hominis, and Balantidium coli.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two of the hallmarks of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    are that the drug achieves high serum concentrations following oral administration and that its tissue penetration is excellent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Systemic metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is well absorbed after oral administration and is virtually 100 percent bioavailable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    generally distributes well into body tissues and, unlike",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    , effectively penetrates the blood-brain barrier. In patients without meningeal inflammation, cerebrospinal fluid (CSF) levels approximate 45 percent of corresponding serum concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/57\">",
"     57",
"    </a>",
"    ]. Those with meningitis experience similar CSF and serum concentrations. Metronidazole exhibits excellent penetration into brain abscesses, where concentrations approximate that of the serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/58\">",
"     58",
"    </a>",
"    ]. Metronidazole also distributes well into muscle tissue of patients with sepsis or those undergoing surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is minimally protein bound, with approximately 80 percent or more circulating as free drug. Concentrations sufficient for therapeutic activity are achieved in hepatic abscesses as well as alveolar bone. Among patients with common bile duct obstruction, metronidazole concentrations in the common bile duct following intravenous administration were reportedly 56 to 99 percent that of serum. Among patients with gallstones but preserved gallbladder function and among those with absent gallbladder function but a patent cystic duct, metronidazole concentrations in the gallbladder bile, common duct bile, and serum were similar. By contrast, little to no metronidazole was recovered from gallbladder bile among patients who had a stone blocking the cystic duct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    exhibits a dose-dependent metabolism, and is metabolized in the liver to glucuronide and oxidative products, including a hydroxy-metabolite, which has 30 to 65 percent of the activity of the parent compound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/62\">",
"     62",
"    </a>",
"    ]. Six to 18 percent of metronidazole is excreted unchanged in urine; the metabolites are also excreted in the urine.",
"   </p>",
"   <p>",
"    The half-life of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    in patients with normal renal function is six to nine hours and is unchanged in those with renal insufficiency. Some studies have demonstrated that elimination of metronidazole metabolites may be reduced among those with renal insufficiency, but there are no specific recommendations for dose-reduction in this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/63\">",
"     63",
"    </a>",
"    ]. Hemodialysis may increase the clearance of metronidazole by 100 percent or more, resulting in a shortened half-life of only 2.1 to 3.3 hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/63-66\">",
"     63-66",
"    </a>",
"    ]. The wide therapeutic index of the drug may make dose supplementation necessary only in seriously ill patients. The pharmacokinetics of metronidazole and its metabolites are not appreciably affected by chronic ambulatory peritoneal dialysis, with peritoneal dialysis accounting for only 8.9 percent of total body clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/67\">",
"     67",
"    </a>",
"    ]. However, the half-life of the drug may be extended to 18 to 20 hours in those with hepatic failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/68-79\">",
"     68-79",
"    </a>",
"    ]. The delay in elimination is directly related to the extent of liver impairment.",
"   </p>",
"   <p>",
"    Among children and adolescents, the pharmacokinetics of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    are similar to that of adults. However, metabolic elimination of metronidazole is significantly decreased among premature neonates, with clearance and half-life correlating with gestational age. Careful dose adjustments are thus recommended for this patient population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/56,73,74\">",
"     56,73,74",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Topically administered metronidazole",
"    </span>",
"    &nbsp;&mdash;&nbsp;When applied to the face,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    gel is absorbed systemically to a negligible degree [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/75\">",
"     75",
"    </a>",
"    ]. When administered intravaginally, metronidazole gel is absorbed to varying degrees, depending upon formulation. The commercial 0.75 percent intravaginal gel produced peak serum concentrations of 0.2 to 0.3",
"    <span class=\"nowrap\">",
"     mg/L,",
"    </span>",
"    which is significantly less than that observed after a single 500 mg oral dose (8 to 13",
"    <span class=\"nowrap\">",
"     mg/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/75\">",
"     75",
"    </a>",
"    ]. However, vaginal suppositories have produced slightly higher peak serum concentrations of 1.1 to 1.9",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (approximately 10 percent of concentrations achieved with oral administration) than the commercial intravaginal gel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TOXICITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common adverse effects associated with systemic",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    therapy are gastrointestinal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Gastrointestinal",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal symptoms such as nausea, anorexia, vomiting, diarrhea, abdominal cramping, and constipation have been associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . An unpleasant metallic taste is also often experienced by those taking metronidazole systemically. Furry tongue, glossitis, and stomatitis have also been experienced, and are associated with Candidal overgrowth. Although the drug is active against C. difficile, cases of C. difficile colitis have been reported, rarely, among patients receiving metronidazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nervous system",
"    </span>",
"    &nbsp;&mdash;&nbsp;Seizures, peripheral neuropathy, dizziness, vertigo, ataxia, confusion, irritability, weakness, insomnia, headache, and tremors have been reported among patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , particularly among those receiving high doses of the drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/74,78,79\">",
"     74,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypersensitivity reactions have been reported among patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and may include urticaria, erythematous rash, flushing, bronchospasm, and serum sickness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/80\">",
"     80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Genitourinary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient darkening of the urine to a deep red-brown color is common among patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . Dysuria, cystitis, incontinence, vaginal Candida overgrowth, and decreased libido have also been reported less commonly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less common adverse reactions reported with use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    include joint pain, thrombophlebitis; hematologic effects such as reversible neutropenia and thrombocytopenia have rarely occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. Several case reports have also documented pancreatitis and hepatitis associated with use of metronidazole, although these events are rare [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/83,84\">",
"     83,84",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Metronidazole topical (dermatologic) gel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic effects are rare with topical application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    gel, since very little metronidazole is absorbed systemically. Local effects including skin irritation, transient skin erythema, and mild dryness or burning of the skin are uncommon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Metronidazole vaginal gel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genitourinary effects include symptomatic Candida",
"    <span class=\"nowrap\">",
"     cervicitis/vaginitis,",
"    </span>",
"    vaginal, perineal, or vulvar itching, vaginal discharge and vulvar swelling. Cramps and abdominal or uterine pain have also been reported among women using",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    intravaginally. Nausea, metallic taste, constipation, diarrhea, decreased appetite, dizziness, and headache have been reported less commonly. Increased or decreased white blood counts and rash are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     DRUG INTERACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ingestion of alcohol during",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    therapy (administered orally or vaginally) can result in a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    -like reaction characterized by flushing, tachycardia, palpitations, nausea, and vomiting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/85\">",
"     85",
"    </a>",
"    ]. Ethanol-containing medications such as elixirs as well as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    capsules, IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/51/20276?source=see_link\">",
"     anidulafungin",
"    </a>",
"    , IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and many",
"    <span class=\"nowrap\">",
"     cough/cold",
"    </span>",
"    syrups can also lead to a disulfiram-like reaction when ingested with metronidazole. In addition, use of metronidazole with disulfiram can result in an acute psychosis or confusional state [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/56\">",
"     56",
"    </a>",
"    ]. Sudden deaths have been attributed to",
"    <span class=\"nowrap\">",
"     metronidazole/ethanol",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     metronidazole/disulfiram",
"    </span>",
"    reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    can promote renal retention of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    , resulting in increased lithium levels and lithium toxicity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Metronidazole can also decrease elimination of ergot derivatives, so concomitant use of these agents is not recommended.",
"   </p>",
"   <p>",
"    Most drug interactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    occur in the liver, where metronidazole is metabolized. It has been suggested that metronidazole selectively inhibits aromatic oxidase reactions in the liver, which may explain its inhibition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    metabolism. Metronidazole decreases the clearance of phenytoin approximately 15 percent and thus prolongs its elimination half-life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/89\">",
"     89",
"    </a>",
"    ]. This may result in increased serum concentrations of phenytoin. Caution should also be used when administering",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/51/14138?source=see_link\">",
"     fosphenytoin",
"    </a>",
"    and metronidazole concomitantly. Metronidazole can increase the anticoagulant effect of warfarin via its S(-)-warfarin stereoisomer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/90\">",
"     90",
"    </a>",
"    ]. Thus, patients receiving the two agents concomitantly should have prothrombin time monitored closely and warfarin doses adjusted accordingly. One case report of carbamazepine toxicity in a patient five days after initiation of metronidazole suggests a potential drug interaction may also exist between metronidazole and carbamazepine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A potential interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    in a 71-year old female resulted in QTc prolongation and torsades de pointes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/92\">",
"     92",
"    </a>",
"    ]. Cytochrome P450-3R4 inhibition by metronidazole may have resulted in increased serum concentrations of amiodarone, leading to marked QT interval prolongation and torsades.",
"   </p>",
"   <p>",
"    A few investigators have reported significant increases in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    serum concentrations after patients were initiated on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/93-95\">",
"     93-95",
"    </a>",
"    ]. In one patient, cyclosporine increased 97 percent during concomitant metronidazole treatment and then returned to baseline after metronidazole was discontinued. In another patient, tacrolimus increased 99 percent and then returned to baseline levels after cessation of metronidazole. These reports suggest that caution should be used when dosing these agents concomitantly, with dose adjustments of cyclosporine and tacrolimus made as necessary.",
"   </p>",
"   <p>",
"    A small study reported a significant interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    . Patients received metronidazole as graft-versus-host-disease prophylaxis in the setting of hematopoietic cell transplantation had significantly higher levels of busulfan than controls who received busulfan alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/96\">",
"     96",
"    </a>",
"    ]. More adverse events were noted in the group of subjects receiving metronidazole and busulfan together (multiorgan failure, veno-occlusive disease, and hemorrhagic cystitis), so the authors recommend avoiding administration of these agents together.",
"   </p>",
"   <p>",
"    Hepatic enzyme inducers such as barbiturates,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    can significantly reduce plasma concentrations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    by increasing its clearance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/97\">",
"     97",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    may also enhance hepatic clearance of metronidazole [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/98\">",
"     98",
"    </a>",
"    ]. These interactions can result in clinical failure of metronidazole therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/97\">",
"     97",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"     Cimetidine",
"    </a>",
"    may increase serum metronidazole concentrations by inhibiting hepatic enzyme activity, but data regarding this interaction are conflicting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/99\">",
"     99",
"    </a>",
"    ]. Binding interactions with the gastrointestinal tract can also occur between metronidazole and aluminum- or magnesium-containing antacids, as well as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/33/36374?source=see_link\">",
"     cholestyramine",
"    </a>",
"    . The interactions result in approximately 15 to 20 percent decreased bioavailability of metronidazole.",
"   </p>",
"   <p>",
"    Coadministration of flavonoid extract of milk thistle, silymarin, can lead to increased clearance of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    , possibly through silymarin induction of intestinal p-glycoprotein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/100\">",
"     100",
"    </a>",
"    ]. Thus concomitant use of these agents should be avoided.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SPECIAL POPULATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    has been classified by the US Food and Drug Administration as pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"mobipreview.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). The use of metronidazole in pregnancy is somewhat controversial. Metronidazole crosses the placenta and rapidly enters the fetal circulation. Since there are no adequate well-controlled studies demonstrating safety in pregnant women, metronidazole should only be used in pregnancy only if it is clearly needed and it should be avoided during the first trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nursing",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     Metronidazole",
"    </a>",
"    is excreted in the breast milk after systemic administration at concentrations similar to those in the serum. Its half-life in breast milk is approximately 9 to 10 hours. Thus it is recommended that nursing be discontinued during, and for three days after, metronidazole therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Hemodialysis/chronic ambulatory peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    is significantly removed by hemodialysis, no specific dose recommendations are made for this patient population. Dose modifications are not recommended for patients undergoing CAPD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Renal/hepatic dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific dose adjustments are recommended for patients with renal or hepatic dysfunction receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    . However, since accumulation of the drug and its metabolites can occur in those with hepatic dysfunction, lower doses may be considered based upon severity of illness and patient tolerability. Doses of 500 mg intravenously once or twice daily have been recommended for patients with severe liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31817/abstract/26,66,101\">",
"     26,66,101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1051243296\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      is one of the mainstay drugs for the treatment of anaerobic infections and the treatment of choice for most patients with mild to moderate Clostridium difficile-associated diarrhea. It is approved by the US Food and Drug Administration for the treatment of anaerobic and protozoal infections. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mechanism of action of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      against obligate anaerobes occurs through a four-step process that includes entry into the organism, reductive activation by intracellular transport proteins, interactions with intracellular targets, and breakdown of cytotoxic intermediate products. Metronidazole is also cytotoxic to facultative anaerobic bacteria such as Helicobacter pylori and Gardnerella vaginalis, but the mechanism of action against these organisms is not well understood. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Mechanism of action'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite extensive worldwide use, acquired resistance to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      among anaerobic bacteria is rare. Resistance to metronidazole has been reported more frequently with H. pylori. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Resistance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Two of the hallmarks of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      are that the drug achieves high serum concentrations following oral administration and that its tissue penetration is excellent. Metronidazole generally distributes well into body tissues and, unlike",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      , effectively penetrates the blood-brain barrier. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pharmacokinetics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common adverse effects associated with systemic",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      therapy are gastrointestinal (eg, nausea, anorexia, vomiting, diarrhea, abdominal cramping, constipation). Metronidazole can also cause nervous system effects (eg, peripheral neuropathy, confusion, dizziness). Metronidazole has also been associated with hypersensitivity reactions. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Toxicity'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"     <li>",
"      Ingestion of alcohol during",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      therapy (administered orally or vaginally) can result in a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/17/5397?source=see_link\">",
"       disulfiram",
"      </a>",
"      -like reaction characterized by flushing, tachycardia, palpitations, nausea, and vomiting. Ethanol-containing medications such as elixirs as well as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/33/19992?source=see_link\">",
"       tipranavir",
"      </a>",
"      capsules, IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/51/20276?source=see_link\">",
"       anidulafungin",
"      </a>",
"      , IV",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      , and many",
"      <span class=\"nowrap\">",
"       cough/cold",
"      </span>",
"      syrups can also lead to a disulfiram-like reaction when ingested with metronidazole. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       Metronidazole",
"      </a>",
"      can promote renal retention of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      , resulting in increased lithium levels and lithium toxicity. Metronidazole can also decrease elimination of ergot derivatives, so concomitant use of these agents is not recommended. Most drug interactions with metronidazole occur in the liver, where metronidazole is metabolized. It has been suggested that metronidazole selectively inhibits aromatic oxidase reactions in the liver, which may explain its inhibition of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      metabolism. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Agents that induce hepatic enzymes, such as barbiturates,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      , can reduce levels of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      . These interactions have been associated with clinical failure of metronidazole. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Since there are no adequate well-controlled studies demonstrating safety in pregnant women,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      should only be used during pregnancy only if it clearly needed and it should be avoided during the first trimester. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/1\">",
"      L&ouml;fmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis 2010; 50 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/2\">",
"      Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010; 31:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/3\">",
"      Edwards DI. Nitroimidazole drugs--action and resistance mechanisms. I. Mechanisms of action. J Antimicrob Chemother 1993; 31:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/4\">",
"      Edwards DI. Reduction of nitroimidazoles in vitro and DNA damage. Biochem Pharmacol 1986; 35:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/5\">",
"      M&uuml;ller M. Reductive activation of nitroimidazoles in anaerobic microorganisms. Biochem Pharmacol 1986; 35:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/6\">",
"      Tocher JH, Edwards DI. The interaction of reduced metronidazole with DNA bases and nucleosides. Int J Radiat Oncol Biol Phys 1992; 22:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/7\">",
"      Tocher JH, Edwards DI. Evidence for the direct interaction of reduced metronidazole derivatives with DNA bases. Biochem Pharmacol 1994; 48:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/8\">",
"      Goldman P, Koch RL, Yeung TC, et al. Comparing the reduction of nitroimidazoles in bacteria and mammalian tissues and relating it to biological activity. Biochem Pharmacol 1986; 35:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/9\">",
"      Stratton CW, Weeks LS, Aldridge KE. Comparison of the bactericidal activity of clindamycin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis 1991; 14:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/10\">",
"      Stratton CW, Weeks LS, Aldridge KE. Inhibitory and bactericidal activity of selected beta-lactam agents alone and in combination with beta-lactamase inhibitors compared with that of cefoxitin and metronidazole against cefoxitin-susceptible and cefoxitin-resistant isolates of the Bacteroides fragilis group. Diagn Microbiol Infect Dis 1992; 15:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/11\">",
"      Ravdin JI, Skilogiannis J. In vitro susceptibilities of Entamoeba histolytica to azithromycin, CP-63,956, erythromycin, and metronidazole. Antimicrob Agents Chemother 1989; 33:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/12\">",
"      Nix DE, Tyrrell R, M&uuml;ller M. Pharmacodynamics of metronidazole determined by a time-kill assay for Trichomonas vaginalis. Antimicrob Agents Chemother 1995; 39:1848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/13\">",
"      Ralph ED, Kirby WM. Unique bactericidal action of metronidazole against Bacteroides fragilis and Clostridium perfringens. Antimicrob Agents Chemother 1975; 8:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/14\">",
"      Ralph ED, Amatnieks YE. Potentially synergistic antimicrobial combinations with metronidazole against Bacteroides fragilis. Antimicrob Agents Chemother 1980; 17:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/15\">",
"      Cuchural GJ Jr, Tally FP, Jacobus NV, et al. Antimicrobial susceptibilities of 1,292 isolates of the Bacteroides fragilis group in the United States: comparison of 1981 with 1982. Antimicrob Agents Chemother 1984; 26:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/16\">",
"      Musial CE, Rosenblatt JE. Antimicrobial susceptibilities of anaerobic bacteria isolated at the Mayo Clinic during 1982 through 1987: comparison with results from 1977 through 1981. Mayo Clin Proc 1989; 64:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/17\">",
"      Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 1999; 43:2417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/18\">",
"      Aldridge KE, Ashcraft D, O'Brien M, Sanders CV. Bacteremia due to Bacteroides fragilis group: distribution of species, beta-lactamase production, and antimicrobial susceptibility patterns. Antimicrob Agents Chemother 2003; 47:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/19\">",
"      van Winkelhoff AJ, Herrera Gonzales D, Winkel EG, et al. Antimicrobial resistance in the subgingival microflora in patients with adult periodontitis. A comparison between The Netherlands and Spain. J Clin Periodontol 2000; 27:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/20\">",
"      Duerden BI. Role of the reference laboratory in susceptibility testing of anaerobes and a survey of isolates referred from laboratories in England and Wales during 1993-1994. Clin Infect Dis 1995; 20 Suppl 2:S180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/21\">",
"      Labb&eacute; AC, Bourgault AM, Vincelette J, et al. Trends in antimicrobial resistance among clinical isolates of the Bacteroides fragilis group from 1992 to 1997 in Montreal, Canada. Antimicrob Agents Chemother 1999; 43:2517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/22\">",
"      Shore KP, Pottumarthy S, Morris AJ. Susceptibility of anaerobic bacteria in Auckland: 1991-1996. N Z Med J 1999; 112:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/23\">",
"      Brazier JS, Stubbs SL, Duerden BI. Metronidazole resistance among clinical isolates belonging to the Bacteroides fragilis group: time to be concerned? J Antimicrob Chemother 1999; 44:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/24\">",
"      Barbut F, Decr&eacute; D, Burghoffer B, et al. Antimicrobial susceptibilities and serogroups of clinical strains of Clostridium difficile isolated in France in 1991 and 1997. Antimicrob Agents Chemother 1999; 43:2607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/25\">",
"      Reysset G, Haggoud A, Sebald M. Genetics of resistance of Bacteroides species to 5-nitroimidazole. Clin Infect Dis 1993; 16 Suppl 4:S401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/26\">",
"      Rasmussen BA, Bush K, Tally FP. Antimicrobial resistance in Bacteroides. Clin Infect Dis 1993; 16 Suppl 4:S390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/27\">",
"      Narikawa S, Suzuki T, Yamamoto M, Nakamura M. Lactate dehydrogenase activity as a cause of metronidazole resistance in Bacteroides fragilis NCTC 11295. J Antimicrob Chemother 1991; 28:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/28\">",
"      Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/29\">",
"      Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. Am J Gastroenterol 1998; 93:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/30\">",
"      M&eacute;graud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43:2747.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/31\">",
"      Lacey SL, Moss SF, Taylor GW. Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori. J Antimicrob Chemother 1993; 32:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/32\">",
"      Moore RA, Beckthold B, Bryan LE. Metronidazole uptake in Helicobacter pylori. Can J Microbiol 1995; 41:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/33\">",
"      van Zwet AA, Thijs JC, Schievink-de Vries W, et al. In vitro studies on stability and development of metronidazole resistance in Helicobacter pylori. Antimicrob Agents Chemother 1994; 38:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/34\">",
"      Tankovic J, Lamarque D, Delchier JC, et al. Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori. Antimicrob Agents Chemother 2000; 44:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/35\">",
"      Logan RP, Gummett PA, Misiewicz JJ, et al. One week eradication regimen for Helicobacter pylori. Lancet 1991; 338:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/36\">",
"      Owen RJ, Bell GD, Desai M, et al. Biotype and molecular fingerprints of metronidazole-resistant strains of Helicobacter pylori from antral gastric mucosa. J Med Microbiol 1993; 38:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/37\">",
"      Wong WM, Gu Q, Wang WH, et al. Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance. Clin Infect Dis 2003; 37:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/38\">",
"      Dore MP, Leandro G, Realdi G, et al. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/39\">",
"      Krajden S, Lossick JG, Wilk E, et al. Persistent Trichomonas vaginalis infection due to a metronidazole-resistant strain. CMAJ 1986; 134:1373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/40\">",
"      M&uuml;ller M, Meingassner JG, Miller WA, Ledger WJ. Three metronidazole-resistant strains of Trichomonas vaginalis from the United States. Am J Obstet Gynecol 1980; 138:808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/41\">",
"      Dombrowski MP, Sokol RJ, Brown WJ, Bronsteen RA. Intravenous therapy of metronidazole-resistant Trichomonas vaginalis. Obstet Gynecol 1987; 69:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/42\">",
"      Kulda J. Trichomonads, hydrogenosomes and drug resistance. Int J Parasitol 1999; 29:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/43\">",
"      Edwards DI. Nitroimidazole drugs--action and resistance mechanisms. II. Mechanisms of resistance. J Antimicrob Chemother 1993; 31:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/44\">",
"      Quon DV, d'Oliveira CE, Johnson PJ. Reduced transcription of the ferredoxin gene in metronidazole-resistant Trichomonas vaginalis. Proc Natl Acad Sci U S A 1992; 89:4402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/45\">",
"      Nguyen MH, Yu VL, Morris AJ, et al. Antimicrobial resistance and clinical outcome of Bacteroides bacteremia: findings of a multicenter prospective observational trial. Clin Infect Dis 2000; 30:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/46\">",
"      Baron EJ, Ropers G, Summanen P, Courcol RJ. Bactericidal activity of selected antimicrobial agents against Bilophila wadsworthia and Bacteroides gracilis. Clin Infect Dis 1993; 16 Suppl 4:S339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/47\">",
"      Pankuch GA, Jacobs MR, Appelbaum PC. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin. Antimicrob Agents Chemother 1993; 37:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/48\">",
"      Sheikh W, Pitkin DH, Nadler H. Antibacterial activity of meropenem and selected comparative agents against anaerobic bacteria at seven North American centers. Clin Infect Dis 1993; 16 Suppl 4:S361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/49\">",
"      Alexander CJ, Citron DM, Brazier JS, Goldstein EJ. Identification and antimicrobial resistance patterns of clinical isolates of Clostridium clostridioforme, Clostridium innocuum, and Clostridium ramosum compared with those of clinical isolates of Clostridium perfringens. J Clin Microbiol 1995; 33:3209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/50\">",
"      Brazier JS, Levett PN, Stannard AJ, et al. Antibiotic susceptibility of clinical isolates of clostridia. J Antimicrob Chemother 1985; 15:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/51\">",
"      Goldstein EJ, Citron DM, Cherubin CE, Hillier SL. Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 1993; 31:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/52\">",
"      Jones BM, Geary I, Lee ME, Duerden BI. Comparison of the in vitro activities of fenticonazole, other imidazoles, metronidazole, and tetracycline against organisms associated with bacterial vaginosis and skin infections. Antimicrob Agents Chemother 1989; 33:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/53\">",
"      Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds. Antimicrob Agents Chemother 1987; 31:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/54\">",
"      Bannatyne RM, Jackowski J, Cheung R, Biers K. Susceptibility of Gardnerella vaginalis to metronidazole, its bioactive metabolites, and tinidazole. Am J Clin Pathol 1987; 87:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/55\">",
"      Easmon CS, Ison CA, Kaye CM, et al. Pharmacokinetics of metronidazole and its principal metabolites and their activity against Gardnerella vaginalis. Br J Vener Dis 1982; 58:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/56\">",
"      Lau AH, Lam NP, Piscitelli SC, et al. Clinical pharmacokinetics of metronidazole and other nitroimidazole anti-infectives. Clin Pharmacokinet 1992; 23:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/57\">",
"      Jokipii AM, Myllyl&auml; VV, Hokkanen E, Jokipii L. Penetration of the blood brain barrier by metronidazole and tinidazole. J Antimicrob Chemother 1977; 3:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/58\">",
"      Warner JF, Perkins RL, Cordero L. Metronidazole therapy of anaerobic bacteremia, meningitis, and brain abscess. Arch Intern Med 1979; 139:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/59\">",
"      Karjagin J, P&auml;hkla R, Karki T, Starkopf J. Distribution of metronidazole in muscle tissue of patients with septic shock and its efficacy against Bacteroides fragilis in vitro. J Antimicrob Chemother 2005; 55:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/60\">",
"      Karjagin J, P&auml;hkla R, Starkopf J. Perioperative penetration of metronidazole into muscle tissue: a microdialysis study. Eur J Clin Pharmacol 2004; 59:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/61\">",
"      Nielsen ML, Justesen T. Excretion of metroindazole in human bile. Investigations of hepatic bile, common duct bile, and gallbladder bile. Scand J Gastroenterol 1977; 12:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/62\">",
"      Jensen JC, Gugler R. Single- and multiple-dose metronidazole kinetics. Clin Pharmacol Ther 1983; 34:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/63\">",
"      Kreeft JH, Ogilvie RI, Dufresne LR. Metronidazole kinetics in dialysis patients. Surgery 1983; 93:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/64\">",
"      Lau AH, Chang CW, Sabatini S. Hemodialysis clearance of metronidazole and its metabolites. Antimicrob Agents Chemother 1986; 29:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/65\">",
"      Roux AF, Moirot E, Delhotal B, et al. Metronidazole kinetics in patients with acute renal failure on dialysis: a cumulative study. Clin Pharmacol Ther 1984; 36:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/66\">",
"      Somogyi A, Kong C, Sabto J, et al. Disposition and removal of metronidazole in patients undergoing haemodialysis. Eur J Clin Pharmacol 1983; 25:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/67\">",
"      Guay DR, Meatherall RC, Baxter H, et al. Pharmacokinetics of metronidazole in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1984; 25:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/68\">",
"      Farrell G, Baird-Lambert J, Cvejic M, Buchanan N. Disposition and metabolism of metronidazole in patients with liver failure. Hepatology 1984; 4:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/69\">",
"      Farrell G, Buchanan N, Baird-Lambert J. Impaired elimination of metronidazole in decompensated chronic liver disease. Br Med J (Clin Res Ed) 1984; 288:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/70\">",
"      Daneshmend TK, Roberts CJ. Impaired elimination of metronidazole in decompensated chronic liver disease. Br Med J (Clin Res Ed) 1984; 288:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/71\">",
"      Plaisance KI, Quintiliani R, Nightingale CH. The pharmacokinetics of metronidazole and its metabolites in critically ill patients. J Antimicrob Chemother 1988; 21:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/72\">",
"      Lau AH, Evans R, Chang CW, Seligsohn R. Pharmacokinetics of metronidazole in patients with alcoholic liver disease. Antimicrob Agents Chemother 1987; 31:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/73\">",
"      Upadhyaya P, Bhatnagar V, Basu N. Pharmacokinetics of intravenous metronidazole in neonates. J Pediatr Surg 1988; 23:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/74\">",
"      Kusumi RK, Plouffe JF, Wyatt RH, Fass RJ. Central nervous system toxicity associated with metronidazole therapy. Ann Intern Med 1980; 93:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/75\">",
"      Lamp KC, Freeman CD, Klutman NE, Lacy MK. Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials. Clin Pharmacokinet 1999; 36:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/76\">",
"      Urtasun RC, Rabin HR, Partington J. Human pharmacokinetics and toxicity of high-dose metronidazole administered orally and intravenously. Surgery 1983; 93:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/77\">",
"      Saginur R, Hawley CR, Bartlett JG. Colitis associated with metronidazole therapy. J Infect Dis 1980; 141:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/78\">",
"      Frytak S, Moertel CH, Childs DS. Neurologic toxicity associated with high-dose metronidazole therapy. Ann Intern Med 1978; 88:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/79\">",
"      Halloran TJ. Convulsions associated with high cumulative doses of metronidazole. Drug Intell Clin Pharm 1982; 16:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/80\">",
"      Knowles S, Choudhury T, Shear NH. Metronidazole hypersensitivity. Ann Pharmacother 1994; 28:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/81\">",
"      McKendrick MW, Geddes AM. Neutropenia associated with metronidazole. Br Med J 1979; 2:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/82\">",
"      Smith JA. Neutropenia associated with metronidazole therapy. Can Med Assoc J 1980; 123:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/83\">",
"      Celifarco A, Warschauer C, Burakoff R. Metronidazole-induced pancreatitis. Am J Gastroenterol 1989; 84:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/84\">",
"      Sanford KA, Mayle JE, Dean HA, Greenbaum DS. Metronidazole-associated pancreatitis. Ann Intern Med 1988; 109:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/85\">",
"      Alexander I. 'Alcohol-antabuse' syndrome in patients receiving metronidazole during gynaecological treatment. Br J Clin Pract 1985; 39:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/86\">",
"      Heath MJ, Pachar JV, Perez Martinez AL, Toseland PA. An exceptional case of lethal disulfiram-alcohol reaction. Forensic Sci Int 1992; 56:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/87\">",
"      Teicher MH, Altesman RI, Cole JO, Schatzberg AF. Possible nephrotoxic interaction of lithium and metronidazole. JAMA 1987; 257:3365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/88\">",
"      Lassen E. Effects of acute and short-time antibiotic treatment on renal lithium elimination and serum lithium levels in the rat. Acta Pharmacol Toxicol (Copenh) 1985; 56:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/89\">",
"      Blyden GT, Scavone JM, Greenblatt DJ. Metronidazole impairs clearance of phenytoin but not of alprazolam or lorazepam. J Clin Pharmacol 1988; 28:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/90\">",
"      O'Reilly RA. The stereoselective interaction of warfarin and metronidazole in man. N Engl J Med 1976; 295:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/91\">",
"      Patterson BD. Possible interaction between metronidazole and carbamazepine. Ann Pharmacother 1994; 28:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/92\">",
"      Kounas SP, Letsas KP, Sideris A, et al. QT interval prolongation and torsades de pointes due to a coadministration of metronidazole and amiodarone. Pacing Clin Electrophysiol 2005; 28:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/93\">",
"      Zylber-Katz E, Rubinger D, Berlatzky Y. Cyclosporine interactions with metronidazole and cimetidine. Drug Intell Clin Pharm 1988; 22:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/94\">",
"      Herzig K, Johnson DW. Marked elevation of blood cyclosporin and tacrolimus levels due to concurrent metronidazole therapy. Nephrol Dial Transplant 1999; 14:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/95\">",
"      Page RL 2nd, Klem PM, Rogers C. Potential elevation of tacrolimus trough concentrations with concomitant metronidazole therapy. Ann Pharmacother 2005; 39:1109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/96\">",
"      Nilsson C, Aschan J, Hentschke P, et al. The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2003; 31:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/97\">",
"      Eradiri O, Jamali F, Thomson AB. Interaction of metronidazole with phenobarbital, cimetidine, prednisone, and sulfasalazine in Crohn's disease. Biopharm Drug Dispos 1988; 9:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/98\">",
"      Mead PB, Gibson M, Schentag JJ, Ziemniak JA. Possible alteration of metronidazole metabolism by phenobarbital. N Engl J Med 1982; 306:1490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/99\">",
"      Loft S, D&oslash;ssing M, Sonne J, et al. Lack of effect of cimetidine on the pharmacokinetics and metabolism of a single oral dose of metronidazole. Eur J Clin Pharmacol 1988; 35:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/100\">",
"      Rajnarayana K, Reddy MS, Vidyasagar J, Krishna DR. Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole. Arzneimittelforschung 2004; 54:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31817/abstract/101\">",
"      Loft S, Sonne J, D&oslash;ssing M, Andreasen PB. Metronidazole pharmacokinetics in patients with hepatic encephalopathy. Scand J Gastroenterol 1987; 22:117.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 464 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-8D13A6BE0D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31817=[""].join("\n");
var outline_f31_4_31817=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1051243296\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MECHANISM OF ACTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RESISTANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Anaerobes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Helicobacter pylori",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Susceptibility testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SPECTRUM OF ACTIVITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Systemic metronidazole",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Topically administered metronidazole",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TOXICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Gastrointestinal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nervous system",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Genitourinary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Metronidazole topical (dermatologic) gel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Metronidazole vaginal gel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      DRUG INTERACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SPECIAL POPULATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nursing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Hemodialysis/chronic ambulatory peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Renal/hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1051243296\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/464\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/464|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/39/42617?source=related_link\">",
"      Anaerobic bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/39/23159?source=related_link\">",
"      Clindamycin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/29/20954?source=related_link\">",
"      Clostridium difficile in adults: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/16/33031?source=related_link\">",
"      Extraintestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/56/33671?source=related_link\">",
"      Intestinal Entamoeba histolytica amebiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/53/1881?source=related_link\">",
"      Trichomonas vaginalis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_4_31818="Initial treatment of epilepsy in adults";
var content_f31_4_31818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Initial treatment of epilepsy in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31818/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31818/contributors\">",
"     Steven Karceski, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31818/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31818/contributors\">",
"     Timothy A Pedley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/4/31818/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/4/31818/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/4/31818/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is the syndrome of two or more unprovoked seizures in a person's lifetime. Individuals who have had two or more unprovoked epileptic seizures are more likely than not to have more seizures. Not only are seizures disruptive in a patient's life, they can also cause injury and are associated with disability and lower rates of employment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Uncontrolled generalized tonic-clonic seizures in patients with epilepsy are also believed to contribute to the almost threefold increased mortality associated with this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/1,3-6\">",
"     1,3-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The management of patients with epilepsy is focused on three main goals: controlling seizures, avoiding or minimizing treatment side effects, and maintaining or restoring quality of life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/3,7\">",
"     3,7",
"    </a>",
"    ]. The initial treatment of epilepsy is with an antiepileptic drug (AED) in monotherapy. With an expanding list of available AEDs and no single AED that is clearly superior in terms of efficacy or tolerability, clinicians must individualize the choice of AED for each patient.",
"   </p>",
"   <p>",
"    This topic will discuss the approach to the initial treatment of epilepsy. Other topics discuss the evaluation of patients with seizures and epilepsy, other aspects of epilepsy therapy, and features of specific AEDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link\">",
"     \"Evaluation of the first seizure in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link\">",
"     \"Overview of the management of epilepsy in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2890?source=see_link\">",
"     \"Evaluation and management of drug-resistant epilepsy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     WHEN TO START AED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiepileptic drug (AED) therapy is generally reserved for patients who are at increased risk for recurrent seizures. Depending on a number of considerations, AED therapy may not be indicated after a first epileptic seizure, particularly if that seizure was provoked (ie, an acute symptomatic seizure). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link&amp;anchor=H4#H4\">",
"     \"Evaluation of the first seizure in adults\", section on 'Acute symptomatic seizures'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AED treatment is generally started after the second seizure because seizure recurrence indicates that the patient has a substantially increased risk for additional seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. In one prospective case series, the risk of another seizure after two unprovoked seizures was 73 percent at four years (most of these patients were treated with AEDs) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/9\">",
"     9",
"    </a>",
"    ]. Certain seizure types (typical absence, myoclonic, complex partial and epileptic seizures) are often already recurrent at the time of presentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk of seizure recurrence after a first seizure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrence after a single, unprovoked seizure was 14 percent at one year, 29 percent at three years, and 34 percent at five years in one prospective hospital-based study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/11\">",
"     11",
"    </a>",
"    ]. However, most individuals in this study were treated with AEDs. Prospective, randomized trials of individuals with a first unprovoked seizure estimate the two-year recurrence risk in untreated patients to be 40 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/8,12,13\">",
"     8,12,13",
"    </a>",
"    ]. The risk of recurrence is highest immediately after the first seizure and diminishes with time; 80 to 90 percent of patients who have recurrent seizures do so within two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These and other studies have identified three high risk features for seizure recurrence after a first unprovoked seizure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/8,10-15\">",
"     8,10-15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epileptiform abnormalities on EEG. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32425?source=see_link\">",
"       \"Electroencephalography (EEG) in the diagnosis of seizures and epilepsy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Remote symptomatic cause, as identified by clinical history or neuroimaging (eg, brain tumor, brain malformation). Acute symptomatic seizures have a lower risk for subsequent epilepsy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=see_link&amp;anchor=H4#H4\">",
"       \"Evaluation of the first seizure in adults\", section on 'Acute symptomatic seizures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Abnormal neurologic examination, including focal findings and intellectual disability.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although a single unprovoked seizure is usually not treated with medication, AED treatment after a first seizure may be considered in any of these higher risk subgroups. Although there are no prospective trials to support this idea, many clinicians believe that the risk is even higher when a person has two or more of these high risk features. Other potential risk factors for seizure recurrence have been investigated and remain more uncertain. As an example, patients who have a first presentation with status epilepticus or with multiple seizures within a single day are more likely to be treated with AEDs than are those with a single short-duration seizure. However, limited data suggest that presentation with status epilepticus, in the absence of other risk factors, does not increase the risk of seizure recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/8,10,11,17\">",
"     8,10,11,17",
"    </a>",
"    ]. Similarly, whether a history of prior febrile seizures is associated with an increased risk of seizure recurrence after a first unprovoked afebrile seizure is uncertain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/8,10,11,15\">",
"     8,10,11,15",
"    </a>",
"    ]. Study results have conflicted as to whether a family history of epilepsy impacts recurrence risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/8,10,11,13,15\">",
"     8,10,11,13,15",
"    </a>",
"    ]. This varies according to the epilepsy syndrome; several epilepsy syndromes have been identified as genetic in origin. Finally, ome observations suggest that a first seizure that occurs during sleep is associated with a greater risk of recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/10,15\">",
"     10,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Benefit of early versus deferred treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate AED treatment reduces the incidence of seizure recurrence in the short-term. However, studies suggest that starting an AED has little impact on long-term outcome. Randomized, controlled trials have found that immediate treatment reduces the risk of seizure recurrence in the first one to two years by 30 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/10,12-14\">",
"     10,12-14",
"    </a>",
"    ]. However, at four and five years after the first seizure, patients had similar rates of complete seizure remission whether AED treatment was initiated immediately after the first seizure or deferred until a second seizure occurred. At least one randomized trial found that 20-year mortality was not impacted by immediate versus deferred treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the aggregate, quality of life outcomes, as measured in one randomized study, were not different with early versus deferred treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/19\">",
"     19",
"    </a>",
"    ]. However, the questionnaires demonstrated significant tradeoffs between the adverse effects of seizures versus adverse effects of taking AEDs, suggesting that individual patient preferences should be considered. As one example, patients randomized to early AED treatment were more likely to be able to drive than patients whose treatment was deferred. A need to drive or operate heavy machinery along with other occupational and psychological consequences of suffering a recurrent seizure are important considerations when deciding whether to start AED therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SELECTION OF AN AED",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is initially treated with AED monotherapy. Almost half of patients will become seizure-free with their first AED trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Clinicians must weigh relative efficacy and potential for adverse effects of each drug. Unfortunately, data in this regard are somewhat limited. In the absence of data identifying the most effective AED, physicians formulate treatment plans based upon other, often patient-specific, factors such as potential side effects, drug interactions, and comorbid medical illnesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     AED comparison trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;No single AED is clearly the most effective or best tolerated. Randomized controlled clinical trials (RCTs) assessing efficacy and tolerability provide the least biased evidence of efficacy, however, these typically compare active therapy to a subtherapeutic dose of the same agent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    to placebo rather than to an effective dose of another AED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/22\">",
"     22",
"    </a>",
"    ]. Another limitation of most RCTs in epilepsy is that these are usually performed testing new AEDs as add-on treatment in patients with treatment-resistant illness. Such patients may not be representative of general clinical population.",
"   </p>",
"   <p>",
"    A few randomized trials have compared AED regimens in monotherapy as initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       Gabapentin",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/25,26\">",
"       25,26",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/27\">",
"       27",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/29\">",
"       29",
"      </a>",
"      ] or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/30\">",
"       30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       Oxcarbazepine",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/31,32\">",
"       31,32",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/33\">",
"       33",
"      </a>",
"      ] and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"       Zonisamide",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       Levetiracetam",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While none of these trials showed a difference in efficacy between drugs, these studies were generally of short duration (24 or 48 weeks). Such studies can compare the incidence of short term side effects between drugs, but they have limited power to assess relative efficacy. In general, but with some exceptions, the newer AED was somewhat superior with respect to tolerability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/22\">",
"     22",
"    </a>",
"    ]. Because so few data exist regarding drug comparisons, some authors have compared different AEDs using patient data from RCTs. However, such studies can be problematic, especially when patient populations and drug doses vary between trials; this substantively limits the ability to compare the studied treatment. As an example, a study comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    in patients with newly diagnosed partial seizures may have been limited by use of suboptimal dosing of pregabalin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/28,37\">",
"     28,37",
"    </a>",
"    ]. In general, such studies have lacked power either to refute or substantively confirm these results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/38-42\">",
"     38-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, the Standard and New Antiepileptic Drugs (SANAD) trial was a large trial (1721 patients with partial epilepsy and 716 patients with generalized seizures) completed in the United Kingdom that compared AED treatments for the initial treatment of epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. In an effort to balance methodologic rigor and practicality, this trial was not blinded [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/46\">",
"     46",
"    </a>",
"    ]. The treating physician determined how quickly to titrate the medication, instead of following a standardized blinded protocol. This approach may have better approximated the \"real life\" use of these drugs than would a blinded trial. Outcome measures were time to treatment failure (for either inadequate seizure control or intolerable side effects) and time to achievement of a 12-month seizure remission. The mean follow-up time exceeded three years. The main findings were:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients treated for partial epilepsy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      had the longest time to treatment failure compared with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/44\">",
"       44",
"      </a>",
"      ]. Lamotrigine and carbamazepine were associated with the shortest times to 12-month seizure remission.",
"     </li>",
"     <li>",
"      For patients treated for generalized epilepsy,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      were superior to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      in regard to time to treatment failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/45\">",
"       45",
"      </a>",
"      ]. For time to 12-month seizure remission, valproate and topiramate were more efficacious compared with lamotrigine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The investigators concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    should be considered the drug of first choice for partial epilepsy and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    for generalized epilepsy.",
"   </p>",
"   <p>",
"    However, because the SANAD trial was unblinded, there was potential for bias. Also, it provided only sparse data regarding the potential of rare, often idiosyncratic, serious adverse events (eg, potential for teratogenicity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ). These results also do not account for other patient-specific preferences regarding the likelihood of different side effects, need for drug monitoring, potential for drug interactions, and dosing frequency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/47\">",
"     47",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    was not included in this study, and because",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    was added on later in the trial, the power of the data regarding this drug is lower than for other AEDs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Epilepsy syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;In selecting an AED for a patient with new onset epilepsy, it is important to differentiate between a partial versus generalized epilepsy syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/48\">",
"     48",
"    </a>",
"    ]. AEDs are classified as either broad or narrow spectrum agents (",
"    <a class=\"graphic graphic_table graphicRef78021 \" href=\"mobipreview.htm?19/32/19979\">",
"     table 1",
"    </a>",
"    ). While broad spectrum agents treat both partial and generalized epilepsy syndromes, narrow spectrum agents treat one or the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most of the narrow spectrum agents are effective for localization-related or partial epilepsies and may even worsen primary generalized epilepsy. The exception is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    , a narrow spectrum agent used for absence seizures (a generalized epilepsy), which is generally ineffective for partial seizures. Broad spectrum agents are effective for both types [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/50\">",
"     50",
"    </a>",
"    ]. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    (a narrow spectrum agent) may work well for a patient with temporal lobe epilepsy (a partial epilepsy), but is unlikely to be effective in juvenile myoclonic epilepsy (a generalized epilepsy). If the clinician is unsure whether the epilepsy syndrome is partial or generalized, a broad spectrum agent is usually chosen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Specific etiologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the distinction between generalized and partial epilepsy discussed above, specific etiologies of epilepsy may impact the treatment choice.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Post-stroke epilepsy is generally easily controlled with AED monotherapy. The choice of AED may be influenced by specific concerns, such as potential impact of the AED on post-stroke functional recovery and the potential for drug interactions with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and salicylates (see",
"      <a class=\"local\" href=\"#H12\">",
"       'Drug interactions'",
"      </a>",
"      below) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/51\">",
"       51",
"      </a>",
"      ]. The treatment of post-stroke epilepsy is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H21#H21\">",
"       \"Overview of the management of epilepsy in adults\", section on 'Post-stroke seizures'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Brain tumors are associated with epilepsy in 30 to 70 percent of patients, depending on the tumor type. The choice of AED in this setting is influenced by potential drug interactions with chemotherapeutic agents leading to decreased efficacy of both treatments, as well as the increased potential for allergic cutaneous reactions when AEDs are used during radiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=see_link\">",
"       \"Seizures in patients with primary and metastatic brain tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with AIDS may develop central nervous system infections and secondary epilepsy. This is estimated to occur in 3 to 11 percent of patients with AIDS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/54\">",
"       54",
"      </a>",
"      ]. There are potential concerns regarding drug interactions and drug side effects in this setting. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Others'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     AED pharmacokinetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important pharmacologic features of individual AEDs are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Dosing frequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The half-lives of AEDs vary considerably (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ). For many individuals, the frequency with which a drug must be taken is an important factor in compliance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    seizure control. Optimal dose frequency for individual drugs can vary between patients. Most AEDs are prescribed in two daily doses. AEDs that often require more frequent dosing include immediate-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    , regular and delayed-release",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    . Once daily dosing may be possible with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , extended-release valproate,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    , and extended-release formulations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    (the last two are not yet available in the United States).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Potential adverse events",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adverse effects of AEDs make a significant contribution to reduced quality of life in individuals with epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/55\">",
"     55",
"    </a>",
"    ]. While many AED side effects (eg, drowsiness, dizziness, diplopia, and imbalance) seem to be common to this entire class of medicines, others are more specific to an individual drug. These should be considered in selecting an AED since certain side effects are either more likely or more problematic in certain patients. Common neurotoxic and systemic side effects are summarized in the Table (",
"    <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"     table 3",
"    </a>",
"    ). Less common, often idiosyncratic, but potentially serious adverse events are summarized separately (",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most AEDs are associated with a negative impact on cognition, but some are more problematic than others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/56\">",
"     56",
"    </a>",
"    ]. Among the older AEDs, studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    is associated with greater impairments compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    , which have similar, but more modest negative effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/57,58\">",
"     57,58",
"    </a>",
"    ]. Among the newer AEDs,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    have been found to be less problematic than carbamazepine in their effects on cognition. Negative cognitive effects are similar with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    and carbamazepine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/59\">",
"     59",
"    </a>",
"    ]. Finally, a significant minority of patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    discontinue the drug because of clinically apparent cognitive difficulties. In direct comparison studies, cognitive profiles in patients taking topiramate were worse than those taking valproate, lamotrigine, or gabapentin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug rash with eosinophilia and systemic symptoms (DRESS) are rare but severe idiosyncratic reactions, characterized by fever and mucocutaneous lesions. SJS and TEN have been most often associated with the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"     table 4",
"    </a>",
"    ), and less commonly with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ; however, they have been described with almost all AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. The period of highest risk is within the first two months of use. For carbamazepine (and possibly phenytoin), the risk may be higher in patients with HLA-B*1502 allele, which occurs almost exclusively in patients of Asian ancestry, including South Asian Indians. The FDA recommends screening such patients for this allele prior to starting carbamazepine and possibly phenytoin. This is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Specific adverse reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H3#H3\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Carbamazepine'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H4#H4\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Phenytoin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=see_link\">",
"     \"Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AEDs have been linked to increased suicidality. In fact, all AEDs now carry a &ldquo;black box&rdquo; warning regarding the use of AEDs and the risk of suicidal thinking and behavior. Some experts advise screening for depression at diagnosis of epilepsy and on at each follow-up visit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/62\">",
"     62",
"    </a>",
"    ]. This is discussed in more detail separately(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Specific adverse reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H669264#H669264\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Depression and psychiatric disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Weight gain is associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    . Weight loss has been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The selection of an AED should consider other prescribed medications for potential drug interactions. AEDs that are hepatic-enzyme inducers increase the metabolism of other medications that are broken down by the same pathway. As an example,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    induces the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    potentially leading to subtherapeutic INR",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an increased dose requirement of warfarin. Enzyme induction occurs with all older AEDs (phenytoin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ) except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    . Enzyme induction also occurs with a few of the more recently approved AEDs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/46\">",
"     46",
"    </a>",
"    ]. Commonly prescribed drugs with the potential to interact with enzyme-inducing AEDs include statins, calcium channel blockers, serotonin reuptake inhibitors, antipsychotics, tricyclic antidepressants, oral contraceptive therapy, and warfarin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/63\">",
"     63",
"    </a>",
"    ]. In contrast, valproate is a hepatic enzyme inhibitor and may cause significant increases in serum concentrations of medications that are metabolized in the liver.",
"   </p>",
"   <p>",
"    Other drug interactions relate to protein binding. Addition of a drug that is highly protein-bound will displace another protein-bound drug, increasing its free fraction. In the setting of reduced serum albumin, this effect is amplified.",
"   </p>",
"   <p>",
"    An incomplete list of some important interactions between AEDs and nonAED drugs is provided (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Clinicians should review each item on a patient's medication list for potential drug interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;AED use in elderly patients is complicated by several factors, including age-related alterations in protein binding, reduced hepatic metabolism, and diminished renal clearance of medications. In addition, polypharmacy is more often a concern in older adults. The selection of AED treatment in the elderly is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=see_link\">",
"     \"Treatment of seizures and epilepsy in the elderly patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Concurrent Illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medical comorbidities are important to consider when selecting an AED. Many AEDs are either metabolized by the liver, excreted by the kidneys, or both (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ). When a person has hepatic or renal disease, it may be necessary to avoid certain AEDs or to adjust the dose. Other comorbidities can be problematic because of potential drug side effects or drug interactions, while others may represent an opportunity to choose an AED that has efficacy in both conditions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Renally excreted drugs include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/19/35125?source=see_link\">",
"     lacosamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/49,66,67\">",
"     49,66,67",
"    </a>",
"    ]. The dose of these drugs should be lowered in the setting of renal impairment. In patients on hemodialysis, a low dose after each dialysis may be sufficient to provide therapeutic levels of these AEDs. In addition to these AEDs, hemodialysis also efficiently removes AEDs that are water-soluble and are not highly protein-bound. As a result, supplemental doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    , lacosamide, and levetiracetam may be required after dialysis. AED regimens should be individualized in hemodialysis patients based on drug levels and clinical response. The effects of peritoneal dialysis on AED metabolism are not well studied and AED treatment in such patients may require additional monitoring.",
"   </p>",
"   <p>",
"    Albuminuria (causing low serum albumin) and acidosis reduce protein binding fractions and binding affinity, leading to increased fractions of free drug [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/66\">",
"     66",
"    </a>",
"    ]. For highly protein-bound AEDs (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ), subtherapeutic total drug levels may be both sufficient for efficacy and required to avoid toxicity in this setting. Free drug levels of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    may be monitored, but such tests are less routinely available for other AEDs.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    are associated with nephrolithiasis and should probably be avoided in patients with a history of or who are prone to this condition. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    .) Renal tubular acidosis can also occur with these AEDs; patients with preexisting conditions that make them prone to metabolic acidosis (eg, severe respiratory disorders, diarrhea) should also consider avoiding these drugs or have more frequent monitoring of serum bicarbonate levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the setting of renal transplantation, potential drug interactions between AEDs and immunosuppressive therapy should be considered. Enzyme-inducing AEDs may lower serum immunosuppressant levels, while enzyme-inhibitors may increase levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hepatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some AEDs are associated with hepatic toxicity and should be avoided in patients with pre-existing liver disease. These include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/31/25079?source=see_link\">",
"     felbamate",
"    </a>",
"    , and to a lesser extent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/66,69\">",
"     66,69",
"    </a>",
"    ]. Many other AEDs are metabolized in the liver (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ), requiring caution and dose adjustment when used in patients with hepatic disease. These include carbamazepine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , phenytoin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     Levetiracetam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"     pregabalin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    are less problematic for use in patients with liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Psychiatric disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persons with epilepsy have a higher than expected prevalence of comorbid psychiatric disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/70-74\">",
"     70-74",
"    </a>",
"    ]. The association may relate to shared perturbations in neurotransmitter action, alterations to neural networks or both [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/71,73,75\">",
"     71,73,75",
"    </a>",
"    ]. In persons with epilepsy, the presence of depression correlates more strongly with a poor quality of life than the frequency of the seizures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some AEDs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"     oxcarbazepine",
"    </a>",
"    ) appear to have mood stabilizing properties [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. Their efficacy in this regard is best established for bipolar disorder. However, many physicians view these medications as attractive in patients with comorbid anxiety and depression. In contrast, some AEDs, in particular those that potentiate GABA neurotransmission (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/22/26982?source=see_link\">",
"     tiagabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    ), have been reported to cause or exacerbate a depressed mood and perhaps should be avoided in patients with comorbid depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/80\">",
"     80",
"    </a>",
"    ]. Similarly, drugs that have been reported to provoke psychosis (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"     levetiracetam",
"    </a>",
"    , topiramate, vigabatrin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/2/10279?source=see_link\">",
"     zonisamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"     ethosuximide",
"    </a>",
"    ) may be less desirable in patients with that history.",
"   </p>",
"   <p>",
"    Use of one of the AEDs thought to be effective in mood stabilization does not substitute for a full psychiatric evaluation and independent treatment of a coexisting psychiatric disorder. Further impetus for this comes from the fact that as a class, AEDs are associated with an increased risk of suicide. All patients with epilepsy treated with AEDs should be monitored for changes in mood and suicidality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H9#H9\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Specific adverse reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Drug interactions are also a potential concern in patients with psychiatric disorders. Enzyme-inducing AEDs (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ) can decrease the plasma concentration of many antidepressants including tricyclic agents and selective serotonin reuptake inhibitors, as well as antipsychotic drugs and benzodiazepines (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Migraine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies suggest that migraine may be more prevalent in patients with epilepsy and vice versa [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/81,82\">",
"     81,82",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     Valproate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"     gabapentin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    are AEDs that have demonstrated efficacy for migraine prevention in placebo-controlled trials. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=see_link&amp;anchor=H9#H9\">",
"     \"Preventive treatment of migraine in adults\", section on 'Anticonvulsants'",
"    </a>",
"    .) This may provide an opportunity to limit polypharmacy in individuals with both migraine and epilepsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Osteoporosis risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;AEDs in chronic use have been associated with bone loss. Initially this association was observed for enzyme-inducing AEDs (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ), but later was found to extend to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    as well as to some of the newer nonenzyme-inducing AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/83-85\">",
"     83-85",
"    </a>",
"    ]. The evidence associating osteoporosis and AED therapy may be strongest for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    . Osteoporosis is particularly problematic for patients with epilepsy, as seizures are associated with falls and bone fractures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/68,86,87\">",
"     68,86,87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    should perhaps be avoided in patients in whom there is concern for bone loss, there is insufficient data to recommend avoiding or choosing any other specific AED in order to limit the risk of osteoporosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/68\">",
"     68",
"    </a>",
"    ]. Rather, monitoring of bone density, routine supplementation of calcium and vitamin D, and a consistent exercise regimen are suggested for all patients on chronic AED therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36969?source=see_link\">",
"     \"Antiepileptic drugs and bone disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Others",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetes &mdash; Because of its association with weight gain, insulin resistance, the metabolic syndrome, and polycystic ovarian syndrome, use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      in individuals with diabetes or obesity should be carefully considered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/88\">",
"       88",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       Carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"       vigabatrin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?19/19/19768?source=see_link\">",
"       gabapentin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/31/16887?source=see_link\">",
"       pregabalin",
"      </a>",
"      are also, but less frequently, associated with weight gain (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Potential adverse events'",
"      </a>",
"      above).",
"      <br/>",
"      <br/>",
"      Some AEDs (gabapentin, pregabalin, and possibly carbamazepine and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ) have efficacy in treating pain associated with diabetic neuropathy. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12986?source=see_link&amp;anchor=H11#H11\">",
"       \"Treatment of diabetic neuropathy\", section on 'Anticonvulsants'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Thyroid disease &mdash; While many AEDs, in particular the enzyme-inducing agents, can alter thyroid hormone levels, this is generally subclinical and should not impact drug choice [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/88,89\">",
"       88,89",
"      </a>",
"      ]. Enzyme-inducing agents should probably be avoided in patients with severe thyroid dysfunction.",
"     </li>",
"     <li>",
"      Cancer &mdash; The choice of AED in patients being treated for systemic cancer is influenced by potential drug interactions between enzyme-inducing AEDs (",
"      <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"       table 2",
"      </a>",
"      ) and chemotherapeutic agents that can lead to decreased efficacy of both treatments [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/52,53\">",
"       52,53",
"      </a>",
"      ]. By inhibiting their metabolism,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      may increase the toxicity of certain cancer chemotherapy agents. There also may be an increased potential for allergic cutaneous reactions when AEDs are used during radiotherapy.",
"     </li>",
"     <li>",
"      HIV &mdash; Enzyme-inducing AEDs and those that are highly protein-bound (",
"      <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"       table 2",
"      </a>",
"      ) may interact with highly active antiretroviral therapy (HAART) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/54,90,91\">",
"       54,90,91",
"      </a>",
"      ]. Of particular concern is that these drug interactions may cause minor reductions in the levels of protease inhibitors that could lead to loss of viral suppression and the emergence of drug resistance. There are also concerns that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      may be associated with increased viral replication, and that",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      -associated skin rash may be more common in HIV-positive patients.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       Lamotrigine",
"      </a>",
"      doses may need to be increased with certain medications including",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/31/506?source=see_link\">",
"       atazanavir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Cardiovascular disease &mdash; Clinicians should consider potential drug interactions between enzyme-inducing AEDs and statins, calcium channel blockers, and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/64,65,92\">",
"       64,65,92",
"      </a>",
"      ]. While,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      has been associated with heart block and other bradyarrhythmias in susceptible individuals [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/93\">",
"       93",
"      </a>",
"      ], clinically significant ECG changes are uncommon with carbamazepine in elderly patients who do not have a pre-existing conduction defect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/94\">",
"       94",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Because the cytochrome P450 enzymes are involved in cholesterol synthesis, it is possible that enzyme-inducing AEDs may thereby affect vascular risk. In one small series, switching patients from carbamazepine or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      to noninducing AEDs",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/52/43847?source=see_link\">",
"       levetiracetam",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"       lamotrigine",
"      </a>",
"      was associated with improvements in serologic markers of vascular risk (eg, total cholesterol, triglycerides, C-reactive protein) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/95\">",
"       95",
"      </a>",
"      ]. Some studies have found that long-term monotherapy with carbamazepine, phenytoin, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      , is associated with markers of increased cardiovascular risk, such as carotid intimal thickening, abnormal cholesterol, homocysteine, and folate metabolism, and elevated levels of c-reactive protein [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/96,97\">",
"       96,97",
"      </a>",
"      ]. However, no studies have clearly linked any specific AEDs to a higher or lower risk of vascular events.",
"     </li>",
"     <li>",
"      Blood disorders &mdash; Certain AEDs (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/54/13158?source=see_link\">",
"       ethosuximide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      ) are associated with neutropenia and agranulocytosis, and should be avoided in patients with blood disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/98,99\">",
"       98,99",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21850?source=see_link\">",
"       \"Drug-induced neutropenia and agranulocytosis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Similarly, drugs associated with thrombocytopenia (eg, carbamazepine, valproate, phenytoin) should be avoided in patients with a low platelet count or a history of other bleeding diatheses. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=see_link\">",
"       \"Drug-induced thrombocytopenia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Women of childbearing age",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of issues are important in women of childbearing age, especially if they are considering becoming or are already pregnant.",
"   </p>",
"   <p>",
"    Folate should be prescribed to all women of childbearing age who are taking AEDs. Patients taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    should receive daily",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation (4",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for one to three months prior to conception. Women who are taking other AEDs should take the more standard lower dose of folic acid (0.4 to 0.8 mg per day). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link&amp;anchor=H4#H4\">",
"     \"Management of epilepsy and pregnancy\", section on 'Folic acid supplementation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Oral contraceptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women should be informed about the interactions between AED therapies and oral contraceptives. The expected contraceptive failure rate of 0.7 per 100 woman-years using oral contraceptives is increased to 3.1 per 100 woman-years in patients who concomitantly take enzyme-inducing AEDs (",
"    <a class=\"graphic graphic_table graphicRef60182 \" href=\"mobipreview.htm?26/46/27374\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/100-103\">",
"     100-103",
"    </a>",
"    ]. While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/8/27783?source=see_link\">",
"     vigabatrin",
"    </a>",
"    is not an enzyme inducer, lower levels of ethinyl estradiol have been reported in volunteers taking this AED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/104\">",
"     104",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the use of estrogen-progestin contraceptives\", section on 'Drug interactions'",
"    </a>",
"    .) If an enzyme-inducing AED is nonetheless deemed to be the drug of choice in a woman taking oral contraception; alternative regimens or forms of contraception should be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Oral contraceptive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the effect of AEDs on oral contraceptive metabolism, oral contraceptives can increase the metabolism of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    , thereby reducing the plasma drug concentration. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link&amp;anchor=H5#H5\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Lamotrigine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Catamenial epilepsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with epilepsy report an association between the occurrence of their seizures and certain phases of their menstrual cycle. Seizures that are triggered by hormones are called catamenial. Research has demonstrated that estrogen is proconvulsant, while progesterone is anticonvulsant. Estrogen peaks twice during the menstrual cycle: just before ovulation and just before menstruation. It is during these phases of the menstrual cycle that hormone-triggered seizures occur most often.",
"   </p>",
"   <p>",
"    The mainstay of treatment of catamenial seizures is an AED that is most effective for the woman's epilepsy syndrome. However, when catamenial seizures are not controlled with AEDs, the physician may consider adding an oral contraceptive on the theoretical basis that suppressing estrogen peaks will lead to better seizure control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Pregnancy and postpartum",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of epilepsy during pregnancy must balance competing risks. Seizures, particularly convulsive seizures, are believed to be harmful to the fetus. At the same time, both major and minor malformations are more common in fetuses exposed to AEDs in utero compared with offspring of untreated women with epilepsy and women without epilepsy. The overall risk of major malformations is 4 to 6 percent in exposed infants;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"     valproate",
"    </a>",
"    is a major contributor to this risk. Polypharmacy increases the risk. The timing (early versus late in gestation) and dose of exposure are also likely to be important. While no AED has been definitively shown to be safe in pregnancy, the evidence linking valproate to fetal malformations is sufficiently convincing to recommend avoiding its initiation in pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=see_link\">",
"     \"Risks associated with epilepsy and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of epilepsy in pregnancy and during breast feeding is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=see_link\">",
"     \"Management of epilepsy and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     FDA indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA indication for use of AEDs may influence physician prescribing habits. For many newer AEDs, the FDA indications are based on studies that showed effectiveness as add-on treatment in persons with refractory epilepsy. Monotherapy trials are performed infrequently because most physicians and patients are reluctant to be treated with placebo when effective treatments exist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/22\">",
"     22",
"    </a>",
"    ]. As a result, many of these AEDs are not FDA-approved as initial monotherapy. Some physicians may be initially reluctant to use newer AEDs as monotherapy in the initial treatment of epilepsy pending advice from colleagues",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    published expert opinion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Cost of Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;For many patients, the cost of their medication is also an issue and whether a specific AED is on a list of preferred medications approved by a third party payer may also be influential in the choice of AED. For areas of the world and for individual patients with restricted resources,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    may be the treatment of choice for partial epilepsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     OPTIMIZING TREATMENT OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Starting treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful treatment can be optimized by a systematic approach that includes patient education [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. Treatment should be started with a single drug (monotherapy). In general, the strategy is to gradually titrate the dosage to that which is maximally tolerated",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    produces optimal seizure control (start low and go slow). Pooled analysis from two large prospective studies found that with this approach, adverse event reporting was no higher in treated versus untreated patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/108\">",
"     108",
"    </a>",
"    ]. Variables other than AED treatment were found to be associated with adverse event reporting, most notably comorbid depression. The recommended initial dose and suggested titration schedule is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=see_link\">",
"     \"Pharmacology of antiepileptic drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Before treatment is initiated, the physician needs to counsel the patient and family to increase their understanding of epilepsy and their ability to report necessary and relevant information. These discussions will improve the likelihood that the patient will comply with the plan of treatment.",
"   </p>",
"   <p>",
"    The physician should impress upon the patient, family, and patient's friends the critical need to follow the prescribed drug regimen. Nonadherence to AED treatment regimen is associated with increased risk of mortality, as well as hospitalization and injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the management of epilepsy in adults\", section on 'Complications of epilepsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Written instructions on how and when to take the drugs should be provided and should explain the dosing regimen and any potential adverse effects or drug-drug interactions (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 5",
"    </a>",
"    ). The patient must also be warned not to stop taking an AED and not to allow a prescription to run out or expire.",
"   </p>",
"   <p>",
"    Patients should be urged not to start any other prescription, over-the-counter medications, dietary supplements, or herbal remedies without first contacting their physician because these might affect serum concentrations of their AEDs (",
"    <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/63,109\">",
"     63,109",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Drug interactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Seizure calendar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and family members should be asked to record seizures and AED doses on a calendar, which can then be brought or sent to the physician for review. Seizure triggers (eg, stress, sleep deprivation, alcohol, menses) should be indicated. The patient and family should note on the calendar the hour at which any symptoms occur.",
"   </p>",
"   <p>",
"    The seizure calendar helps to monitor and encourage compliance, as well as identify triggers. The seizure calendar also may be used to track the patient's response to drug therapy, including possible side effects. In one study of 71 patients completing daily seizure diaries, both lack of sleep and higher self-reported stress and anxiety were associated with seizure occurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/110\">",
"     110",
"    </a>",
"    ]. Seizures were also associated with the patients' own prediction of the likelihood of seizure occurrence. Physicians should be aware that patients are often unaware of their seizures and may significantly underestimate the number of seizures that occur, especially those that occur during sleep or that disrupt consciousness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Generic substitution",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of generic medications as a treatment for people with epilepsy has attracted much attention and debate. Anecdotal reports, small case series, and patient surveys suggest that generic substitution of AEDs may be problematic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/112-114\">",
"     112-114",
"    </a>",
"    ], and that the small, FDA-allowed variations in pharmacokinetics between a name brand and its generic equivalent (and between generic equivalents) may lead to either toxicity or seizures in some patients who, for unknown reasons, are particularly vulnerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/115-119\">",
"     115-119",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One study of a medical and pharmacy claims database observed that generic switching of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/28/6602?source=see_link\">",
"     lamotrigine",
"    </a>",
"    was associated with increases in the mean daily dose prescribed, as well as number of physician visits and hospitalizations compared to the time period in which branded lamotrigine was used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/120\">",
"     120",
"    </a>",
"    ]. Another retrospective study of breakthrough seizures that occurred in association with generic substitution found that AED blood levels at the time of the seizure were on average 33 percent lower than previous levels obtained when the patient was using branded AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/121\">",
"     121",
"    </a>",
"    ]. Finally, a case-control study found that changes in AED formulation involving generics was a risk factor for emergency or hospital-level treatment of epilepsy (OR 1.8) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/122\">",
"     122",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a systematic review and meta-analysis of seven trials in which the frequency of seizure events were compared between a brand name AED and a generic alternative found no difference in the odds of seizures between treatment regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/123\">",
"     123",
"    </a>",
"    ]. The FDA also maintains that there is no convincing evidence that people with epilepsy have lessened seizure control when taking generic medications.",
"   </p>",
"   <p>",
"    Until definitive, prospective randomized clinical trials comparing generic versus brand name medication are done, patients should be aware that pharmacists or mail-order pharmacies sometimes make generic substitutions at the point of sale, and that they should check with their physician prior to accepting this substitution. Clinicians should consider the possibility of generic substitution as a cause of unexpected break-through seizures or toxicity, along with other possible explanations. In addition, clinicians may wish to obtain laboratory monitoring with plasma drug levels when a change is made in drug formulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;A complete blood count, liver function tests, BUN, and measurement of creatinine and electrolytes levels should be done prior to starting AED therapy. Albumin levels should also be obtained prior to starting treatment with one of the highly protein bound AEDs.",
"   </p>",
"   <p>",
"    Regular follow-up visits should be scheduled to check drug concentrations, blood counts, and hepatic and renal function. These visits are also used to address concerns the patient may have about taking the medication and possible side effects, or psychosocial aspects of their disorder. Drug levels should be checked at least yearly in patients who are not having seizures and not undergoing medication dose changes. Chemistry and hematology studies are usually checked in association with drug levels.",
"   </p>",
"   <p>",
"    Drug levels can be helpful in the management of AEDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/4/31818/abstract/124\">",
"     124",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      To establish an individual therapeutic concentration when a patient is in remission.",
"     </li>",
"     <li>",
"      To assist in the diagnosis of clinical AED toxicity.",
"     </li>",
"     <li>",
"      To assess compliance.",
"     </li>",
"     <li>",
"      To guide dose adjustments, particularly in the setting of drug formulation changes, when an interacting medication is added to or removed from a patient's regimen, or during pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=see_link\">",
"       \"Patient information: Seizures (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=see_link\">",
"       \"Patient information: Epilepsy in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=see_link\">",
"       \"Patient information: Seizures in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epilepsy is usually managed initially with antiepileptic drug (AED) monotherapy. When to start treatment and with what agent is individualized in order to optimize both efficacy and tolerability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend initiating AED therapy in individuals who are at high risk of recurrent seizures (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Such patients include those who have had two or more unprovoked seizures.",
"     </li>",
"     <li>",
"      AED treatment is reasonable in patients after a single unprovoked seizure if they also have a potential symptomatic cause of epilepsy (eg, stroke or trauma history), epileptiform features on electroencephalogram, a relevant abnormality on neuroimaging study (CT or MRI), or an abnormal neurologic examination. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'When to start AED therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AED treatment after a single unprovoked seizure in patients may be deferred depending on the presence or absence of other risk factors and on individual patient preferences (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Benefit of early versus deferred treatment'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The selection of AED considers the type of epilepsy or epilepsy syndrome (",
"      <a class=\"graphic graphic_table graphicRef78021 \" href=\"mobipreview.htm?19/32/19979\">",
"       table 1",
"      </a>",
"      ) and potential side effects (",
"      <a class=\"graphic graphic_table graphicRef59755 \" href=\"mobipreview.htm?3/28/3533\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef78896 \" href=\"mobipreview.htm?29/34/30252\">",
"       table 4",
"      </a>",
"      ), as well as other prescribed medications (",
"      <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"       table 5",
"      </a>",
"      ) and comorbidities. Gender and patient age, and cost and availability of medication may also be relevant factors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Selection of an AED'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In general, enzyme-inducing AEDs (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"       phenytoin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/10/25770?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/40/29321?source=see_link\">",
"       phenobarbital",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/25/40344?source=see_link\">",
"       oxcarbazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ) are the most problematic for drug interactions with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      and oral contraceptive therapy, as well as certain anti-cancer and anti-infective drugs (",
"      <a class=\"graphic graphic_table graphicRef79729 \" href=\"mobipreview.htm?31/44/32461\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because AEDs are either metabolized by the liver or excreted by the kidneys, renal and hepatic disease impacts on both the choice of AED as well as the prescribing regimen. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Renal disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H16\">",
"       'Hepatic disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women of childbearing age should be counseled regarding possible teratogenic effects of AEDs and should consider taking supplemental folate to limit the risk. Initiation of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/11/25785?source=see_link\">",
"       valproate",
"      </a>",
"      should be avoided in pregnancy. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Women of childbearing age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regular outpatient follow-up appointments and the use of seizure calendars can help maximize the success of epilepsy treatment. (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Optimizing treatment outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with epilepsy have a higher than expected incidence of mood problems, anxiety, and depression. AEDs have been associated with suicidality. Patients treated with AEDs should be monitored for changes in mood and suicidality. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Psychiatric disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/1\">",
"      Faught E, Duh MS, Weiner JR, et al. Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study. Neurology 2008; 71:1572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/2\">",
"      Holland P, Lane S, Whitehead M, et al. Labor market participation following onset of seizures and early epilepsy: Findings from a UK cohort. Epilepsia 2009; 50:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/3\">",
"      Sperling MR, Feldman H, Kinman J, et al. Seizure control and mortality in epilepsy. Ann Neurol 1999; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/4\">",
"      Nei M, Bagla R. Seizure-related injury and death. Curr Neurol Neurosci Rep 2007; 7:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/5\">",
"      Forsgren L, Hauser WA, Olafsson E, et al. Mortality of epilepsy in developed countries: a review. Epilepsia 2005; 46 Suppl 11:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/6\">",
"      Lhatoo SD, Sander JW. Cause-specific mortality in epilepsy. Epilepsia 2005; 46 Suppl 11:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/7\">",
"      Schachter SC. Antiepileptic drug therapy: general treatment principles and application for special patient populations. Epilepsia 1999; 40 Suppl 9:S20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/8\">",
"      Kim LG, Johnson TL, Marson AG, et al. Prediction of risk of seizure recurrence after a single seizure and early epilepsy: further results from the MESS trial. Lancet Neurol 2006; 5:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/9\">",
"      Hauser WA, Rich SS, Lee JR, et al. Risk of recurrent seizures after two unprovoked seizures. N Engl J Med 1998; 338:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/10\">",
"      Berg AT. Risk of recurrence after a first unprovoked seizure. Epilepsia 2008; 49 Suppl 1:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/11\">",
"      Hauser WA, Rich SS, Annegers JF, Anderson VE. Seizure recurrence after a 1st unprovoked seizure: an extended follow-up. Neurology 1990; 40:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/12\">",
"      Marson A, Jacoby A, Johnson A, et al. Immediate versus deferred antiepileptic drug treatment for early epilepsy and single seizures: a randomised controlled trial. Lancet 2005; 365:2007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/13\">",
"      Randomized clinical trial on the efficacy of antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic seizure. First Seizure Trial Group (FIR.S.T. Group). Neurology 1993; 43:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/14\">",
"      Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology 1997; 49:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/15\">",
"      Ramos Lizana J, Cassinello Garci&aacute; E, Carrasco Marina LL, et al. Seizure recurrence after a first unprovoked seizure in childhood: a prospective study. Epilepsia 2000; 41:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/16\">",
"      Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a first acute symptomatic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia 2009; 50:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/17\">",
"      Kho LK, Lawn ND, Dunne JW, Linto J. First seizure presentation: do multiple seizures within 24 hours predict recurrence? Neurology 2006; 67:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/18\">",
"      Leone MA, Vallalta R, Solari A, et al. Treatment of first tonic-clonic seizure does not affect mortality: long-term follow-up of a randomised clinical trial. J Neurol Neurosurg Psychiatry 2011; 82:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/19\">",
"      Jacoby A, Gamble C, Doughty J, et al. Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures. Neurology 2007; 68:1188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/20\">",
"      Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000; 342:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/21\">",
"      Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002; 58:S2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/22\">",
"      French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004; 62:1252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/23\">",
"      Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2013; 54:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/24\">",
"      Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998; 51:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/25\">",
"      Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999; 37:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/26\">",
"      Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/27\">",
"      Steiner TJ, Dellaportas CI, Findley LJ, et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy: a double-blind comparison with phenytoin. Epilepsia 1999; 40:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/28\">",
"      Kwan P, Brodie MJ, K&auml;lvi&auml;inen R, et al. Efficacy and safety of pregabalin versus lamotrigine in patients with newly diagnosed partial seizures: a phase 3, double-blind, randomised, parallel-group trial. Lancet Neurol 2011; 10:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/29\">",
"      Privitera MD, Brodie MJ, Mattson RH, et al. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurol Scand 2003; 107:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/30\">",
"      Ramsay E, Faught E, Krumholz A, et al. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 2010; 51:1970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/31\">",
"      Bill PA, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997; 27:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/32\">",
"      Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997; 27:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/33\">",
"      Christe W, Kr&auml;mer G, Vigonius U, et al. A double-blind controlled clinical trial: oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Res 1997; 26:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/34\">",
"      Dam M, Ekberg R, L&oslash;yning Y, et al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989; 3:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/35\">",
"      Baulac M, Brodie MJ, Patten A, et al. Efficacy and tolerability of zonisamide versus controlled-release carbamazepine for newly diagnosed partial epilepsy: a phase 3, randomised, double-blind, non-inferiority trial. Lancet Neurol 2012; 11:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/36\">",
"      Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/37\">",
"      French J. What is a fair comparison in head-to-head trials of antiepileptic drugs? Lancet Neurol 2011; 10:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/38\">",
"      Privitera MD. Evidence-based medicine and antiepileptic drugs. Epilepsia 1999; 40 Suppl 5:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/39\">",
"      Williamson PR, Marson AG, Tudur C, et al. Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract 2000; 6:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/40\">",
"      Gamble C, Williamson PR, Chadwick DW, Marson AG. A meta-analysis of individual patient responses to lamotrigine or carbamazepine monotherapy. Neurology 2006; 66:1310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/41\">",
"      Muller M, Marson AG, Williamson PR. Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2006; :CD003615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/42\">",
"      Tudur Smith C, Marson AG, Clough HE, Williamson PR. Carbamazepine versus phenytoin monotherapy for epilepsy. Cochrane Database Syst Rev 2002; :CD001911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/43\">",
"      Marson AG, Appleton R, Baker GA, et al. A randomised controlled trial examining the longer-term outcomes of standard versus new antiepileptic drugs. The SANAD trial. Health Technol Assess 2007; 11:iii.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/44\">",
"      Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/45\">",
"      Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet 2007; 369:1016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/46\">",
"      Chadwick D, Marson T. Choosing a first drug treatment for epilepsy after SANAD: randomized controlled trials, systematic reviews, guidelines and treating patients. Epilepsia 2007; 48:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/47\">",
"      French JA. First-choice drug for newly diagnosed epilepsy. Lancet 2007; 369:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/48\">",
"      L&uuml;ders HO, Turnbull J, Kaffashi F. Are the dichotomies generalized versus focal epilepsies and idiopathic versus symptomatic epilepsies still valid in modern epileptology? Epilepsia 2009; 50:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/49\">",
"      Bazil CW. Antiepileptic drugs in the 21st century. CNS Spectr 2001; 6:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/50\">",
"      Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia 1998; 39:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/51\">",
"      Ryvlin P, Montavont A, Nighoghossian N. Optimizing therapy of seizures in stroke patients. Neurology 2006; 67:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/52\">",
"      Vecht CJ, van Breemen M. Optimizing therapy of seizures in patients with brain tumors. Neurology 2006; 67:S10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/53\">",
"      Michelucci R. Optimizing therapy of seizures in neurosurgery. Neurology 2006; 67:S14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/54\">",
"      Bhigjee AI, Rosemberg S. Optimizing therapy of seizures in patients with HIV and cysticercosis. Neurology 2006; 67:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/55\">",
"      Perucca P, Carter J, Vahle V, Gilliam FG. Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy. Neurology 2009; 72:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/56\">",
"      Hessen E, Lossius MI, Gjerstad L. Antiepileptic monotherapy significantly impairs normative scores on common tests of executive functions. Acta Neurol Scand 2009; 119:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/57\">",
"      Motamedi G, Meador K. Epilepsy and cognition. Epilepsy Behav 2003; 4 Suppl 2:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/58\">",
"      Meador KJ. Cognitive and memory effects of the new antiepileptic drugs. Epilepsy Res 2006; 68:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/59\">",
"      Koch MW, Polman SK. Oxcarbazepine versus carbamazepine monotherapy for partial onset seizures. Cochrane Database Syst Rev 2009; :CD006453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/60\">",
"      Yang CY, Dao RL, Lee TJ, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology 2011; 77:2025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/61\">",
"      Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/62\">",
"      Kerr MP, Mensah S, Besag F, et al. International consensus clinical practice statements for the treatment of neuropsychiatric conditions associated with epilepsy. Epilepsia 2011; 52:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/63\">",
"      Gidal BE, French JA, Grossman P, Le Teuff G. Assessment of potential drug interactions in patients with epilepsy: impact of age and sex. Neurology 2009; 72:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/64\">",
"      Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol 2003; 2:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/65\">",
"      Patsalos PN, Fr&ouml;scher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 2002; 43:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/66\">",
"      Lacerda G, Krummel T, Sabourdy C, et al. Optimizing therapy of seizures in patients with renal or hepatic dysfunction. Neurology 2006; 67:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/67\">",
"      Israni RK, Kasbekar N, Haynes K, Berns JS. Use of antiepileptic drugs in patients with kidney disease. Semin Dial 2006; 19:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/68\">",
"      Sheth RD. Metabolic concerns associated with antiepileptic medications. Neurology 2004; 63:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/69\">",
"      Ahmed SN, Siddiqi ZA. Antiepileptic drugs and liver disease. Seizure 2006; 15:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/70\">",
"      Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: expert opinion, 2005. Epilepsy Behav 2005; 7 Suppl 1:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/71\">",
"      Gabbs MG, Barry JJ. The link between mood disorders and epilepsy: why is it important to diagnose and treat?. Adv Stud Med 2005; 5:S572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/72\">",
"      Ettinger AB, Reed ML, Goldberg JF, Hirschfeld RM. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 2005; 65:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/73\">",
"      Kanner AM. Depression in epilepsy: a neurobiologic perspective. Epilepsy Curr 2005; 5:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/74\">",
"      Beyenburg S, Mitchell AJ, Schmidt D, et al. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav 2005; 7:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/75\">",
"      Karceski SC. Exploring the connection between mood disorders and epilepsy. Pract Neurol 2005; 4:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/76\">",
"      Gilliam FG, Mendiratta A, Pack AM, Bazil CW. Epilepsy and common comorbidities: improving the outpatient epilepsy encounter. Epileptic Disord 2005; 7 Suppl 1:S27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/77\">",
"      Brodtkorb E, Mula M. Optimizing therapy of seizures in adult patients with psychiatric comorbidity. Neurology 2006; 67:S39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/78\">",
"      Garc&iacute;a-Morales I, de la Pe&ntilde;a Mayor P, Kanner AM. Psychiatric comorbidities in epilepsy: identification and treatment. Neurologist 2008; 14:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/79\">",
"      Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009; 50:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/80\">",
"      Mula M, Hesdorffer DC, Trimble M, Sander JW. The role of titration schedule of topiramate for the development of depression in patients with epilepsy. Epilepsia 2009; 50:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/81\">",
"      De Simone R, Ranieri A, Marano E, et al. Migraine and epilepsy: clinical and pathophysiological relations. Neurol Sci 2007; 28 Suppl 2:S150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/82\">",
"      Bigal ME, Lipton RB, Cohen J, Silberstein SD. Epilepsy and migraine. Epilepsy Behav 2003; 4 Suppl 2:S13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/83\">",
"      Pack AM, Morrell MJ, Marcus R, et al. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Ann Neurol 2005; 57:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/84\">",
"      Pack A. Effects of Treatment on Endocrine Function in Patients with Epilepsy. Curr Treat Options Neurol 2005; 7:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/85\">",
"      Pack AM, Morrell MJ, Randall A, et al. Bone health in young women with epilepsy after one year of antiepileptic drug monotherapy. Neurology 2008; 70:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/86\">",
"      Mattson RH, Gidal BE. Fractures, epilepsy, and antiepileptic drugs. Epilepsy Behav 2004; 5 Suppl 2:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/87\">",
"      Tomson T, Beghi E, Sundqvist A, Johannessen SI. Medical risks in epilepsy: a review with focus on physical injuries, mortality, traffic accidents and their prevention. Epilepsy Res 2004; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/88\">",
"      Steinhoff BJ. Optimizing therapy of seizures in patients with endocrine disorders. Neurology 2006; 67:S23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/89\">",
"      Lossius MI, Taub&oslash;ll E, Mowinckel P, Gjerstad L. Reversible effects of antiepileptic drugs on thyroid hormones in men and women with epilepsy: a prospective randomized double-blind withdrawal study. Epilepsy Behav 2009; 16:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/90\">",
"      Birbeck GL, French JA, Perucca E, et al. Antiepileptic drug selection for people with HIV/AIDS: evidence-based guidelines from the ILAE and AAN. Epilepsia 2012; 53:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/91\">",
"      Birbeck GL, French JA, Perucca E, et al. Evidence-based guideline: Antiepileptic drug selection for people with HIV/AIDS: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Ad Hoc Task Force of the Commission on Therapeutic Strategies of the International League Against Epilepsy. Neurology 2012; 78:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/92\">",
"      Bullman J, Nicholls A, Van Landingham K, et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia 2011; 52:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/93\">",
"      Kenneb&auml;ck G, Bergfeldt L, Tomson T, et al. Carbamazepine induced bradycardia--a problem in general or only in susceptible patients? A 24-h long-term electrocardiogram study. Epilepsy Res 1992; 13:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/94\">",
"      Saetre E, Abdelnoor M, Amlie JP, et al. Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained-release carbamazepine. Epilepsia 2009; 50:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/95\">",
"      Mintzer S, Skidmore CT, Abidin CJ, et al. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann Neurol 2009; 65:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/96\">",
"      Erdemir A, Cullu N, Yi U, et al. Evaluation of serum lipids and carotid artery intima media thickness in epileptic children treated with valproic acid. Brain Dev 2009; 31:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/97\">",
"      Chuang YC, Chuang HY, Lin TK, et al. Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis. Epilepsia 2012; 53:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/98\">",
"      French JA, Pedley TA. Clinical practice. Initial management of epilepsy. N Engl J Med 2008; 359:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/99\">",
"      Rahman A, Mican LM, Fischer C, Campbell AH. Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents. Ann Pharmacother 2009; 43:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/100\">",
"      Morrell MJ, Sarto GE, Shafer PO, et al. Health issues for women with epilepsy: a descriptive survey to assess knowledge and awareness among healthcare providers. J Womens Health Gend Based Med 2000; 9:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/101\">",
"      Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/102\">",
"      Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/103\">",
"      Zupanc ML. Antiepileptic drugs and hormonal contraceptives in adolescent women with epilepsy. Neurology 2006; 66:S37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/104\">",
"      ACOG Committee on Practice Bulletins-Gynecology. ACOG practice bulletin. No. 73: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/105\">",
"      Perucca E. Treatment of epilepsy in developing countries. BMJ 2007; 334:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/106\">",
"      Glauser T, Ben-Menachem E, Bourgeois B, et al. ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia 2006; 47:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/107\">",
"      Perucca E. NICE guidance on newer drugs for epilepsy in adults. BMJ 2004; 328:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/108\">",
"      Perucca P, Jacoby A, Marson AG, et al. Adverse antiepileptic drug effects in new-onset seizures: a case-control study. Neurology 2011; 76:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/109\">",
"      Kaiboriboon K, Guevara M, Alldredge BK. Understanding herb and dietary supplement use in patients with epilepsy. Epilepsia 2009; 50:1927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/110\">",
"      Haut SR, Hall CB, Masur J, Lipton RB. Seizure occurrence: precipitants and prediction. Neurology 2007; 69:1905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/111\">",
"      Hoppe C, Poepel A, Elger CE. Epilepsy: accuracy of patient seizure counts. Arch Neurol 2007; 64:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/112\">",
"      Berg MJ, Gross RA, Haskins LS, et al. Generic substitution in the treatment of epilepsy: patient and physician perceptions. Epilepsy Behav 2008; 13:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/113\">",
"      McAuley JW, Chen AY, Elliott JO, Shneker BF. An assessment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav 2009; 14:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/114\">",
"      Papsdorf TB, Ablah E, Ram S, et al. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2009; 14:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/115\">",
"      Liow K, Barkley GL, Pollard JR, et al. Position statement on the coverage of anticonvulsant drugs for the treatment of epilepsy. Neurology 2007; 68:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/116\">",
"      Berg MJ. What's the problem with generic antiepileptic drugs?: a call to action. Neurology 2007; 68:1245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/117\">",
"      Kr&auml;mer G, Biraben A, Carreno M, et al. Current approaches to the use of generic antiepileptic drugs. Epilepsy Behav 2007; 11:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/118\">",
"      Bialer M. Generic products of antiepileptic drugs (AEDs): is it an issue? Epilepsia 2007; 48:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/119\">",
"      Nielsen KA, Dahl M, T&oslash;mmerup E, Wolf P. Comparative daily profiles with different preparations of lamotrigine: a pilot investigation. Epilepsy Behav 2008; 13:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/120\">",
"      LeLorier J, Duh MS, Paradis PE, et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008; 70:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/121\">",
"      Berg MJ, Gross RA, Tomaszewski KJ, et al. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology 2008; 71:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/122\">",
"      Zachry WM 3rd, Doan QD, Clewell JD, Smith BJ. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formulation changes. Epilepsia 2009; 50:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/123\">",
"      Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs 2010; 70:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/4/31818/abstract/124\">",
"      Patsalos PN, Berry DJ, Bourgeois BF, et al. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia 2008; 49:1239.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2212 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31818=[""].join("\n");
var outline_f31_4_31818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      WHEN TO START AED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk of seizure recurrence after a first seizure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Benefit of early versus deferred treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SELECTION OF AN AED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      AED comparison trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Epilepsy syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Specific etiologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      AED pharmacokinetics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Dosing frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Potential adverse events",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Drug interactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Aging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Concurrent Illnesses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hepatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Psychiatric disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Migraine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Osteoporosis risk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Others",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Women of childbearing age",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Oral contraceptive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Catamenial epilepsy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Pregnancy and postpartum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      FDA indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Cost of Medications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      OPTIMIZING TREATMENT OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Starting treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Seizure calendar",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Generic substitution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/2212\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/2212|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/32/19979\" title=\"table 1\">",
"      Broad versus narrow-spectrum AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/46/27374\" title=\"table 2\">",
"      AED pharmacologic properties",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/28/3533\" title=\"table 3\">",
"      Common side effects of AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/34/30252\" title=\"table 4\">",
"      Rare serious side effects AEDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/44/32461\" title=\"table 5\">",
"      AED nonAED drug interactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/6/36969?source=related_link\">",
"      Antiepileptic drugs and bone disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/40/1673?source=related_link\">",
"      Drug-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32425?source=related_link\">",
"      Electroencephalography (EEG) in the diagnosis of seizures and epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/52/2890?source=related_link\">",
"      Evaluation and management of drug-resistant epilepsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/9/25753?source=related_link\">",
"      Evaluation of the first seizure in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/16/15625?source=related_link\">",
"      Management of epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40570?source=related_link\">",
"      Overview of the management of epilepsy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/5/18522?source=related_link\">",
"      Overview of the use of estrogen-progestin contraceptives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?42/40/43650?source=related_link\">",
"      Patient information: Epilepsy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/56/28546?source=related_link\">",
"      Patient information: Seizures (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/27/34229?source=related_link\">",
"      Patient information: Seizures in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/56/42889?source=related_link\">",
"      Preventive treatment of migraine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/16/18697?source=related_link\">",
"      Seizures in patients with primary and metastatic brain tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/29/17882?source=related_link\">",
"      Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/43/12986?source=related_link\">",
"      Treatment of diabetic neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/6/17512?source=related_link\">",
"      Treatment of seizures and epilepsy in the elderly patient",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_4_31819="Carnitine in disorders of fatty acid metabolism";
var content_f31_4_31819=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70936&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Plasma carnitine levels in disorders of fatty acid metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Enzyme defect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Total carnitine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Free carnitine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Free:total carnitine ratio",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Carnitine transporter",
"       </td>",
"       <td>",
"        Very low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Normal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CPT I",
"       </td>",
"       <td>",
"        Normal or high",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Translocase and CPT II",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Very low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        VLCAD, LCAD, MCAD, SCAD, LCHAD, SCHAD ETF and ETF dehydrogenase, 2,4-dienoyl-CoA reductase",
"       </td>",
"       <td>",
"        Normal or low",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Normal or low",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CoA: coenzyme A; CPT: carnitine palmitoyl transferase; ETF: electron transfer flavoprotein; LCAD: long-chain acyl-CoA dehydrogenase; LCHAD: long-chain 3-hydroxyacyl-CoA dehydrogenase; MCAD: medium-chain acyl-CoA dehydrogenase; SCAD: short-chain acyl-CoA dehydrogenase; SCHAD: short-chain 3-hydroxyacyl-CoA dehydrogenase; VLCAD: very long-chain acyl-CoA dehydrogenase.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Vockley J. Mayo Clin Proc 1994; 69:249.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31819=[""].join("\n");
var outline_f31_4_31819=null;
var title_f31_4_31820="Categories of synovial fluid";
var content_f31_4_31820=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F76506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F76506&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Categories of synovial fluid based upon clinical and laboratory findings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Measure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Normal",
"       </td>",
"       <td class=\"subtitle1\">",
"        Noninflammatory",
"       </td>",
"       <td class=\"subtitle1\">",
"        Inflammatory",
"       </td>",
"       <td class=\"subtitle1\">",
"        Septic",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hemorrhagic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Volume, mL (knee)",
"       </td>",
"       <td>",
"        &lt;3.5",
"       </td>",
"       <td>",
"        Often &gt;3.5",
"       </td>",
"       <td>",
"        Often &gt;3.5",
"       </td>",
"       <td>",
"        Often &gt;3.5",
"       </td>",
"       <td>",
"        Usually &gt;3.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Clarity",
"       </td>",
"       <td>",
"        Transparent",
"       </td>",
"       <td>",
"        Transparent",
"       </td>",
"       <td>",
"        Translucent-opaque",
"       </td>",
"       <td>",
"        Opaque",
"       </td>",
"       <td>",
"        Bloody",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Color",
"       </td>",
"       <td>",
"        Clear",
"       </td>",
"       <td>",
"        Yellow",
"       </td>",
"       <td>",
"        Yellow to opalescent",
"       </td>",
"       <td>",
"        Yellow to green",
"       </td>",
"       <td>",
"        Red",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Viscosity",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        WBC, per mm3",
"       </td>",
"       <td>",
"        &lt;200",
"       </td>",
"       <td>",
"        0-1,000",
"       </td>",
"       <td>",
"        1,000-100,000",
"       </td>",
"       <td>",
"        15,000-&gt;100,000*",
"       </td>",
"       <td>",
"        200-2,000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        PMNs, percent",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        &lt;25",
"       </td>",
"       <td>",
"        &ge;50",
"       </td>",
"       <td>",
"        &ge;75",
"       </td>",
"       <td>",
"        50-75",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Culture",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"       <td>",
"        Often positive",
"       </td>",
"       <td>",
"        Negative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Total protein, g/dL",
"       </td>",
"       <td>",
"        1-2",
"       </td>",
"       <td>",
"        1-3",
"       </td>",
"       <td>",
"        3-5",
"       </td>",
"       <td>",
"        3-5",
"       </td>",
"       <td>",
"        4-6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glucose, mg/dL",
"       </td>",
"       <td>",
"        Nearly equal to blood",
"       </td>",
"       <td>",
"        Nearly equal to blood",
"       </td>",
"       <td>",
"        &gt;25, lower than blood",
"       </td>",
"       <td>",
"        &lt;25, much lower than blood",
"       </td>",
"       <td>",
"        Nearly equal to blood",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Lower part of range with infections caused by partially treated or low virulence organisms.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31820=[""].join("\n");
var outline_f31_4_31820=null;
var title_f31_4_31821="Carbohydrate profiles in IDDM";
var content_f31_4_31821=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F76488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F76488&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 527px\">",
"   <div class=\"ttl\">",
"    Carbohydrate intake profiles in different patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 507px; height: 195px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carbohydrate intake (each column represents one meal or snack and each box represents 15 g) throughout the day in two patients with excellent glycemic control. The more active, younger man (right panel) takes in more carbohydrate, but both patients maintain a relatively constant profile each day (not shown).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31821=[""].join("\n");
var outline_f31_4_31821=null;
var title_f31_4_31822="Right upper lobe atelectasis B";
var content_f31_4_31822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F59863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F59863&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right upper lobe atelectasis in an adolescent",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Portable supine radiograph of a 12-year-old following intubation. There are focal opacities within the right upper lung and retrocardiac left lower lobe. The curvilinear inferior margin of the right-sided opacity represents a significantly elevated minor fissure, consistent with right upper lobe collapse; the left lower lobe opacity is less specific.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31822=[""].join("\n");
var outline_f31_4_31822=null;
var title_f31_4_31823="SPRM coact corepress";
var content_f31_4_31823=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77646&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Action of SPRMs",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    With SPRMs, it is likely that the ratio of recruitment of coactivator to corepressor within a given cell type determines the biological effect of the SPRM and whether it is predominantly an agonist, antagonist or mixed agonist-antagonist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_4_31823=[""].join("\n");
var outline_f31_4_31823=null;
